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Inapropriada, Cuidados de Saúde Primários 
resumo 
 
 
Relatórios da Organização Mundial da Saúde indicam que a expectativa de 
vida está a aumentar. Demência e depressão estão entre as patologias que 
mais afetam os idosos; uma população frágil, com recursos e fundos limitados. 
Muitas vezes, o primeiro ponto de contato para estes pacientes é o médico de 
família nos cuidados de  saúde primários. Com isso em mente, o objetivo geral 
desta tese foi implementar, nos cuidados de saúde primários, testes cognitivos 
e de depressão previamente validados, de modo a identificar possíveis 
pacientes em risco de demência e depressão. O estudo também abordou o 
uso de polifarmácia, bem como o uso de medicação potencialmente 
inapropriada (PIM) em idosos. 
Para realizar a investigação proposta, foi criada uma coorte baseada nos 
cuidados de saúde primários (pcb-Coorte); compreendendo 568 indivíduos, 
uma vez considerados os critérios de exclusão. Ao aplicar o ‘Clinical Dementia 
Rating’ (CDR), 68 indivíduos (12%) têm uma pontuação de CDR≥1, dos quais 
7 com menos de 65 anos de idade. O pcb-Coorte também foi caracterizado 
para as comorbidades, e correlações significativas com: condições 
neurológicas, doenças gastrointestinais (GID), respiratórias e osteoarticulares 
(OA) são evidentes. A genotipagem para a APOE foi realizada, e uma 
correlação com o alelo de risco para demência, ε4, e baixo desempenho 
cognitivo (CDR≥1) é clara. Subsequentemente os critérios do DSM-5 para 
transtornos neurocognitivos (NCD) foram aplicados. O grupo de estudo diminui 
para 286 indivíduos, dos quais 61 exibem NCD-ligeiro (22%) e 36 NCD-major 
(13%); 10 têm menos de 65 anos de idade. Correlações com condições 
neurológicas e doenças respiratórias são sustentadas, mas aquelas com o 
genótipo de risco APOE e GID não são. 
A depressão também afeta os idosos e no pcb-Coorte, 174 dos 568 tiveram 
pontuação positiva na GDS (Escala Geriátrica de Depressão) e 282 têm 
possível depressão, dos quais 74 estão confirmados com um diagnóstico de 
depressão. Para ambos os grupos de depressão possível e confirmada (174 e 
74) as correlações com OA, GID e uma história de depressão, são evidentes, e 
mantêm-se mesmo quando versões mais curtas da GDS são analisadas. 
Os idosos também representam um grupo de risco para uso potencialmente de 
polifarmácia e PIM. Os critérios de Beers foram aplicados ao pcb-Coorte para 
indivíduos com mais de 65 anos e 361 indivíduos tinham informações 
relevantes sobre o uso de medicamentos. Deste grupo de estudo 94.5% 
apresentam polifarmácia e 47.4% utilizam pelo menos 1 PIM, sendo o grupo 
principal os Benzodiazepínicos. Claramente isto é uma preocupação, pois o 
risco para os pacientes é aumentado. 
É possível a partir do trabalho realizado propor várias recomendações. Ou 
seja, monitorizar os indivíduos no ponto primário de atendimento para 
identificar possíveis casos de demência e depressão que podem ser 
recomendados para consultas especializadas. Isto talvez pudesse ser feito 
através da organização de campanhas nos cuidados de saúde primários. O 
trabalho futuro focar-se-á nestes aspectos com a intenção de contribuir para a 
qualidade de vida dos idosos. 
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abstract 
 
European Health reports from the World Health Organization reveal that life 
expectancy is steadily increasing. Dementia and depression are among the 
pathologies that most affect the elderly; a frail population, with limited resources 
and funds. Often the first point of contact for these patients is the family doctor 
in primary health care settings. With this in mind the overall goal of this thesis 
was to implement, in a primary health care setting, previously validated 
cognitive and depression tests, so as to identify putative at risk patients namely 
for dementia and depression. The study also addressed polypharmacy usage 
as well as inappropriate polypharmacy medication (PIM) in the elderly. 
To carry out the proposed research a primary care based cohort (pcb-Cohort) 
was set up; comprising 568 individuals once the exclusion criteria are 
considered. Upon applying the Clinical Dementia Rate (CDR), 68 individuals 
(12%) have a score of CDR≥1, of these 7 are less than 65 years old. The pcb-
Cohort was also scored for comorbidities and significant correlations with: 
neurological conditions, gastrointestinal disorders (GID), respiratory and 
osteoarticular (OA) diseases are evident. Genotyping for APOE was also 
carried out, and a correlation with the risk allele for dementia, ε4, and poor 
CDR scores (CDR≥1) is evident. The DSM-5 criteria for neurocognitive 
disorders (NCD) were subsequently applied. The study group falls to 286 
individuals of who 61 exhibit NCD-mild (22%) and 36 NCD-major (13%); 10 are 
less than 65 years old. Correlations with neurological conditions and respiratory 
diseases are sustained but those with GID and APOE genotype are not. 
Depression also afflicts the aged and in the pcb-Cohort, 174 of the 568 scored 
positive in the GDS (Geriatric Depression Scale) and 282 have possible 
depression, of which 74 are confirmed with a depression diagnosis. For both 
possible and confirmed depression (174 and 74) correlations were evident with 
OA, GID and a history of depression, and sustained even when shorter 
versions of the GDS were analyzed. 
The elderly are a risk group for potentially polypharmacy and PIM usage. The 
Beers criteria were applied to the pcb-Cohort for individuals over 65 years old 
and 361 individuals have relevant medication usage information. From this 
study group 94.5% exhibit polypharmacy and 47.4% use at least 1 PIM and the 
major group is Benzodiazepines. Clearly this is a concern as risk for the 
patients is increased. 
It is possible from the work carried out to propose several recommendations. 
Namely monitoring individuals at the primary point of care to identify potential 
cases of dementia and depression that can then be recommended for specialist 
consultations. This could perhaps be carried out by organizing campaigns at 
primary health care centres. Future work will focus on these aspects with the 
intent of contributing to the quality of life in the elderly. 
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BZ – Benzodiazepines; 
CDR- Clinical Dementia Rating; 
CDT- Clock Drawing test; 
CI- Confidence Interval; 
‘CNPD- Comissão Naciontal de Proteção de Dados’ (National Commission for Data Protection); 
COX- Cyclooxygenase; 
CrCl- Clearance of Creatinine; 
Crammer´s V- Statistical test to association between two qualitative characteristics; 
CSF- Cerebrospinal fluid; 
CT- Computerized tomography; 
CVD – Cardiac and vascular disease;  
DEP- Depression; 
DLB- Dementia with Lewy bodies 
DM- Diabetes mellitus; 
DNA- Deoxyribonucleic acid; 
DSM-5- Diagnostic and Statistical Manual of Mental Disorders, 5thedition; 
DYS- Dyslipidaemia;  
EU- European Union; 
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‘FCT- Fundação para Ciência e Tecnologia (Foundation for Science and Technology); 
FTD- Frontotemporal dementia; 
FN- False negative; 
FP- False positive; 
GDS- Geriatric Depression Scale; 
GDS-- Individuals with negative GDS; 
GDS+- Individuals with positive GDS; 
GDS4Lit- Short version of GDS with 4 questions, from previous literature; 
GDS4- Short version of GDS with 4 questions, applied to the pcb-Cohort; 
GDS5- Short version of GDS with 5 questions, applied to the pcb-Cohort; 
GDS6- Short version of GDS with 6 questions, applied to the pcb-Cohort; 
GDS7- Short version of GDS with 7 questions, applied to the pcb-Cohort; 
GDS8- Short version of GDS with 8 questions, applied to the pcb-Cohort; 
GDS15Lit- Geriatric Depression Scale with 15 questions, from previous literature; 
GEECD- Grupo de Estudo em Envelhecimento Cerebral e Demência (in english: Study Group on 
Brain Aging and Dementia); 
GID- Gastrointestinal disease;  
GP- General practitioners; 
GUD- Genitourinary disease;  
HDL- High density lipoprotein; 
HEMATO- Hematologic disease;  
HIV- Human immunodeficiency virus; 
HYP- Hypertension arterial;  
IADL- Instrumental Activities of Daily Living; 
‘INE- Instituto Nacional de Estatística’ (National Institute of Statistics); 
KI- Katz Index; 
LDL- Low density lipoprotein; 
LR- Likelihood ratio; 
LUTS- Lower urinary tract symptoms; 
MCI- Mild Cognitive Impairment; 
mmHg- Millimetre of mercury; 
MMSE- Mini Mental State Examination; 
NCD-major-- Neurocognitive disorder major 
NCD-mild- Neurocognitive disorder mild 
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NCD-normal- Normal cognitive performance 
NEURO- Neuropathologies; 
NFT(s)- Neurofibrillary tangle(s); 
NINCDS-ADRDA- National Institute for Communicative Disorders and Stroke-   
  Alzheimer's disease and Related Disorders Association; 
NSAID´s – Nonsteroidal anti-inflammatory drugs; 
OA- Osteoarticular disease; 
ONCO- Oncology disease;  
OR- Odds ratio; 
pcb-Cohort- Primary care-based cohort; 
PD- Parkinson’s disease; 
PIM- Potentially Inappropriate Medication; 
PIM-1- Medication of the Table 1 of Beers criteria; 
PIM-2- Medication of the Table 2 of Beers criteria; 
PIM-3- Medication of the Table 3 of Beers criteria; 
PNV- Predictive negative value; 
PPV- Predictive positive value; 
PSP- Progressive supranuclear paraparesis; 
RESP- Respiratory disease; 
SD- Standard deviation; 
SIADH- Syndrome of inappropriate antidiuretic hormone secretion; 
SNRIs- Serotonin and noradrenalin receptor inhibitors; 
SP(s)- Senile plaque(s); 
SPSS- Statistical package for the social sciences; 
SSRI- Selective serotonin receptor inhibitors; 
NRTI´s- Nucleoside/Nucleotide reverse transcriptase inhibitors; 
t – Student’s –t-Test;  
TC- Total cholesterol; 
TCA-Tricyclic antidepressants; 
TN – True negative; 
TP – True positive; 
VaD- Vascular dementia; 
WHO- World Health Organization; 
χ2- Chi-square. 
  
_______________________________________________________________________ 
 
_______________________________________________________________________ 
Characterization of the pcb-Cohort in the Aveiro region of Portugal 19 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
Introduction 
 
 
 
 
 
 
 
 
 
 
  
_______________________________________________________________________ 
_______________________________________________________________________ 
Departamento de Ciências Médicas/UA- 2017/201820 20 
 
 
  
_______________________________________________________________________ 
 
_______________________________________________________________________ 
Characterization of the pcb-Cohort in the Aveiro region of Portugal 21 
 
1.1 Ageing in Portugal and in Baixo Vouga 
In recent years there has been a change in the age structure in Portugal, with 
a notable decrease in the younger population and a growth in the elderly. The ageing 
process in Portugal is aggravated by the progressive increase in longevity. The elderly, 
particularly individuals over 75 years old, account for almost half of the population [1]. 
Based on the national 2011 census (most recent), Portugal has a total 
population of 10.3 million, of these 9.8 million individuals living in the continent [2]. In 
Baixo Vouga, for the same period, the population was 390 822 of which 72 045 are 
over 65 years of age. From the total population in this region, 187 078 are male and 
203 744 females. 
In 2013, the resident population in Portugal comprised 14.6% young people 
(up to 14 years old), 65.6% of legal working age (between 15 and 64) and 19.9% of 
elderly (more than 65 years old) [3]. The proportion of resident population aged 65 
years or older was 18,8% [3]. In 2013 the ageing index in Portugal was 136 elderly 
(residents aged 65 or over per 100 residents under the age of 15), whereas in the Baixo 
Vouga region, this was 138 elderly people for every 100 younger individuals [3]. In 
other words, the ageing index in the Aveiro region is marginally higher when compared 
to the rest of Portugal.  
Perspectives for the future are of considerable concern, given that the ageing 
trend in Portugal conforms to that followed by member countries of the European 
Union (EU). That is, an increase is anticipated of 0.3% compared with the previous year 
and an increase of 2.4 % compared with the last 10 years. In recent years, life 
expectancy in the EU has improved due to better living conditions and improved public 
health. In addition, Portugal belongs to the EU countries with better life expectancies. 
In the EU, life expectation is around 80.6 years, whereas in Portugal, it is 81.3 years, 
placing Portugal among the most aged countries of the European Union [4]. 
 
1.2  Normal Ageing 
Physiologically we become compromised as a function of age. Ageing can be 
detected at a cellular, systems or cognitive level. At a cellular level several changes are 
evident and these have consequences at a clinical level [5]. Ageing affects systems of 
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the human body, for instance in the cardiovascular system, decreased cardiac 
contractile capacity, increased collagenolytic and elastolytic activity, as well as 
decreased smooth muscle tone can be detected. Together this leads to increased 
peripheral vascular resistance, an increase in isolated systolic hypertension, 
hypertrophy of the heart chambers, increased susceptibility to atrial fibrillation, 
decreased cardiac output and increased susceptibility to ischemia and stroke [5]. Many 
other functions can be compromised, affecting many other organs. In case of the 
kidney, the following may happen: a reduction in renal mass, a decrease in cortical 
thickness, a reduction in glomeruli, a decrease in glomerular lobulation, global 
glomerular and vascular sclerosis, tubular atrophy and fibrosis. Therefore, there is 
impairment of kidney responsiveness acute ischemia and injury, and can exhibit 
increased progression leading to chronic kidney disease, and decreased glomerular 
filtration rate, or creatinine clearance (ClCr) [5]. Ageing is likewise evident in the 
respiratory system; there is a decline in the elasticity of the bony thorax, loss of muscle 
mass and weakening of the muscles used for respiration and reduced mechanical 
capacity, a decrease in alveolar gas exchange surface area and a decrease in central 
nervous system’s responsiveness. About changes in the mucosa of the gastrointestinal 
tract, with age, there is a reduction in the endogenous protective factors, and an 
increase in the aggressors. Both are related to changes in the secretion of endogenous 
substances. All the above mentioned alterations explain the high prevalence of H. 
pylori in older individuals [6]. Perhaps the most readily visible ageing signs of the 
human body, are those that affect the most extensive human tissue; the skin: in the 
ageing skin, there is deterioration of the protective layer of the skin, decreased cell 
turnover, and reduction in the number of keratinocytes and fibroblasts. Therefore, 
there is diminished cellular repair, increased incidence of dermatitis, infections, and 
pressure ulcers.  
Many other generalized changes occur. Ageing of the immune system 
predisposes to infection, increases the chance of reactivation of viral and 
mycobacterial infections and the response to autoimmunity becomes more 
pronounced [7]. Other changes include depleted iron stores, low response to acute 
haemorrhage, poor endocrine response, loss of lean body mass (muscle), and 
decreased thermoregulation [5]. Additionally, ageing causes a decrease in neural 
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density; there is loss of fibres of the motor, sensory and autonomic systems; decrease 
of the sympathetic and parasympathetic tone, and baroreceptor dysfunction. Together 
these alterations compromise homeostasis, postural hypotension, and can be the 
cause of syncope [7]. 
Significantly, cognitive deficits can occur with ageing and these are associated 
with compromised cortical functions. These include reduced cognitive skills, decreased 
executive capacities and memory loss. Of note, the ability to respond to injury 
differentiates normal ageing from neurodegenerative disorders [8]. The cortical 
volume reduction of a typical older individual (65 years old or more) is around 0.5% in 
most regions, with more pronounced loss in the frontal and temporal lobes. However, 
patients with Cognitive Impairment or Mild Alzheimer disease have an annual brain 
atrophy several times higher than that of healthy individuals, and the most affected 
lobe is usually the temporal lobe [8]. This is further discussed below. 
 
1.3  Diseases Associated with Ageing 
Given the physiological changes related to ageing, the ageing process is 
associated with several disease processes. Among these the most relevant pathologies 
include cardiac and vascular disease (CVD), Diabetes Mellitus (DM), cancer and 
neuropathologies [9]. This contrasts with other common causes of death in the past 
(typically infectious diseases), mainly because there have been improvements in health 
and working conditions, diet changes, improved vaccination programs, and the 
development of antibiotics. Consequently there are clinical and public health 
implications, because CVD leads to more deaths than other causes together [10,11]. In 
fact, CVD is the number one killer of men and women, in Portugal [3] and in the world 
[12]. The risk factors for CVD are well known: hypertension (HYP), dyslipidaemia (DYS), 
DM, smoking, inflammation and abdominal obesity. The optimal preventive factors are 
defined as; total cholesterol (TC) between 180 and 199 mg/dL, systolic blood pressure 
between 120 and 139 mmHg, diastolic blood pressure between 80 and 89 mmHg, 
being a non-smoker and non-diabetic [9,13]. In 2016, an estimated 56.9 million people 
died worldwide. The 4 main causes are cardiovascular diseases, cancers, diabetes and 
chronic lung diseases [14]. The second cause of death in Portugal [3] and in the world 
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[12] is cancer. Cancer is related to multiple biological changes, involving, in particular, 
deoxyribonucleic acid (DNA) mutations. These mutations result in the deregulation of 
cell proliferation and differentiation, and the loss of normal cell function. Other 
changes include abnormal metabolism and hormonal function leading to malignant cell 
transformations and ultimately cancer [7,15,16]. 
Many chronic diseases associated with ageing involve factors that can be 
controlled. Ageing itself is a process that cannot be regulated, but it can be influenced 
for example, by changes in eating habits. In fact, controlling calorie intake can decrease 
chronic diseases and the ageing process [9,17–21]. 
Another significant group of age associated chronic diseases are 
neurodegenerative disorders and the exacerbation of cognitive decline. There are 
studies showing that peripheral metabolic deregulation in patients with DM and CVD, 
accelerates age associated cognitive decline. On the other hand, high levels of omega-
3 intake, calorie restriction, normal body mass index (ratio between 20 and 24), high 
HDL cholesterol/low LDL cholesterol levels and controlled blood pressure are 
associated with preserved cortical mass [22,23].  
It follows that another important public health problem is dementia [24,25]. 
The World Alzheimer Report 2016 estimates that in 2015 there were 46.8 million 
people worldwide living with dementia and this number it expected to reach 131.5 
million in 2050 [25]. Alzheimer Europe website shows an estimated 182.526. that the 
number of individuals with dementia in Portugal in 2012 was This represents 1.71% of 
the total population of 10.699.333. Therefore in Portugal, the number of individuals 
with dementia as a percentage of the population is somewhat higher than the EU 
average of 1.55% [26]. To summarize, as the population ages alongside increasing life 
expectancy, the number of individuals with dementia is also increasing. 
 
1.4  Dementia  
1.4.1 Prevalence 
The global dementia prevalence in 2010 was estimated at 4.7% in people over 
60 years old. The region with the highest prevalence worldwide is Latin America, with 
8.48% [27]. These values ranged from 2.6% in Africa to 6.2% in Europe and 6.7% in the 
_______________________________________________________________________ 
 
_______________________________________________________________________ 
Characterization of the pcb-Cohort in the Aveiro region of Portugal 25 
 
USA [28]. It was estimated that in 2010, 35.6 million individuals lived with dementia 
worldwide, with numbers expected to almost double every 20 years, to 74.7 million in 
2030 and 131.5 million in 2050 [11]. In 2010, 58% of all people with dementia lived in 
countries with low or middle incomes, this is anticipated to rise to 63% in 2030 and 
71% in 2050 [27–29]. Clearly this is of significant economic impact and it follows that 
individuals should be appropriately diagnosed with dementia.  
 
1.4.2 Definition and Diagnosis 
Dementia is defined as alterations in memory and other cognitive capacities 
[30]. The new clinical definition of dementia conforms to that published in the DSM–5 
(Diagnostic and Statistical Manual of Mental Disorders, 5thedition) [31]. The manual 
suggests that dementia is interpreted as a major neurocognitive disorder (NCD-major).  
For cases of NCD-major there has to be evidence of a significant cognitive decline from 
the previous level of performance in one or more of the following cognitive domains 
(complex attention, executive function, learning and memory, language, perceptual 
ability and motor or social cognition), as perceived by the patient or informant 
[28,30,32,33]. This is established through standardized neuropsychological tests. NCD-
major states that the deficits must interfere with the independent activities of daily 
living (IADL), that these are not due to delirium, or that the cognitive deficits are not 
due to any other mental disorder (i.e. depression, schizophrenia) [31,34,35]. 
Table 1 details the new DSM–5 criteria for neurocognitive disorders [31] 
[36,37]. To summarize, alterations in at least one cognitive domain must be present, as 
recognized by the clinician, close observer or by the patient himself, objectified by 
clinical tests and by a change in the performance of the IADL, excluding (as mentioned 
above) delirium, major depression and schizophrenia.  
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Table 1 Criteria for neurocognitive disorders according to the DSM–5 
 
Taken from DSM–5 [31]. 
 
The DSM-5 differentiates between major neurocognitive disorder (NCD-
major) and mild neurocognitive disorder (NCD-mild) [31,38–41]. In NCD-mild, the 
cognitive decline is modest, and it does not interfere with carrying IADL. Therefore, the 
term MCI is being substituted by the term mild neurocognitive disorder (NCD-mild). 
The term MCI was initially proposed in 1999 by Peterson [42]. A change in 
cognition, in comparison to the person’s previous cognitive level was noted [43].  In 
this case, the deficits do not interfere with the independent realization of complex life 
activities. It is still necessary that such deficits are not associated with delirium or other 
psychiatric disorders [31,42].  
MCI/NCD-mild although controversial, is an important stage because many 
patients classified as MCI/ NCD-mild can convert to dementia, mainly AD [41,43]. It is a 
disorder/condition of uncertain etiology. Some studies have found increased neuritic 
plaques in the neocortex as well as cerebral infarction and deposition of Lewy bodies 
[44,45]. Other studies showed increased acetylcholinesterase activity in the 
hippocampus of patients with MCI/NCD-mild [46]. To complicate matters further, 
treatable causes of dementia can occur. These include Vitamin B12 and folate 
deficiency, hypothyroidism, depression, infectious disease, normal pressure 
hydrocephalus, tumours, subdural hematoma, drug intoxication, alcohol abuse, 
kidney/liver/pulmonary/adrenal insufficiency and vasculitis [28,30,47–49]. 
DSM-5 Criteria for neurocognitive disorders 
A. Evidence of significant cognitive decline compared to previous performance in one or 
more of the following domains (complex attention, executive function, learning and 
memory, language, perceptual, motor, ability or social cognition) based on: 
1. Concern of; the individual, acknowledgeable informant, or a clinician, that can 
confirm that there has been a significant decline in cognitive function; and 
B. A substantial deficit on cognitive performance, preferably documented by standardized 
neuropsychological or quantitative tests, in the absence of the latter another quantified 
clinical assessment. 
C. Cognitive deficits that interfere in the performance of independent daily life activities 
(i.e., it is necessary help in complex daily life instrumental activities, such as paying bills 
or managing medication). 
D. Cognitive deficits do not occur exclusively in the context of a delirium. 
E. Cognitive deficits are not accounted for by another mental disorder (e.g., major 
depressive disorder, schizophrenia). 
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Dementia diagnosis entails recording the patient’s complete medical history, 
followed by a physical examination, including a neurological examination. It is also 
necessary to apply cognitive tests or neuropsychological tests. The next step is to 
request complementary means of diagnosis, such as blood count, biochemical, 
serological and imaging tests. Currently, including the evaluation biomarkers from 
blood or cerebrospinal fluid is already contemplated, such as to obtain a reliable 
diagnosis and promote differential dementia diagnosis [33,35,50–53]. 
Extracellular amyloid containing senile plaques (rich in the Aβ peptide) and 
intracellular neurofibrillary tangles (rich in phosphorylated TAU) are considered the 
central histopathological AD features, and, as such, they represent natural biomarkers 
[54–57]. It follows that monitoring levels of this triplet (Aβ, total TAU and 
phosphorylated TAU) provide useful diagnostic tools. Aβ peptides, total TAU and 
phosphorylated TAU levels can all be quantified in the cerebrospinal fluid (CSF) and 
provide excellent complementary diagnostic tools. Presently studies are focusing on 
using patient plasma with mild cognitive impairment and AD, as the source for 
measuring the same triplet, however, positive reliable results have still to be 
forthcoming [58–60].  
 
1.4.3 Motives of Cognitive Impairment 
Dementia can be characterized into subtypes, as depicted in Table 2, taken 
from Prince et al [61]. The main causes include Alzheimer's disease (AD), Vascular 
dementia (VaD), Dementia with Lewy bodies (DLB) and Frontotemporal dementia 
(FTD). 
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Table 2 Characterization of dementia subtypes 
 
Table taken from Prince et al [61]. 
 
AD is the most common cause of dementia. In 1906, Dr. Alois Alzheimer 
described this pathology for the first time. The basic physiopathology of this disease, 
has already mentioned, is the deposition of extracellular neuritic plaques/senile 
plaques (SPs) and intracellular neurofibrillary tangles (NFTs) within the neuronal brain 
cells [62]. This is considered the most common dementia subtype (estimates vary from 
50-75% or 60-80%) [28]. 
Several AD risk factors have been described. Higher education levels correlate 
with decreased incidence and prevalence of dementia of the AD type [63]. Positive 
correlations with AD have been reported for patients with CVD, hypertension, 
diabetes, dyslipidaemia, smoking habits and those who are overweight [27,28,62]. 
At a microscopic and biochemical level, it is consensual that the 
histopathological changes of AD; namely the SPs and NFTs, lead to neuronal loss and 
progressive reactive gliosis. Several hypotheses for the development of AD have been 
proposed (Figure 1), among them the amyloid cascade hypothesis, whereby the toxic 
peptide Abeta can trigger a series of events. These involve oxidative processes, 
excitotoxicity, protein aggregation, inflammation and hyper phosphorylation of TAU 
protein, among others. The result is a deficit in synapses, in neurotransmission and, 
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consequently, in cognition due to the destruction of the affected anatomical brain 
regions [64–67].  
 
 
Figure 1 Cascades contributing to the development of Alzheimer’s disease 
Possible cascades involved in physiopathology of the first cause of dementia; Alzheimer’s disease. PS1, Presenilin 1; 
PS2, Presenilin 2; NOS, nitric oxide synthase expression; NO, nitric oxide; ROS, reactive oxygen species; IDE, insulin 
degrading enzyme; SPs, senile plaques; NFTs, neurofibrillary tangles. Dashed black line denotes that A can influence 
tau hyperphosphorylation.  Taken from Oliveira et al, 2016 [67]. 
 
 
The second most common cause of all dementias is VaD. In this type of 
dementia, there is a positive correlation between the onset of cognitive deficits and 
cerebrovascular events. Patient evaluation includes collecting the clinical history, 
carrying out a physical examination and analysis neuroimaging tests, as well as scoring 
for the presence of cerebrovascular disease [28,31]. The latter is a significant risk 
factor in this pathology. In VaD, the most affected domain is the one related to 
complex attention and frontal executive functions (planning, decision making, working 
memory and others). Cognitive decline occurs due to large areas of infarction in 
cortical regions such as the hippocampus, medial dorsal nucleus of the thalamus, 
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dorsal or cingulate gyrus. In other words, micro strokes in the cortical area, multiple 
lacunar infarcts and cortical laminar necrosis are all associated with reduced perfusion 
and neuronal oxygenation. This typically occurs in patients with CVDs such as 
hypertension, diabetes or vasculitis [33,68–70]. 
 
 
 
Figure 2 Vascular dementia characterization 
Adapted from the risk factors and characteristic features of VaD [70]. 
*Metabolic syndrome is defined when at least three of the above described findings are present in the clinical 
evaluation of the patients: central obesity, hypertension, dyslipidaemia, insulin resistance. 
 
 
Dementia with Lewy bodies (DLB) is the third most common cause of 
neurocognitive disorders and the second cause of neurodegenerative disease is 
[71,72]. DLB is characterized by the presence of core symptoms that are floating 
cognition with pronounced variations in attention and waking, recurrent visual 
hallucinations that are well formed and detailed. Additionally, spontaneous features of 
Parkinsonism start before the development of cognitive decline [31].  
The pathophysiology of DLB has similar mechanisms to those described for 
Parkinson's disease (PD). Both diseases are characterized by the formation of Lewy 
bodies and Lewy neuritis’ formation. This leads to an abnormal accumulation of the 
synaptic protein called alpha synuclein. Macroscopically depigmentation of the 
substantia nigra and corpus coeruleus can be found, sparing of the cortex and the 
amygdala can also be detected [33,53,56,57,71,73–75]. 
Another cause of neurocognitive disorder is Frontotemporal dementia (FTD). 
The diagnostic criteria include behavioural symptoms: behavioural disinhibition, 
RISK FACTORS
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Metabolic  Syndrome *
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apathy or inertia, lack of sympathy or empathy, stereotyped behaviour, hyperorality 
and change in diet. In addition, in a clinical context, there may also be a prominent 
decline in cognition and in executive skills. The patient can also exhibit a decline in the 
ability to speak, in the form of speech production, grammar, choice of words, naming 
objects or understanding words. In this type of dementia, learning, memory and 
perceptive-motor function are relatively preserved [76]. 
Frontotemporal dementias include a set of pathologies that have the same 
spectrum of clinical changes (progressive deterioration of language and personality 
changes). Macroscopically, it is possible to see the atrophy of the frontal and temporal 
lobes. There is FTD with Parkinsonism linked to TAU mutations in brain regions which 
are affected by atrophic neuronal loss and gliosis due to the presence of TAU 
containing tangles [77]. In Pick's disease subtype, there is diffuse brain atrophy with 
asymmetry of the temporal and frontal lobes. Microscopically, cell Pick and Pick 
corpuscles can be found. In subtype Progressive Supranuclear Palsy (PSP) there is a 
diffuse neuronal loss of the Globus pallidum, subthalamic nucleus, substantia nigra, 
and colliculus among others. NFTs are found in the affected regions. In corticobasal 
degeneration, there is a cortical atrophy of the motor cortex, premotor and parietal 
lobe, with neuronal loss, gliosis, and the presence of neuronal achromasia. In FTD 
without TAU pathology, the frontal and the temporal lobes are also affected but 
without TAU deposition, instead the presence of ubiquitin is evident [30,33,77–80]. 
There are, however, other causes of dementia. PD is associated with dementia 
but typically in later phases. In other words dementia occurs once PD is installed [81]. 
Likewise, in Huntington's disease (HD), dementia occurs once the former is already 
clinically well established. In HD cases dementia can occur earlier if there is a positive 
family history or positive genetic compliance. Also for Prion disease (Creutzfeldt-Jakob 
disease) the patient already clinically exhibits the motor characteristics such as 
myoclonus and ataxia before dementia onset [49]. 
Furthermore, there are metabolic and endocrine causes of dementia. 
Examples include: uraemia, Addison's disease; toxins and drug (alcohol, opioids, 
sedatives) usage; vitamin deficiency (B12, folate, thiamine, nicotinic acid) [49]; 
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autoimmune and inflammatory disorders (systemic lupus erythematosus, vasculitis); 
and infectious diseases (Human Immunodeficiency Virus, syphilis) [48]. 
 
1.4.4 Risk Factors in Dementia 
Risk factors for developing cognitive impairment can be modifiable or non-
modifiable. Age is undoubtedly a major factor described in many studies and it is 
considered a non-modifiable risk factor [66,82,83]. Equally non-modifiable is an 
individual’s genotype. The Apolipoprotein E (APOE) genotype is considered a risk factor 
relevant to AD [82], DLB [74]; FTD and PD [53]. Among the acquired and modifiable risk 
factors, those of vascular origin are of particular concern; obesity, hypertension, 
diabetes, dyslipidaemia, metabolic syndrome, smoking, high levels of homocysteine, 
traumatic brain injury [19,22,84].  
AD has an unknown etiology, except in familial early onset cases, in which a 
specific genetic mutation has been assigned. In this scenario, genetic factors appear to 
be extremely relevant. It is known that a positive family history of AD is the only factor 
associated with systemic disease, independently of age [85]. AD can be transmitted in 
an autosomal dominant manner and different genetic subtypes determine the age of 
onset and evolution. Genetic defects located on chromosomes 14 and 21 are related 
to early onset forms of AD (below 65 years old). The chromosomes implicated so far in 
genetic subtypes are chromosome 14 (PSEN1/presenilin 1 gene), 21 (APP gene), 1 
(PSEN2/presenilin 2 gene) and 19 (genotypes: APOE ε4/ε4, APOE ε3/ε3) [86,87]. In the 
case of genetic testing, there is a significantly stronger association with the APOE ε4 
(allele 4), placing the latter as a risk factor [88].  
In Portugal, studies have reported mutations in the presenilin’s’ coding regions 
and at exons 16 and 17 of the APP gene, in patients from the Iberian Peninsula with a 
clinical diagnosis of early AD onset [89]. A person with European ancestry who is 
homozygous for the alleleε4 (about 2 % of the population) has an increased risk of 
developing AD, which is three to four times higher than that of an individual of 
European descent that does not have an alleleε4. Furthermore, the age of onset is 
likely to be around 10 to 15 years earlier, compared to the sporadic AD age of onset 
[88,90,91]. 
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Other studies refer that there are protective factors for dementia, which 
include high education levels (in line with reports for AD, as mentioned above). This is 
supported by the theory of cognitive reserve, whereby new neuronal pathways are 
made to compensate for deficits neuronal caused by neuritis [63,92,93]. Again in line 
with AD, other protective factors appear to be healthy life style habits, such as physical 
activity and calorie restriction [22,94,95]. As risk factor, to depending on the type of 
dementia, the association with gender can be variable [82,95–97]. 
 
1.4.5 Cognitive Tests 
Many tests may be applied in the clinical diagnosis of dementia. In Portugal 
there is an important manual entitled "Escalas e Testes na Demência (Scales and Tests 
in Dementia)". This manual is in its third edition and represents the work of several 
professionals, who over the years have been able to translate and implement the main 
instruments already validated at an international level, to the situation in Portugal. 
These questionnaires can, from this manual, be applied to the Portuguese population. 
It is therefore a work of singular importance for clinical practice and research [98]. 
Some of these tests and scales are described in more detail below. 
The first example, here considered, of a cognitive test is the Clinical Dementia 
Rating (CDR). The CDR was initially developed and tested for staging dementia in AD 
patients. This is a semi-structured questionnaire to be applied to both patient and 
caregiver. It is a screening test for dementia that involves evaluating: 
i-memory; 
ii-orientation;  
iii-judgment and the capacity to resolve problems;  
iv-activities in the community; 
v-activities at home and the ability to follow hobbies and; 
vi-the capacity for personal care.  
 
The first three parameters characterize the cognitive changes. The last three 
characterize the functional changes. The determinant criterion is memory (i) 
impairment [99,100]. These parameters (i-vi) can be affected to varying degrees (each 
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scoring 0-3) and the various combinations permit a CDR score from 0-3 as indicated in 
Hughes et al and Morris et al [99,100]. The final CDR score is not a simple sum of 
factors and is explained below. 
In CDR, all information relative to the past performance is scored. The disability 
is considered in relation to the cognitive loss, not in relation to motor abnormalities, 
depression or personality disorder. In case of doubt, the worst disability is considered. 
Concerning the scores, CDR 0 means no cognitive impairment; CDR 0.5 questionable 
dementia; CDR of 1 mild dementia; CDR 2 moderate dementia; CDR 3  severe dementia 
[100,101]. The conventional CDR is not the simple sum of cognitive parameters. There 
are guidelines that must be observed. As already mentioned, the traditional scoring 
considers memory (M) as the primary category (parameter i). All other categories 
(parameters ii-vi) are secondary (SC-secondary category). The following considerations 
are observed [99,100]: 
• If at least 3 secondary categories (SC) are equal to Memory (M), then the 
total score is equal to CDR given to Memory evaluation; 
• if three or more SC are higher (or<) than the M score, then CDR is equal to 
most of the SC score that is higher (or<) than the M score; 
• when 3 SC have a score on one side of M and the other two SC have a score 
on the opposite side, then CDR has a score equal to M; 
• if M is equal to 0.5 and three or more SC have a score higher than or equal 
to 1, then the CDR is 1; 
• if M is equal to 0.5, CDR cannot be zero; it may only be 0.5 or 1; 
• if M is equal to zero, then the CDR is zero unless two or more SC are higher 
than or equal to 0.5, then the CDR will be 0.5 [100–102]. 
 
CDR-Sum Box is the sum of the six cognitive parameters (i-vi) of the CDR. The 
values range from 0 to 18 points. A sum of 0 is classified as no cognitive impairment. 
The sum between 0.5 and 4 is the same as questionable cognitive impairment. There is 
still a subclass in the second step [103–106]:  
• the sum between 0.5 and 2.5 is classified as questionable impairment: 
• the sum between 3 and 4 classified as very mild dementia;  
• the sum between 4.5 and 9 is classified as mild dementia;  
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• the sum between 9.5 and 15.5 means moderate dementia;  
• the sum between 16 and 18 means severe dementia. 
  
Another important cognitive test is the Mini Mental State Examination (MMSE). 
The MMSE test evaluates orientation, information retention; attention and calculation, 
evocation and language. It was originally conceived in 1975 [107], and is accepted as a 
screening test for dementia. It has a maximum score of 30 points. It is divided into two 
parts. The first section evaluates verbal response on: time orientation (5 points), 
spatial orientation (5 points), memory (3 points) and attention and calculation (5 
points), and memory recall (3 points). This first section has a total of 21 points. The 
second section evaluates the ability to name objects (2 points), language (1 point), 
obeying commands (3 points), writing (1 point), reading and executing tasks (1 point), 
and the ability to copy a complex polygon (1 point). This second section has a 
maximum of 9 points. In 2009 a study was carried out, evaluating the cognitive 
performance based on MMSE but took into consideration the educational level of the 
Portuguese population [108]. Therefore, MMSE was adapted to the Portuguese 
population. 
MMSE is still used today. It has been a valuable tool for dementia screening 
[42,109], with a sensitivity range between 44 and 100% and a specificity between 46-
100% [34,110–113]. It has also been used to evaluate cognitive performance in 
response to treatments [113,114]. The main disadvantage is related to the second part 
of the tool, which requires accurate visual capability and writing skills. Therefore, 
patients with visual problems, low literacy or other language disorders may not be 
accurately evaluated at a cognitive level [115]. 
The Clock Drawing Test (CDT) is the third example, here discussed, for cognitive 
test screening.  CDT is considered as good criteria of cognitive screening instrument of 
dementia and for monitoring cognitive change. It is a good tool to assess motor skills 
and orientation [116]. It was initially implemented according to the assessment criteria 
proposed by Shuman [117]. The maximum score results from drawing a perfect 
clock/watch face (5 points). A score of 4 considers small visual and spatial errors: a 
slight inaccuracy in the spacing of hours; time drawn outside the circle: turning the 
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page to write the numbers so that the numbers appear upside down; drawing lines to 
guide time. A score of 3 refers to an inaccurate representation of the requested time 
even though, the visual and spatial representation is perfect, or has only minor 
deviations. A score of 2 refers to minor visual spatial clutter of time, so that the patient 
cannot indicate the requested time: showing inability to write numbers; drawing the 
numbers counter clockwise; repeating: the cycle continuing beyond 12, numbering the 
time as 13, 14, 15 and so on; omitting numbers, keeping a poor space between 
numbers. A score of 1 refers to severe disruption of those inabilities described for a 
score of 2. A zero score refers to no attempt at all, drawing something that does not 
look like a clock/watch or being unable to write numbers, writing a word or a name 
instead.  
The CDT is a widely used test for cognitive evaluation. It is easy to manage and 
quick to perform [116]. It has a good correlation with MMSE and other cognitive tests 
[118,119]. Further it is useful for evaluating temporal dementia deterioration [120–
122].  
There is, however, an arsenal of clinical trials for screening and diagnosing 
dementia. These include the Montreal Cognitive Assessment (MOCA), the Cambridge 
Computed Neuropsychological Testing Battery for Dementia Assessment, the 
Neuropsychiatric Inventory (NPI), among others, many of which can be found in the 
manual of Dementia Scales and tests for the Portuguese population [98]. In general, 
these tests evaluate the cognitive domains, and serve as important screening and 
diagnosing tools that have been internationally validated for use in clinical practice and 
for research application. 
In dementia, it is very important to assess the degree of dependence in 
patients. Dependence may exist when needing to perform basic activities of daily living 
(ADL) or instrumental activities of daily living (IADL) . The Katz index (KI) [123,124] is a 
widely used and validated instrument worldwide to evaluate performance of the ADL. 
ADL is a very useful tool to detect the patient’s skills in taking care of himself or 
herself, with respect to six functions: bathing, dressing, using the toilet, and controlling 
sphincters [123]. ADL can be classified into 3 categories: Independence (the patient is 
completely autonomous), Partial Dependence (the patient is partially dependent, 
performs activities not properly or with little difficulty) and Complete Dependence (the 
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patient is unable to perform any activity on his/her own). There is the possibility of 8 
different classifications: A- the patient is completely independent; B- the patient is 
independent in all activities, except in one; C- independent in all the previously 
mentioned activities, except bathing, and one other function; D- as criterion C, but also 
dependent with respect to dressing; E- as criterion D, but also dependent with respect 
to utilization of the toilet; F- as criterion E, but also dependent with respect to 
mobility; G- dependent for all 6 functions; Other- when there is no classification in C, D 
, E and F but with dependency on two activities.  
The ADL is a frequently used tool in research and by doctors in their daily 
consultations. This is because ADL helps physicians, caregivers and institutions to 
establish the patients’ needs [123,125–128]. 
Cognitive decline in instrumental activities of daily living (IADL) is part of the 
diagnostic criteria for dementia [31], discussed above. There is a correlation between 
IADL and dementia/AD evaluation [129]. The IADL analyses the skills/capacity and 
social independence of the patient (ability to use the phone, to do the shopping, to 
cook, to do the house shores, to take care of clothing, to move, to be responsible for 
taking medication, to be able to manage his/her own money) [129,130].  
It is important to determine whether the patient has or has not changed the 
performance with respect to instrumental activities. First, according to the DSM-5, it is 
used to separate the diagnosis of NCD-major (changes in IADL are observed) and NCD-
mild (changes in IADL are not observed). Secondly, it allows doctors, family and 
institutions to plan interventions depending on the degree of disability already 
reflected by the patient [131–134]. 
 
1.5 Depression  
Depression and dementia can be confused, as both can show similar signs and 
symptoms [49,135,136]. Although dementia is widely recognized as a characteristic 
age related problem, depression is more frequent [137], and a serious problem in the 
elderly. It reduces the quality of life and it can destabilize medically controlled 
comorbidities in the elderly. Depression was the most disabling disorder worldwide, 
measured in the number of years living with this disability [138]. Pooled prevalence 
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was 17.1% (95% CI 9.7–26.1%) for depressive disorders [139]. Alarmingly in Portugal, a 
study showed that about 33% of the general population presented depressive 
symptoms [140,141]. It is evident that improving Depression care quality is urgently 
needed, furthermore given that cases of depression can go undetected, many cases 
fail to receive minimally adequate treatment [29]. The frequent occurrence of clinically 
relevant depressive symptoms should be considered in health care planning [142], 
particularly at the point of care (primary care healthy).  
 
1.5.1 Definition  
Depression comprises a large, heterogeneous group of psychiatric disorders. 
The DSM-5 criteria for depressive disorders includes the group of pathologies that 
have as common characteristics the presence of sadness, emptiness, irritable mood, 
accompanied by somatic and cognitive alterations that significantly affect the capacity 
to function as an individual. What differs between the various disorders grouped in the 
depressive disorders are issues related to duration, timing, or presumed etiology. 
Bipolar Disorders [37] are not considered a subtype of depression, as was done so in 
DSM-IV. The diagnostic criteria for depression based on the DSM-5 are transcribed 
below. 
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Table 3 Criteria for depressive disorders according to the DSM-5 
 
 
The depressive disorders detailed in DSM-5 include disruptive mood disorder, 
major depressive disorder (including major depressive episode), persistent depressive 
disorder (dysthymia), premenstrual dysphoric disorder, substance/drug-induced 
depressive disorder, depressive disorder due to another medical condition, another 
specified depressive disorder and unspecified depressive disorder. This tool can be 
used in various healthcare settings, including the primary point of care. 
 
 
A. Five (or more) of the following symptoms present during the same two week period and represent 
a change from previous functioning; at least one of these symptoms is (1) depressed mood or (2) loss 
of interest or pleasure. 
 1. Depressed mood most of the day, almost every day, as indicated by subjective 
 report (e.g., feels sad, empty, and hopeless) or by observation by other people (e.g.,  
 seems tearful). (Note: In children and adolescents, it can be irritable.) 
 2. Decreased interest or pleasure in all or almost all activities most of the day, 
 almost every day (indicated by subjective report or observation made by others). 
 3. Significant weight loss or gain without dieting (e.g., a change of more than 5% of body 
 weight in a month), or reduced or increased appetite almost every day. (Note: In 
 children, consider failure to achieve expected weight gain.) 
 4. Insomnia or hypersomnia almost every day. 
 5. Psychomotor agitation or retardation almost every day (observable by other 
 people, not merely subjective feelings of restlessness or being slowed down). 
 6. Fatigue or loss of energy almost every day. 
 7. Feelings of worthlessness or excessive or inappropriate guilt (which may be 
 delusional) almost every day (not merely self-recrimination or guilt about being ill). 
 8. Decreased ability to think or concentrate, or indecision, almost every day (by 
 subjective report or observation made by other people). 
 9. Recurrent thoughts of death (not only fear of dying), recurrent suicidal ideation 
 without a specific plan, suicide attempt or specific plan to commit suicide. 
B. The symptoms cause clinically significant distress or impairment in social, occupational, or other 
important areas of life. 
C. The episode is not attributable to the physiological effects of a substance or other medical 
condition. 
Note: Criteria A-C represent a major depressive episode 
 
D. The occurrence of a major depressive episode is not better accounted for by schizoaffective 
disorder, schizophrenia, schizophreniform disorder, delusional disorder, other schizophrenia spectrum 
disorders and other specified psychotic disorders, or schizophrenia disorder and other unspecified 
psychotic disorder. 
E. There has never been a manic episode or a hypomanic episode. 
Note: This exclusion does not apply if all manic or hypomanic type episodes are substance induced or attributable to the 
psychological effects of another medical condition. Taken from [36]. 
DSM-5 Criteria for Depression 
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1.5.2 Causes and Associated Factors in Depression 
Depression has been shown to be associated with major life changes and stress, 
little or no social support, low socioeconomic status often aggravated by increased 
medical costs, female gender, age and family history of mental illness, chronic physical 
or mental disorders; leading to increased functional impairment and decreased quality 
of life [143].  
As mentioned, depression is a major health problem in women [144], and in 
Europe, the disease has a strong association with low educational level and the “not 
married” status [150]. The relationship between depression and compromised physical 
condition is also recognized [145]. There is a higher prevalence of major depressive 
disorder in patients with chronic medical illnesses. There is evidence in the literature 
that some comorbidities are directly correlated with depression: heart attacks, 
diabetes mellitus, chronic obstructive pulmonary disease, cancer, PD and pain 
[146,147]. Depressive symptoms occur in about 15 to 20% of cases following a 
coronary event [148]. Of note, 20% of patients with cerebral vascular stroke develop 
depression. The world health organization predicts that by 2020, depression will have 
outpaced the negative impacts of other diseases such as ischemic coronary disease, 
neoplasms and CVDs [149]. The pathophysiological explanation is based on the 
autonomic nervous system imbalance, with over sympathetic activity and low 
parasympathetic activity, with decreased cardiac rhythm variability, down regulation 
of beta adrenergic receptors, and decreased sensitivity of baroreceptors, increasing 
susceptibility to arrhythmias. Autonomic imbalance is an independent risk factor for 
cardiovascular mortality [150]. Additionally a significant genetic risk factor associated 
with depression has been identified; namely being an APOE ε4 carrier [151]. 
As mentioned there is a strong link between dementia and depression and in 
fact, post-stroke depression has been associated as a predictor of poor quality of life 
and risk of cognitive impairment [144]. Many elderly patients with major depressive 
disorder have cognitive and mood alterations, and memory loss [135]. The prevalence 
of depression in patients with AD is on average 17%, which may increase in patients 
with VaD [140]. Depression in PD is associated with increased physical disability, 
worsening of quality of life, and decreased social interaction [141].  
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The presence of comorbidities and cognitive alterations are two key factors for 
consideration in the diagnosis and management of depression [138]. It is well known 
that cognitive impairment may persist even after treatment for depression. This is 
probably due to the combined effect of age and depression on changes in the brain; 
such as atrophy and vascular disease. Some epidemiological studies have shown that 
depression appears to be a risk factor for cognitive impairment or dementia [152]. 
 
1.5.3 Testing for Depression using the Geriatric Depression Scale 
It is essential when screening for dementia to also have a test that can correct 
for depression. It is common a patient has dementia and depressive disorder together. 
Further confusion can arise as a given patient can exhibit both conditions as 
comorbidities [27,145,146].  
The Geriatric Depression Scale (GDS) was designed for the screening of 
depression in the geriatric population. Initially 30 items/questions were included [139]. 
It is a scale translated and adapted for several languages. This version has also been 
translated for use in Portugal [153]. GDS consists of questions that address personal, 
family and social factors with dichotomous responses [154–156]. Presently, the GDS 
with 15 questions (GDS15) is commonly implemented in primary health care situations 
[157]. The literature shows that GDS15 represents a useful, fast and reliable tool for 
the screening of depression in adults [156–158]. The questions in the GDS15 are 
described in table 4. 
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Table 4 Sample rating GDS15 
 
 
The GDS15 can be applied to screen for individuals with Depression. Of note, 
note all the criteria for Depressive disorders in the DSM-5 are contemplated in the 
GDS15 questions. Thus, care should be taken in not directly applying the GDS15 as a 
diagnostic tool. Depression is often encountered at the point of care and there is a 
heavy burden to appropriately diagnose and medicate these patients. The medication 
most often used for Depression is discussed in the section below; this is particularly 
relevance as the family clinician has, only in the last few years, been at liberty to freely 
medicate (with the participation of the health ministry) for this condition. 
 
1.6  Medication in the Geriatric Population 
Polypharmacy and Potentially Inappropriate Medication (PIM) use in elderly 
patients is an important question that physicians need to be aware of. People over the 
age of 65 have a higher prevalence of chronic illnesses, disability and dependency than 
younger counterparts [159]. The elderly often takes several drugs at the same time, to 
treat concomitant disease processes [160]. 
 
Geriatric Depression Scale-The questions 
1. Are you basically satisfied with your life? 
2. Have you dropped many of your activities and interests?  
3. Do you feel that your life is empty? 
4. Do you often get bored? 
5. Are you in good spirits most of the time? 
6. Are you afraid that something bad is going to happen to you? 
7. Do you feel happy most of the time? 
8. Do you often feel helpless? 
9. Do you prefer to stay at home, rather than going out and doing new things? 
10. Do you feel you have more problems with memory than most people? 
11. Do you think it is wonderful to be alive now? 
12. Do you feel pretty worthless the way you are now? 
13. Do you feel full of energy? 
14. Do you feel that your situation is hopeless? 
15. Do you think that most people are better off than you are? 
Taken from [158]  
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1.6.1 Polypharmacy 
Polypharmacy is applied in cases involving the use of five or more prescribed 
drugs [160]. The use of multiple medications, commonly prescribed to the elderly, 
leads to reduced compliance with drug treatment regimens and increased risk of 
adverse drug reactions [159]. Further, polymedication increases the risk of prescribing 
PIMs as well as the occurrence of harmful consequences [159]. Adverse drug reactions 
and polypharmacy represent major positive associations with morbidity and mortality, 
and are common among ambulatory geriatric patients and more than a quarter of 
them were preventable [160]. Additionally, and of relevance, the risk-benefit ratio is 
often extrapolated from the younger adults to the geriatric population; obviously this 
is not necessarily valid [161]. Not surprisingly, medication revisions, addressing the 
older population, resulted in a significant reduction of prescribed drugs (average 0.45 
drugs; 95%CI 0.11-0.76) [162]. Likewise, the need to develop and evaluate new 
strategies to reduce the risk of drug-related incidents in the geriatric patient 
population became evident [161,163,164]. In this respect, the Beers Criteria has 
become a significant resource to increase safe care, achieve quality improvement and 
obtain enhanced patient outcomes [162]. This is further discussed below. 
 
1.6.2 Potentially Inappropriate Medication 
In 1991, Dr. Beers and colleagues studied the use of safe and appropriate 
medications in older adults. This study was developed in patients admitted to a 
continuo care facility. Potentially Inappropriate Medication (PIM) was defined as the 
use of potentially inappropriate drugs whose use represents a risk greater than the 
benefit [161]. The work identified a set of drugs, or group of drugs, whose use may be 
classified as PIM in the elderly.  
The definition of PIM considers the following concepts:  
• does the risk outweigh the benefit;  
• over-prescribing: excessive dosage and/or duration of medications 
associated with polypharmacy;  
• mis-prescribing: is there an unfavourable choice of medication, dose, or 
duration;  
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• under-prescribing: not prescribing a clinically recommended 
medication, if the patient does not have any contra-indications for using 
the referred medication [163]. 
Each of the thirty (original set in 1991) Beers Criteria identifies a drug or class of 
drugs that are identified as potentially inappropriate and that are part of the ordinary 
prescription among doctors. They are: sedative-hypnotics, antidepressants, 
antipsychotics, antihypertensive, nonsteroidal anti-inflammatories, oral hypoglycaemic 
agents, analgesics, dementia treatments, platelet inhibitors, histamine blockers, 
antibiotics, decongestants, iron supplements, muscle relaxants, gastrointestinal 
antispasmodics and antiemetic’s. Applying the Beers Criteria is useful for reviewing 
quality assurance, health services research, and clinical practice guidelines. These 
criteria can be used to update and expand future guidelines [161]. 
In essence, the Beers criteria define medications that should generally be 
avoided in the ambulatory elderly patients, the doses or frequency of administration 
that should generally not be exceeded, and the medications that should be avoided in 
older persons who have known clinical conditions [163]. The Beers criteria have been 
used as a clinical guide. 
The Beers Criteria have evolved over time (Table 5). First established in 1991, as 
described above, in 1997, there was an update of the criteria by the same author. A 
panel of experts convened to expand the criteria for the elderly, and not only for those 
institutionalized (as for the 1991 version). This expert panel agreed on the validity of 
28 of the original 30 criteria for inappropriate use of medication in the elderly. In 
addition, this expert panel agreed on 35 additional criteria that define PIMs associated 
with conditions/diseases of the elderly [162]. 
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Table 5 Temporal evolutions of the Beers Criteria 
Year Criteria 
1991 Beers Criteria applied in elderly nursing home [161] 
1997 Revised and applied to older adults in the community [163] 
2003 Revised to include two categories of PIM [162]: 
 Medications that can be avoided 
 Medication that can be avoided based on the patients’ diseases/conditions 
2008 Applied Beers Criteria in the Portuguese Population[165] 
2012 Revised criteria [166] 
 
 
In 2003 (Table 5) the Beers Criteria were again updated [162]. The changes 
were as follows:  
1. Reserpine (Reserpine in doses>0.25 mg) was added to the list;  
2. The criteria encompassing oxybutynin was altered to include both the 
extended-release oxybutynin and the immediate-release formulation; 
3. Whereas previously all iron supplements>325 mg was considered, in the 
revision only ferrous sulphate is included;  
4. Only the short-acting dipyridamole is considered (Persantine- long-acting 
dipyridamole is not, which has better properties than the short-acting dipyridamole in 
older adults except in patients with artificial heart valves). 
 
In 2008, a Portuguese group operationalized the Beers Criteria in Portugal 
[165]. The study had 193 participants, the prevalence of PIM varied from 24% to 73%. 
The application of the criteria revealed that a high number of chronic medication 
usage was a common risk factor to have at least one PIM. Of the 1713 medications 
reviewed, 5.6-14.8% were considered PIMs [164].  
In 2012, Beers Criteria were revised to those used up until 2015. A set of tables 
(Tables 1-3 of the Beers Criteria) describing the Beers Criteria was developed (see 
Supplemental Tables 1-3 in annex 1). Table 1 of the Beers Criteria describes the 34 
PIMs and classes to avoid in older adults. Notably new additions include megestrol, 
glyburide, and sliding-scale insulin. Table 2 of the Beers Criteria shows potentially 
inappropriate medications and classes to avoid in older adults with certain disorders 
_______________________________________________________________________ 
_______________________________________________________________________ 
Departamento de Ciências Médicas/UA- 2017/201846 46 
 
and syndromes that the drugs listed can exacerbate. The change is that in 2012 there 
are new additions: thiazolidinediones or glitazones with heart failure, 
acetylcholinesterase inhibitors with history of syncope, and selective serotonin 
reuptake inhibitors with falls and fractures. Table 3 of the Beers Criteria indicated the 
medications that should be avoided or used with caution in patients above 75 years 
old. 
There are however other explicit criteria besides the Beers Criteria to evaluate 
medication usage. The table below summarizes the more commonly used methods 
(Table 6). 
 
Table 6 Explicit criteria to evaluate the use of medications 
Study (Year)  Explicit Criteria 
McLeod (1997)[167] Canadian Consensus panel list of PIM 
Rancourt Criteria (2004) [168] Developed by geriatrics research team in Canada with four potentially 
inappropriate categories: medications; duration; dosage; and drug-drug 
interactions. 
Lorache Criteria (2007) [169]  Similar Rancourter Criteria applied in France 
STOP/START [170] STOP criteria to detect PIM and START criteria to detect omission in the 
prescribing 
 
 
Of these the STOP/START is the most used. STOP means Screening Tool for 
Older Persons. These criteria have 65 indicators for PIM that include: interactions, 
contraindications, therapeutic duplication, medications that increase the risk of falls. 
These criteria consider various types of therapeutic strategies commonly used in 
clinical situations, of a cardiovascular, central nervous system, psychotropic, 
gastrointestinal, respiratory, skeletal muscle and urogenital nature, but also drugs that 
can induce falls and the use of analgesics. 
In addition to these studies, there are many others. The central objective is to 
apply evidence-based guidelines for avoiding commonly encountered prescribing 
related problems. In general, these goals are achieved through improving medication 
appropriateness, preventing adverse drug events and as a final result, reduce drug 
expenditure [170]. 
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1.6.3 Medicating for Dementia 
In the treatment of cognitive deficits, various types of dementias may be 
underlying the condition. Typical medications include cholinesterase inhibitors; those 
typically available include donepezil, rivastigmine and galantamine. These substances 
increase central cholinergic neurotransmission by inhibiting the decomposition of 
acetylcholine by acetylcholinesterase [88]. However, dementia is typically 
accompanied by non-cognitive symptoms such as agitation, anxiety and depression. In 
the treatment of agitation symptoms, conventional and atypical neuroleptics, 
benzodiazepines, trazodone, and anticonvulsants are effective [171]. 
The treatment of acute anxiety can be managed with benzodiazepine. 
However, if the patient continues to present an anxiety disorder for more than 4 
weeks, a change is recommended to the antidepressant selective serotonin reuptake 
inhibitors (SSRIs). This is so because dependence can develop with the chronic use of 
benzodiazepines [172]. 
In the treatment of depression, in patients with dementia, serotonin reuptake 
inhibitors are preferred, since anticholinergic drugs should be avoided. In patients with 
mood disorders or sub-types, mood stabilizing drugs or their variants may be 
prescribed, such as lithium or valproic acid [173]. 
 
1.6.4 Medicating for Depression 
A large range of drugs are available for managing depression: old and new 
tricyclics, tricyclics atypical antidepressants, reversible and irreversible monoamine 
oxidase inhibitors, SSRIs, selective serotonin and noradrenaline reuptake inhibitors 
(SNRI), noradrenaline reuptake inhibitors [174]. 
Special attention must be paid to interactions and side effects of these drugs. It 
is important for the clinician to master this subject to avoid inappropriate use of 
medication in the elderly population. For example: the major metabolic pathway 
associated with anti-depression drugs involves the enzymes of P450. Through the 
enzymes route 2C and 3A of this system, SSRI can inhibit the metabolism of 
benzodiazepines, calcium channel blockers and theophylline. Additionally, citalopram, 
escitalopram and sertraline should be preferentially indicated in the elderly because 
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they are the least involved SSRIs in the interactions of P450. The clinician should know 
that the side effects of tricyclics are due to ant muscarinic effects. This implies dry 
mouth, blurred vision, constipation, urinary retention and can lead to cardiac 
arrhythmias, so it is not a drug of choice in the elderly population [175]. 
In closing it is important to realize that increasingly the elderly require 
specialized care given their increased risk of dementia, depression and even PIM. 
Further the elderly is the most vulnerable and financially the frailest sector of society. 
Often their major means of health care are the primary health care centres. This 
dissertation considered some these major issues with the intent of being a useful 
contribution for clinicians at point of care.  
 
 
 
 
 
 
 
 
 
 
 
 
  
_______________________________________________________________________ 
 
_______________________________________________________________________ 
Characterization of the pcb-Cohort in the Aveiro region of Portugal 49 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
Study Framework and Objectives 
 
 
 
 
 
 
 
 
 
 
  
_______________________________________________________________________ 
_______________________________________________________________________ 
Departamento de Ciências Médicas/UA- 2017/201850 50 
 
 
 
_______________________________________________________________________ 
 
_______________________________________________________________________ 
Characterization of the pcb-Cohort in the Aveiro region of Portugal 51 
 
2.1 Framework 
Dementia is widely regarded as a public health problem. The incidence of 
dementia in Portugal has increased with the ageing of the population. This was not 
accompanied by a social conscience towards the special needs of the elderly or by a 
corresponding legal framework. Many elderly individuals with dementia live in 
isolation or with little family network. In essence they lose their autonomy, and run the 
risk of seeing their rights, their freedom and even their guarantee as individuals being 
questioned or violated [24] . 
Recognition of dementia at the primary point of care has been confirmed to be 
low in many studies conducted in high-income countries. Findings show that there is 
generally no structured program to identify putative dementia cases in a primary care 
setting and there is no evidence of general practitioner training for diagnosing 
dementia. This translates into limitations with respect to recognizing this condition in 
primary care practices [25]. 
In the Baixo Vouga region of Portugal there is a shortage of studies 
investigating the elderly, particularly with respect to dementia but also depression at 
the primary point of care. From a practical viewpoint it is important to compare the 
various methodologies readily available to identify putative at-risk cases with respect 
to cognitive impairment and depressive status. To do so, a primary care-based cohort 
(pcb-Cohort) was established and characterized with respect to cognition and 
depression in the Aveiro region. It was also possible to collect blood from volunteers, 
thus genotyping for APOE (a well-established risk factor for Alzheimer’s disease) was 
carried out. 
Another essential aspect at the primary point of care is to look at ways of; 
increasing safe care, achieving quality improvements and obtaining enhanced patient 
outcomes. Additionally, the elderly is often, due to frail physical conditions, subjected 
to polypharmacy, thus the Beers Criteria can be used as a significant resource. In this 
respect the number of Potential Inappropriate Medications (PIMs) and polypharmacy 
in individuals in the pcb-Cohort were identified. 
The data presented is expected to provide a valuable profile of patients 50 
years of age or older in the Aveiro region with respect to dementia, depression and 
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PIM. A 50-year-old cut-off is important to identify putative cases as early as possible 
and the family physician is in an ideal position to do so. In other words, it is important 
to identify at risk cases prior to being considered elderly. It is expected that the data 
produced will be a valuable tool, for family physicians. 
 
2.2 General Goal: 
To establish a primary care based cohort (pcb-Cohort) focussing on the primary 
point of care and to test tools to characterize the functional capacity and the 
prevalence of dementia and depression in this sub-population, as well as patterns of 
medication usage in individuals 50 years old or more. 
 
2.3 Specific Objectives: 
1. To establish a cohort of individuals based on the primary point of care (pcb-
Cohort); 
2. To implement a 'pcb-Cohort' of individuals 50 years old or more, in the Baixo 
Vouga region; 
3. To assess the functional ability of the participants in performing Daily Living 
Activities and Instrumental Activities of Daily Living; 
4. To determine the putative dementia and depression prevalence and that of 
other comorbidities in the population under study; 
5. To explore the feasibility of shorter GDS versions (including fewer questions); 
6.  To genotype the pcb-Cohort for APOE (the highest genetic risk factor for 
Alzheimer’s Disease, thus far shown) and to assess any forthcoming 
correlations with cognitive impairment and other comorbidities; 
7. To profile prescription drug usage in the pcb-Cohort; 
8. To identify prevalence of polypharmacy and analyse the factors associated with 
polypharmacy and PIM (Potentially Inappropriate Medication). 
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3.1 Study Design 
A cross-sectional population-based survey on a Portuguese volunteer group, in 
the Aveiro district, was carried out. The intent was to develop a cohort of patients 
attending primary health care; a primary care based cohort (pcb-Cohort). Prior to 
initiating the project, approval for the study was sought and obtained from ARS (see 
annex II). A first consideration when developing a study of the type here presented, is 
the number of individuals that should be included. The Aveiro district had 78450 
habitants in the 2011 CENSUS (in www.ine.pt), and the target size should include at 
least 480 individuals [176]. The study here presented involved 590 individuals (568 
fulfilled the criteria). Of the 22 participants excluded, 9 were less than 50 years old, 12 
were aphasic and could not communicate to fill in the questionnaires and 1 did not 
complete the questionnaire. 
As a first step, a meeting was held with representatives of the primary health 
care centres (Representantes do Agrupamento de Centros de Saúde do Baixo Vouga). 
The study was presented, and participations were encouraged. Five primary health 
care centres were randomly chosen. Individuals attending the respective point of care, 
aged 50 years or older, were invited to participate. Volunteers were extremely willing 
to participate and readily came forward. Participants, many accompanied, provided 
written informed consent, individuals unable to give consent were excluded. 
The study involved four stages (Figure 3). Participants completed a structured 
interview covering their respective life history, general health and well-being. Next, 
cognitive evaluations and dementia screening tests were performed (stage 1). For 
practical reasons, and to avoid recalling participants, blood was collected during stage 
1 (it was used for genotyping, stage 3). In stage 2, the clinical data available from 
clinical records, including comorbidity information were scored. Participants were 
genotyped for APOE (stage 3). In stage 4, analyses of the data collected were carried 
out blind to the data from the other stages. All data collected for each participant were 
evaluated with the Statistical Package for the Social Sciences (SPSS) [177]. 
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Figure 3 Experimental workflow 
Approach used to study the pcb-Cohort. Stage 1: a structured questionnaire was applied to patients 50 years or 
older in primary care in the Aveiro district, Portugal. Stage 2: cognitive testes were carried out, and information 
regarding clinical records collected. Stage 3: blood was collected for APOE genotyping. Stage 4: data was organized 
in SPSS; bivariate and multivariate analyses were performed.  
 
3.2 Inclusion and Exclusion Criteria 
Volunteers were admitted, independent of complaints or deficits in any 
cognitive domain. Mandatory inclusion criteria to be 50 years or older was observed. 
Individuals undergoing oncological treatment, diagnosed with psychiatric disorders 
(excluding depression), aphasia, or unable to answer the questions in the structured 
interview were excluded. To ensure generalizability, exclusion criteria were kept to an 
absolute minimum.  
Volunteers meeting the above criteria signed an informed consent, the research 
was explained, its consequences and the possibility to leave the study at any time were 
guaranteed, without prejudice to the participant. Confidentiality was assured. The 
study is part of a project approved by the ethics committee for health of the Central 
Regional Administration in Coimbra (Comissão de Ética para a Saúde da ARS Centro, 
protocol 012804-04.04.2012), and by the National Committee for Data Protection. 
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3.3 Clinical Interview 
Data collection for the clinical interview, Stage 1 (Figure 3) initiated with a 
structured interview and was then followed up by a cognitive evaluation (see annex 
III). Of the 590 volunteers, 568 fulfilled the inclusion criteria. Participants underwent a 
semi-structured questionnaire addressing sociodemographic characteristics, personal 
and family history. Data concerning medication usage was also collected, but this is 
further discussed below. 
For data analyses by the SPSS, participants in the pcb-Cohort were stratified 
according to age. The following groupings were used: patients from 50 to 64 years old, 
those from 65 to 74 years of age, and finally patients over 75 years old. Education level 
was categorized into three groups: less than 2 years of schooling, from 3 to 6 years of 
schooling, and more than 7 years of schooling. Relative to marital status, subdivisions 
were: patients living with a partner and other situations. For professional status the 
following were considered: active, reformed and unemployed. In terms of monthly 
family income two subgroups were defined: earning less or equal to 1 minimum wage 
and more the one minimum wage. 
During the structured interview (Stage 1, Figure 3) patients were asked if they 
were affected by other comorbidities. Comorbidities scored were: hypertension (HYP), 
dyslipidaemia (DYS), osteoarticular disease (OA), cardiac and vascular disease (CVD), 
depressive disorder previous diagnostic (DEP), gastrointestinal disease (GID), 
genitourinary disease (GUD), diabetes mellitus (DM), respiratory disease (RESP), 
haematology disease (HEMATO), oncology disease (ONCO), neurodegenerative 
diseases (NEURO) and excessive alcohol use (ALCOHOL). The answers were validated in 
Stage 2 (Figure 3) by consulting the clinical records; only the comorbidities identified in 
the clinical records were accepted, this is further described below. For purposes of 
data analyses by SPSS the presence of a given comorbidity in a given individual was 
organized as a Yes/No answer in the SPSS. 
The clinical interview also comprised cognitive evaluation tests (Figure 3). 
Cognitive evaluations and dementia screening tests, irrespective of the clinical 
diagnosis, were performed during the clinical interview. These included CDR [100], 
Mini Mental State Examination (MMSE) [178], Geriatric Depression Scale (GDS) [139], 
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Katz Index to study of Activities of Daily Living (ADL) [128] and Instrumental Activities 
of Daily Living (IADL) [130,179]. The tests CDR, MMSE, GDS and IADL had all been 
previously standardized for the Portuguese population [98,108]. The methodology 
used for each of these tests is well established and was presented in the introduction 
and their application in the pcb-Cohort is described below in the order in which they 
were applied to the participants during the clinical interview.  
 
3.4 Validating Comorbidities 
Access to clinical data compiled by physicians and health professionals, was 
made possible via collaboration with the medical staff at all the sites. Clinical data was 
pooled, and comorbidities confirmed and scored, other relevant information was also 
registered. These results are based on the international disease code that is recorded 
in the patient's computerized clinical files.  
Pathologies indicated by the participants were further validated, by cross-
referencing with the medical files. For individuals scoring positive for arterial HYP this 
was also validated, by confirming that they fulfilled the General Direction of Health 
(Direcção Geral de Saúde-DGS) guidelines for HYP ("Arterial Hypertension: definition 
and classification", Nº 020/2011 of 09/28/2011 with update on 3/19/2013) [10]. A HYP 
diagnosis is defined as the persistent elevation of systolic blood pressure (SBP) equal to 
or greater than 140 mmHg and / or diastolic blood pressure (DBP) equal to or greater 
than 90 mmHg in several temporally distinct measurements, with a level of evidence 
“A”, degree of recommendation “I” [180]. 
The second comorbidity re-evaluated according to the DGS standards was DYS. 
The latter involves evaluating for total cholesterol, HDL cholesterol, and triglycerides, 
following a 12-hour fasting period and subsequently at a minimum interval of 4 weeks 
the laboratory analyses should be repeated. Only then should therapy be initiated. It is 
important to rule out secondary and frequent causes of DYS. Patients scoring positive 
for osteoarticular disease (OA) had to meet clinical and/or imaging criteria for 
orthopaedic, rheumatologic and bone diseases. Regarding depression, the study was 
not designed for detailed application of all the DSM-5 criteria. Effectively the clinical 
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history of the participants and whether they were using antidepressants, of any class, 
for purposes other than symptoms of depression was checked.  
Regarding diseases of the cardiovascular system, in the work here presented, 
these were all grouped (cardio pathologies, cardio arrhythmias, myocardial infarction, 
acute coronary syndrome, coronary revascularization or other arterial 
revascularization procedure, ischemic stroke, peripheral arterial disease). 
Cardiovascular risk was not investigated and therefore these individuals are not 
specifically addressed in the study.  
Another relevant comorbidity to the study here described is diabetes. Standard 
references for diabetes diagnosis rely on the following parameters for plasma in the 
general population [181]: 
a) Fasting glycaemia ≥ 126 mg / dl (or ≥ 7.0 mmol/l); or 
b) Classic symptoms + occasional glycaemia ≥ 200 mg / dl (or≥11.1 mmol/l); or 
c) Glucose ≥ 200 mg / dl (or ≥ 11.1 mmol/l) at 2 hours in the glucose tolerance 
test with 75g of glucose; or 
d) Glycated haemoglobin A1c (HbA1c) ≥ 6.5%. 
Thus, for individuals in the pcb-Cohort, involved in this study they were only 
scored positive for diabetes if one or more of the above parameters was fulfilled. 
Additionally, individuals with glucose intolerance were also scored positive for this 
work. 
Gastrointestinal diseases (GID) were enumerated according to endoscopy and 
colonoscopy results, which were available for the volunteers; in addition to the 
analysis of the complaints in the consultations by the attending physicians. Special 
attention was given to dyspepsia. This pathology obeys the criteria of ROMA II and 
ROMA III [182,183] . Briefly, dyspepsia is described as chronic or recurrent pain, 
burning or discomfort with unpleasant subjective sensation, which may be associated 
with early satiety, postprandial embankment, nausea, vomiting, bloating, abdominal 
distension, located in the upper abdomen, with the absence of probable organic 
disease justifying the symptoms and absence of evidence that the symptoms improve 
or are associated with changes in the rate or characteristics of intestinal bowel 
movements. In addition, the symptoms have a minimum duration of 3 months (12 
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weeks), continuous or intermittent, and present at least for 6 to 12 previous months of 
history according to the ROMA II and III consensuses [182,183]. Therefore, in the group 
of diseases of the gastrointestinal tract are grouped dyspepsia, esophagitis, gastritis, 
duodenitis, inflammatory bowel diseases, diverticulosis, diverticulitis and anusitis. 
The clinical files of the patients were thoroughly investigated. All other 
comorbidities were scored positive based on a previous diagnosis with confirmation by 
a specialist in the reference hospital for the Aveiro Region. Comorbidities not 
confirmed were not included when scoring for the prevalence of the different diseases.  
 
3.5 Applying the CDR and MMSE tests 
Following the structured interview, the cognitive evaluation was performed 
(Figure 3) initiating with the CDR test. For this test a series of questions were asked to 
the participant taking six parameters into account, as described in the introduction 
(memory, orientation, capacity to resolve problems, activities in the community, 
activities at home and personal care). An example of the exact questionnaire used can 
be found in annex III. The questionnaire has been well validated and standard scoring 
procedures were applied. To summarize, a 0 to 3 score was applied [98,100] also 
explained in detail in the introduction, where 0=Normal, 0.5=suspect, questionable or 
very mild dementia, and CDR≥1 (1, 2, 3) that is mild, moderate and severe dementia. 
The individual patient scores were submitted for SPSS for analyses. The results 
obtained are shown in the results chapter. The MMSE was also applied and scored 
from 0-30 [107]. Cut-offs were set, based on normalization for the Portuguese 
population [108]: 0-2 years of literacy cut-off 22; 3-6 years of literacy cut-off 24; ≥7 
years of literacy cut-off 27. Those equal to or below the cut-off were scored as having 
cognitive deficit, those above the cut-off as normal. The procedures are well validated, 
as described in the introduction. 
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3.6 Applying the GDS 
Following the structured interview, the patients underwent another screening 
test (Stage 1, Figure 3): the 15 item Geriatric Depression Scale (GDS15) [157]. Standard 
procedures, described in the introduction (Table 4), were employed. For the actual 
questionnaire implemented please refer to annex III. 
Briefly: GDSQn corresponds to the number of the question in the original 
GDS15 questionnaire. The questions in the original scale are explained in table 4 
(Introduction): GDSQ1 (Q1=question 1)- Are you basically satisfied with your life?; 
GDSQ2- Have you dropped many of your activities and interests?; GDSQ3- Do you feel 
that your life is empty?; GDSQ4- Do you often get bored?; GDSQ5- Are you in good 
spirits most of the time?; GDSQ6- Are you afraid that something bad is going to 
happen to you?; GDSQ7- Do you feel happy most of the time?; GDSQ8-  Do you often 
feel helpless?; GDSQ9- Do you prefer to stay at home rather than going out and doing 
new things?; GDSQ10-  Do you feel you have more problems with memory than most?; 
GDSQ11- Do you think it is wonderful to be alive now?; GDSQ12- Do you feel pretty 
worthless the way you are now?; GDSQ13- Do you feel full of energy?; GDSQ14- Do 
you feel that your situation is hopeless?; GDSQ15-  Do you think that most people are 
better off than you are? 
The score of this scale ranges from 0 to 15. The quotation GDS15 is: 1 point for 
the answers "Yes" in the questions 2,3,4,6,8,9,10,12,14,15; 1 point for the answers 
"No" in the questions: 1,5,7,11,13. The final score indicates the number of depressive 
symptoms. Scores 0-4 are considered normal; 5-8 indicate Mild Depression; 9-11 
indicate Moderate Depression; and 12-15 indicate Severe Depression [184,185].  
For experimental purposes other analyses of the GDS were performed. Among 
these was the shorter version considering 4 items (4 questions – question 1, question 
3, question 6 and question 7, from the GDS15 question list above). This shorter version 
was previously proposed in the literature (GDS4Lit) as a short tool to screen for 
depression [186] . The score in the GDS4Lit is from 0-4, where the cut off is 1. That is 
scores 2-4 are indicative of a depressive state, whereas 0 and 1 are indicative of a non-
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depressive status. In the study here presented other GDS shorter versions, considering 
fewer questions, were likewise explored, as explained in the results section.  
 
3.7 Applying the ADL and IADL tests 
Also during the clinical interview participants in the pcb-Cohort were scored 
with respect to ADL using the Katz score [128] and IADL [129]. For the ADL, questions 
were asked following a standard questionnaire (see annex III) and scoring was as 
follows: A to G, where A is independent, with an increasing dependence, to G which is 
dependent for all activities. For analytical purposes individuals were divided into two 
groups; independent (those scoring A) and denoted a 0 in the SPSS or dependent (all 
others B-G) and denoted a 1 in the SPSS. 
For the IADL, questions were asked following a standard questionnaire (see 
annex III). Scoring observed a validated scale of 8-30, where 8 reflects independent 
individuals for all activities, 9-20 means moderate dependence and more than 20 
means severe dependence. For analytical purposes individuals were divided into two 
groups; independent (those scoring 8) and denoted a 0 in the SPSS or dependent (all 
others) and denoted a 1 in the SPSS. 
 
3.8  Applying the DSM-5 
Subsequently, to add further clinical relevance to the data collected the DSM-5 
was applied to identify profiles consistent with cognitive deficits. For cognitive 
impairment the criteria applied were as identified in table 1 (Introduction). The 
quantitative test applied for fulfilling one of the stipulated criteria DSM-5 was the CDR. 
In summary, individuals in the pcb-Cohort were profiled as exhibiting no deficit, mild or 
major neurocognitive disorder in line with DSM-5 (entered as 0,1 or 2 respectively in 
the SPSS). These values were used for comparative purposes and are presented in the 
results chapter. 
For DSM-5 to evaluate depressive disorders, the criteria applied should be as 
identified in table 3 (Introduction). These criteria consider the number of seizures, at 
least two, and duration of symptoms, which must be at least 2 weeks and usually, 
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tends to be recurrent. Unfortunately, the original survey did not provide all the 
questions that were sufficient to apply the criteria for depressive disorders based on 
the DSM-5. Therefore, in the pcb-Cohort, a diagnosis of depression was accepted only 
when given by the family doctor with the support of the external consultation of 
psychiatry in the reference hospital of the region. 
 
3.9  Blood Collection and Genotyping 
Of the 590 participants, 508 provided a blood sample upon arrival and prior to 
the interview (Figure 4). For each volunteer, blood was collected into 3 EDTA-tubes 
(whole blood, and for serum and plasma processing; 3+5+5ml respectively), according 
to standard procedures. Samples were immediately aliquoted and frozen at-80°C. 
 
 
Figure 4 Study design for APOE genotyping 
A total of 590 volunteers participated. Having applied the inclusion and exclusion criteria, 568 patients remained. 
From these only 508 provided blood samples. APOE: Genotyping for Apolipoprotein E allele’sε2,ε3 andε4 was 
carried out. 
 
APOE genotyping (Figure 4) was carried out by blood direct PCR using a modified 
Phusion Hot Start II High-Fidelity DNA Polymerase (Phusion Blood Direct PCR Master 
Mix, Thermo Scientific). Briefly, PCR of the APOE polymorphic regions was performed 
using 1-2μL of whole blood from each patient, 2x Phusion Blood Direct Master Mix 
Genotyping
N= 508 
Exclusion Criteria:
* < 50 years old: N= 11
* Psychiatric Disorders 
(except depression): N=0
* Ilicit drugs: N=0
* Oncology treatment in 
date of study: N=0
* Incapacity to asnwer 
questionary: N= 11
Volunteers
pcb-Cohort
N = 590
N = 568
N= 508
APOE ε 2
carriers 
N= 38 (7.5%)
APOE ε 3 
carriers 
N= 494 (97.2%)
APOE ε 4 
carriers 
N= 96 (18.9%)
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(Thermo Scientific), 1M betaine (Sigma-Aldrich) and 0,5μM of each primer (APOE-Fw 
5’-CGGGCACGGCTGTCCAAGGAG-3’ and APOE-Rev 5´-CACGCGGCCCTGTTCCACCAG-3´). 
PCR conditions were: 98°C for 5min; 35 cycles of 98°C for 1s, 64°C for 5s and 72°C for 
15s; and a final extension step at 72°C for 1min. This reaction yields a 303 bp PCR 
product. Following purification with sodium acetate (3M, pH5.2) the resulting products 
were sequenced with the APOE-FW primer. Results were analysed to determine the 
nucleotide polymorphisms and the respective APOE genotype. 
For the study design, the number of volunteers, and the APOE frequencies in the 
pcb-Cohort were 590 and 508, respectively and this numbers were representative to 
population of the Aveiro district (the total population is 78450 habitants) [187,188]. 
 
3.10   Medication Usage 
 
3.10.1 Study Design 
The study design for medication usage in the pcb-Cohort is depicted in Figure 4. 
The pcb-Cohort has been extensively characterized and this data has been published 
[189]. Of the 590 volunteers, 366 participants fulfil the Beers Criteria (are 65 years old 
or more) and official records were available for 361 of those patients. 
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Figure 5 Study design for medication usage in the pcb-Cohort 
A total of 590 volunteers from the Aveiro Region (Baixo Vouga), Portugal, participated. Beers Criteria were applied 
to individuals above 65 years old. In this cohort, there are 366 patients ≥ 65 years old fulfilling the criteria. Details 
on medication usage were available for 361 of these participants. Official records were considered for the last 3 
months of medication use, prior to data collection.  
 
The medications used by the pcb-Cohort patients were searched in the medical 
record of each patient. Drugs used over the last three months prior to the data 
collection were considered. For all subjects, a careful review of the computerized 
medical histories and the prescription records was performed. The Regional Health 
Care System made the official information available. Information regarding chronic 
medication use was possible for 361 patients. 
 
3.10.2 Instruments 
Standard questionnaires, were as already described and as reported in Rosa IM 
et al [189], regarding sociodemographic characteristics, clinical information and 
cognitive tests the above mentioned instruments were used to collect the data. Beers 
Criteria were applied to search for PIM (Potentially Inappropriate Medication) within 
the pcb-Cohort. 
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3.11 Statistical Analyses 
In all stages of the statistical analyses, the database was organized and 
analysed using SPSS version 25. P-value<5% was considered to determine significance. 
Categorical variables were assessed through examination of frequencies, while 
continuous variables were assessed through generation of descriptive (means, 
standard deviations) methods to investigate the differences in the group (CDR, 
cognitive performance, depression groups, APOE carriers, polypharmacy, PIM use vs. 
normal groups).  
 
3.11.1 Bivariate Analysis 
Group comparisons for demographic, clinical, and global cognitive variables 
were performed with analyses of variance (ANOVAs) and independent samples t tests 
or Chi square (χ2) tests, as appropriate. The correlations’ analyses were carried and 
adjusted based on the Bonferroni methods. This method was used to initially compare 
all the mainly variables.  
 
 
3.11.2 Multivariate Analysis 
After bivariate analysis of the data, the multivariate analysis was performed. 
For the dichotomous dependent variables (such as GDS and medication analysis), 
logistic regression was used. For dependent variables with more than three 
characteristics, multinomial regression was employed (such as CDR study and 
neurocognitive disorder study). In the statistical processing of the data through 
multivariate analysis by multinomial regression or logistic regression, the Odds ratio 
(OR) is generated. This ratio, when greater than 1, indicates a risk factor. If this ratio is 
less than 1 and greater than zero, it indicates protective factor. In our study, this 
methodology was used to identify the risk factors/protective factors involved with 
neurocognitive disorder.  
OR was calculated for the parameters evaluated. Both AIC- Akaike's information 
criterion and BIC- Schwarz's Bayseian criterion, were calculated based on the log 
likelihood ratio (-2 Log L) to reflect the model’s mediocrity. The final model proved to 
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be preferable to the null model [177]. A two-sided statistical test was carried out, and 
differences were significant if p<0.05. 
 
3.11.2.1 Multivariate analysis in CDR and DSM-5 evaluation 
The multivariate methods used for data processing was Multinomial Regression 
Analyses (MRA). MRA was performed using selected main characteristics as predictor 
variables for dementia (CDR=0.5 and CDR≥1) versus control status (CDR=0). This 
methodology was also used in data processing when the DSM-5 criteria were applied 
to classify neurocognitive disorders. 
 
3.11.2.2 Multivariate analysis in GDS evaluation 
For the GDS evaluation, the multivariate methods used was Logistic Regression, 
by the Enter method, as described in Maroco, 2011 [177] for the characterization of 
depression status in pcb-Cohort. To evaluate the significance of the sociodemographic, 
clinical and genotypic variables here studied, the quality of the fitted model employed 
the Hosmer-Lemeshow Goodness of fit statistic (p>0.05) was used. The contribution of 
variables for the construction of the model were examined by 2-log-likelihood 
(p<0.05). The OR with 95% confidence intervals (CI95%) was computed. 
In case of the depression study, the frequency of depression suggestive 
responses for each specific item on the GDS15 scale was calculated. The questions in 
which at least 50% of respondents presented positive responses, consistent with 
depression, were registered.  
 
3.11.2.3 ROC curve, sensibility, specificity, predictive positive value, predictive, 
negative value 
In statistical analysis, Receiver Operating Characteristic (ROC) analysis is a 
powerful tool for measuring and specifying problems in medical diagnostic 
performance [177]. This analysis by means of a simple and robust graphic method, 
allows studying the variation of the sensitivity and specificity, for different points of 
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cut. The area below the ROC curve is associated with the discriminant power of a 
diagnostic test.  
• Sensitivity (S) is the probability of a test positive in the presence of the 
disease, that is, assesses the ability of the test to detect disease when 
it is present.  
• Specificity (E) is likely to give a negative test in the absence of the 
disease, so it evaluates the ability of the test to ward off the disease 
when it is absent.  
Other statistical parameters that are can be calculated from the sensitivity 
and specificity of a test are: Positive predictive value (PPV) and Negative predictive 
value (NPV).  
• PPV is the ratio of true positives among all positive test subjects. PPV 
expresses the likelihood that a patient with the positive test will have 
the disease.  
• Negative predictive value (NPV): is the proportion of true negative 
among all individuals with negative test. NPV expresses the likelihood 
that a patient with the negative test will not have the disease. 
If a test is more sensitive, the greater its negative predictive value (greater 
safety of the doctor that the person with the negative does not have the disease). If a 
test is more specific, the greater its positive predictive value (greater safety of the 
doctor that the person with the positive has the disease).  
The ROC curve compares the true positives to false positives. This curve 
indicates the sensitivity on the y-axis as a function of a false positive (1-specificity) on 
the x-axis. The area under the curve (AUC) is a useful statistical summary for 
determining the accuracy of the proposed scales. A maximum score is 1; this indicates 
100% true positive and 0% a false negative. The discriminating power of a diagnostic 
test is associated to the area under the curve (AUC) and the larger the area, the better 
the diagnosis test. The classification of the accuracy of the AUC: 0.9-1=excellent; 0.8-
0.9=good; 0.7-0.8=fair; 0.6-0.7=poor; 0.5-0.6=fail [177]. Along with the ROC curve, all 
the coordinate points of the curve are also obtained. These points are useful for 
evaluating the best cut-off point for determining the positive and negative test results. 
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The choice of cut-off point will be decided by the need to increase sensitivity or 
specificity. It should be noted that the values of the table obtained with respect to the 
coordinates of the curve represent the best orientations for which we should consider 
the points of cuts of the short scales.  
In this thesis, the ROC curve analysis was used to evaluate the accuracy based 
in sensibility, specificity, Positive predictive value and Negative predictive value (Figure 
8, Figure 11 and Table 30). 
 
3.11.2.4 Multivariate analyses in medication evaluation 
For the medications usage study, a descriptive analysis of the results was 
performed by comparing the above-mentioned parameters with Tables 1-3 of the 
Beers Criteria (Annex I, supplementary Tables 1-3). Chi-Square was used to compare 
between qualitative characteristics and Student’s t-test and ANOVA were used to 
study the average results. Pearson correlation was applied to compare the number of 
medications used and PIM. The risk of PIM and polypharmacy were calculated using 
the odd ratios from the logistic regression. 
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4.1 Cognitive Evaluation of the pcb-Cohort 
The socio-demographic, clinical and genotypic characteristics as a function of 
the cognitive test scores were evaluated using the procedures described in the 
methods section.  The DSM-5 criteria were subsequently applied to further analyse the 
results obtained. All the methods applied are detailed in chapter 3, examples of the 
questionnaires can be found in Annex III and the results are presented below. 
 
4.1.1 Cognitive Evaluation 
 The pcb-Cohort includes 590 volunteers; this reduces to 568 participants upon 
applying the exclusion criteria, as indicated in the methods chapter. Subjects, 50 years 
old or more, were grouped (Table 7) with respect to CDR scores: CDR=0, 53% (N=301); 
CDR=0.5, 35% (N=199); and CDR≥1, 12% (N=68). The correlations between CDR test 
scores, and the other tests carried out, MMSE, depression (GDS) and the evaluation of 
activities of daily living (AIDL and ADL) are shown in table 7.  
Results for the MMSE, AIDL and ADL are all expressed as a function of the 
grouped CDR scores (Table 7); all show a significant positive correlation. Overall, the 
CDR test identifies more putative dementia cases than the MMSE test (68 versus 54 
positive cases, respectively). In the pcb-Cohort it appears that AIDL is more sensitive 
than the ADL (176 versus 31 dependent individuals respectively). GDS+ patients exhibit 
increasingly higher CDR scores compared to GDS- cases (GDS+ and CDR=0, 51/301 
(16.9%); CDR=0.5, 87/199 (43.7%); and CDR≥1, 36/68 (52.9%) compared to GDS- and 
CDR=0, 250/301 (83%); CDR=0.5, 112/199 (56.3%); and CDR≥1, 32/68 (47%). AIDL and 
ADL percentages of independence, decrease with increasing CDR. To summarize, 
higher CDR scores correlate significantly with positive MMSE and GDS scores, and 
increasing dependence as determined by AIDL and ADL. 
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Table 7 Cognitive evaluation of the pcb-Cohort based on the CDR 
 
Abbreviations: CDR-Clinical Dementia Rate; MMSE-Mini Mental State Examination; GDS-Geriatric 
Depression Scale; IADL-Instrumental Activities Daily Life; ADL-Katz Indices to Basic Activities Life. For 
scores and cut-offs, see methods. ∗
 
Statistical Test: χ2-Chi square test; Statistical Test Association: 
Cramer´s V; The superscripts letters: 
a,b,c
 the same subscript letter denotes a subset of CDR categories 
whose column proportions do not differ significantly from each or at the 0.05 level. Different subscript 
letters denote column proportions which differ significantly from each other at the 0.05 level. In bold, 
the p-value<0.05. % is expressed as a function of the total sample size (568 volunteers). 
 
 
4.1.1.1 Sociodemographic characteristics 
The pcb-Cohort was profiled with respect to sociodemographic characteristics. 
In the pcb-Cohort 71.3% of the participants are female, the relative gender proportion, 
does not change significantly with the different CDR score (68.4%, 77.4% and 66.2%, 
for scores of 0, 0.5 and ≥1 respectively), (Table 8). 
For different parameters, significant differences are evident when the cohort is 
grouped by age. In the age group 50 to 64 years, 64 individuals (32.2%) score CDR=0.5. 
This is a significant at risk group that should be monitored. Likewise, a younger but 
smaller group, the 10.3% (7 individuals) with a CDR≥1 and less than 65 years old, 
represent potential early onset cases of dementia and should also be closely 
monitored. Consistently, mean age increases significantly with increasing CDR score 
from 65.8±8.9, to 67.7±8.5 to 75.4±8.5 (Table 8). 
For the pcb-Cohort ‘Living Arrangement’, is not significant with respect to 
performance based on the CDR. Marital and Professional Status, have moderate 
significance and Monthly Family Income is statistically significant (=0.057) Of note 
Cognitive Tests 
CDR=0 
N=301 
CDR=0.5 
N=199 
CDR≥1 
N=68  
 Cramer’s V p-value* 
MMSE 
MMSE- 
N=514 (90.5%) 
295
a
 
(51.9%) 
187
a
 
(32.9%) 
32
b
 
(5.6%) 
0.550 <0.001 
MMSE+ 
N=54 (9.5%) 
6
a
 
(1.1%) 
12
a
 
(2.1%) 
36
b
 
(6.3%) 
GDS 
GDS- 
N=394 (69.4%) 
250
a
 
(44.0%) 
112
b
 
(19.7%) 
32
b
 
(5.7%) 
0.321 <0.001 
GDS+ 
N=174 (30.6%) 
51
a
 
(9.0%) 
87
b
 
(15.3%) 
36
b
 
(6.3%) 
AIDL 
Independent 
N=392 (69.0%) 
242
a
 
(42.6%) 
127
b
 
(22.4%) 
23
c
 
(4.0%) 
0.325 <0.001 
Dependent 
N=176 (31.0%) 
59
a
 
(10.4%) 
72
b
 
(12.7%) 
45
c
 
(7.9%) 
ADL 
Independent 
N=537 (94.5%) 
299
a
 
(52.6%) 
191
b
 
(33.6%) 
47
c
 
(8.3%) 
0.418 <0.001 
Dependent 
N=31 (5.5% ) 
2
a
 
(0.4%) 
8
b
 
(1.4%) 
21
c
 
(3.7%) 
Abbreviations: CDR-Clinical Dementia Rate; MMSE-Mini Mental State Examination; GDS-Geriatric Depression Scale; IADL-Instrumental Activities Daily 
∗
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19.1% (13 individuals) scoring CDR≥1 are part of the active population (Professional 
Status). However, the data should not be over interpreted in cases where the sample 
number is small. 
 
Table 8 CDR scores as a function of sociodemographic characteristics in the pcb-Cohort 
 
Abbreviations: SD-Standard Deviation; CDR-Clinical Dementia Rate; ∗χ
2
-Chi square test; † F-Anova; The superscript 
letters: 
a,b,c
 the same subscript letter denotes a subset of categories whose column proportions do not differ 
significantly from each other at the 0.05 level. NOTE: % is expressed as a function of the total in each CDR groups 
(CDR Normal N=301, CDR 0.5 N=199, CDR ≥ 1 N=68). In bold, the p-value<0.05.  
 
 
Additionally, there is a significant correlation between education level and CDR 
scores (Table 8). The baseline average (Years of Study) is 5.1 years of education. In the 
non-demented, CDR=0, subjects with more than 7 years formal education represent 
around 28.6% of the total, this value falls significantly to 12.1% and 7.4% for CDR=0.5 
and CDR≥1 respectively.  
 
 
Sociodemographic Characteristic 
pcb-Cohort 
N=568 
CDR=0 
N=301 
CDR=0.5 
N=199 
CDR≥1 
N=68 
p-value 
Gender 
 Male 
 Female  
163(28.7%) 
405(71.3%) 
95
a
 (31.6%) 
206
a
 (68.4%) 
45
a
 (22.6%) 
154
a
 (77.4%) 
23
a
 (33.8%) 
45
a
 (66.2%) 
0.058* 
Age Group 
 [50-64] years  
 [65-74] years  
 ≥75 years  
 
202(35.6%) 
229(40.3%) 
137(24.1%) 
 
131
a
 (43.5%) 
113
a
 (37.5%) 
57
a
 (18.9%) 
 
64
 b
 (32.2%) 
94
a
 (47.2%) 
41
a
 (20.6%) 
 
7
 c
 (10.3%) 
22
a
 (32.4%) 
39
a
 (57.4%) 
<0.001* 
Age  ≥ 65 years 366(64.4%) 17
a
 (56.5%) 135
 b
(67.8%) 61c (89.7%) <0.001* 
Age (years) (Mean ± SD) 67.6 ± 9.2 65.8 ± 8.9
a
 67.7 ± 8.5a 75.4 ± 8.5
 b
 <0.001† 
Marital Status 
 Living with the partner 
 Others Situation  
 
400(70.4%) 
168(29.6%) 
 
221
a
 (73.4%) 
80a (26.6%) 
 
139
 b
(69.8%) 
60 b (30.2%) 
 
40
 a
(58.8%) 
28 a(41.2%) 
0.057* 
Living Arrangement 
 Alone  
 Accompanied  
 
96 (16.9%) 
472(83.1%) 
 
46
a
 (15.3%) 
255
a
 (84.7%) 
 
39
 a
(19.6%) 
160a (80.4%) 
 
11
 a
 (16.2%) 
57
 a
 (83.8%) 
0.445* 
Professional Status 
 Active  
 Reformed  
 Unemployed  
 
176(31.0%) 
361(63.6%) 
31 (5.4%) 
 
100
a
 (33.2%) 
184a (61.1%) 
17
a
 (5.6%) 
 
63
 a
(31.7%) 
123 a(61.8%) 
13
 a
(6.5%) 
 
13
 a
 (19.1%) 
54 b (79.4%) 
1
 a
 (1.5%) 
0.059* 
Monthly Family Income 
 ≤ 1 minimum wage  
 >1 minimum wage  
 
176(31.0%) 
392(69.0%) 
 
76a (25.2 %) 
225
a
 (74.8%) 
 
68 a,b (34.2%) 
131
 a,b 
(65.8) 
 
32 b (47.1%) 
36
 b
 (52.9%) 
<0.001* 
Education Level 
 0-2 years of literacy  
 3-6 years of literacy  
 ≥7 years of literacy 
 
51 (9.0%) 
402(70.8%) 
15(20.2%) 
 
8
a
 (2.7%) 
207a,b(68.8) 
86
a
 (28.6%) 
 
21
 b
 (10.6%) 
154 b (77.4%) 
24
 b
 (12.1) 
 
22
 c
 (32.4%) 
41 a(60.3%) 
5
 b
 (7.4%) 
<0.001* 
Years of Study 5.1 ± 3.6 6.0 ± 4.0a 4.4 ± 2.9 b 3.1 ± 2.6 c <0.001† 
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4.1.1.2 Comorbidities grouped with respect to CDR evaluation 
With ageing individuals are often affected by much other pathology. 
Participants were scored for comorbidities; pathologies affecting each of the 
participants were scored with respect to the conditions specifically identified in the 
individual’s clinical records. Relevant comorbidities, that is, those that most affect the 
greatest number of individuals in the pcb-Cohort, are hypertension (HYP), 
dyslipidaemia (DYS), osteoarticular disease (OA) and cardiac and vascular diseases 
(CDV); 61.8%, 58.6%, 53.7% and 53.2%, respectively (Table 9). Other comorbidities 
affecting a significant percentage of the pcb-Cohort are depression (DEP) 32%, 
gastrointestinal disease (GID) 26.6%, genitourinary disease (GUD) 21.5% and diabetes 
(DM) 20.2%. Prevalence is lower for individuals with respiratory (RESP) 16.4%, 
haematological (HEMATO) 10.6%, oncological (ONCO) 5.6%, neurophatologies 
(NEURO) 3.9% diseases and excessive alcohol use 2.5%.  
 
Table 9 Correlation between gender and comorbidities in the pcb-Cohort  
 
Abbreviations: CDR-Clinical Dementia Rate; HYP-Hypertension arterial; DYS-
Dyslipidaemia; OA-Osteoarthicular disease; CVD-Cardiac and vascular Disease; 
DEP-Depression; GID-Gastrointestinal Disease; GUD-Genitourinary Disease; DM-
Diabetes Mellitus; RESP-Respiratory Disease; HEMATO-Hematologic Disease; 
ONCO-Oncology Disease; NEURO-Neuropathologies; ALCOHOL-Alcohol 
Excessive Use. ∗ Statistical test: χ2-Chi square test. The superscript letters: a,b,c 
the same subscript letter denotes a subset of categories whose column 
proportions do not differ significantly from each other at the 0.05 level. 
Different subscript letters denote column proportions which differ significantly 
from each other at the 0.05 level. In bold, the p-value<0.05. % is expressed as a 
function of the total for each of the columns (N=568, N=163 and N=405 
respectively).  
 
Comorbidities 
pcb-Cohort 
N=568 
Gender 
p-value* Male 
N=163 
Female 
N=405 
HYP 351 (61.8%) 101
a 
(62.0%) 250
a
 (61.7%) 0.958 
DYS 333 (58.6%) 92
a 
(56.4%) 241
a 
(59.5%) 0.502 
OA 305 (53.7%) 53a (32.5%) 252b (62.2%) <0.001 
CVD 302 (53.2%) 95a (58.3%) 207a (51.1%) 0.121 
DEP 182 (32.0%) 22
a
 (13.5%) 160
b
 (39.5%) <0.001 
GID 151 (26.6%) 31
a
 (19%) 120
b
 (29.6%) 0.010 
GUD 122 (21.5%) 49
a 
(30.1%) 73
b
 (18.0%) 0.002 
DM 115 (20.2%) 36
a 
(22.1%) 79
a 
(19.5%) 0.489 
RESP 93 (16.4%) 20
a 
(12.3%) 73
a 
(18.0%) 0.094 
HEMATO 60 (10.6%) 9a (5.5%) 51b (12.6%) 0.013 
ONCO 32 (5.6%) 6
a 
(3.7%) 26
a 
(6.4%) 0.200 
NEURO 22 (3.9%) 6
a 
(3.7%) 16
a 
(4.0%) 0.880 
ALCOHOL 14 (2.5%) 12
a 
(7.4%) 2
b 
(0.5%) <0.001 
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Close analysis of the prevalence of distinct comorbidities with respect to gender 
revealed some significant correlations. OA and DEP significantly affect more women 
than men with a p-value<0.001. In contrast men have a significantly higher prevalence 
of GUD and alcohol use, p-value=0.002 and<0.001, respectively. Two more 
comorbidities significantly affect women more than men, namely HEMATO and GID, at 
a p-value of 0.013 and 0.010, respectively. In general terms these results are in line 
with the distinct conditions that affect the different genders and further discussed in 
the discussion chapter. 
Subsequently, comorbidity prevalence was evaluated with respect to the CDR 
scores (Table 10). A significant correlation (p<0.001) is obvious with NEURO, where the 
% of individuals affected rises from 0.7% (CDR=0), to 4% (CDR=0.5) to 17.6% (CDR≥1). 
Significant differences are also evident for OA and GID, but only for CDR=0.5 and not 
for CDR≥1. A possible explanation is that the N is smaller for CDR≥1 (Table 10). 
Depression is moderately significant (p=0.052) with respect to cognitive performance 
and RESP is significant p<0.047. In patients with OA (Table 10), there is a higher 
proportion of suspected cognitive impairment (CDR=0.5), with statistical significance 
(p=0.008). The same is observed for patients with GID, there is a higher proportion of 
patients with suspected cognitive performance (CDR=0.5), with statistical significance. 
It should also be noted that patients with respiratory pathologies present a significant 
tendency for mild cognitive impairment (CDR=0.5). Undoubtedly, patients with 
neurodegenerative disease have a more pronounced cognitive deficit (CDR≥1). 
_______________________________________________________________________ 
_______________________________________________________________________ 
Departamento de Ciências Médicas/UA- 2017/201880 80 
 
Table 10 Comorbidities and Clinical Dementia Rate evaluation in the pcb-Cohort 
 
Abbreviations: CDR-Clinical Dementia Rate; HYP-Hypertension arterial; DYS-Dyslipidaemia; 
OA-Osteoarthicular disease; CVD-Cardiac and vascular Disease; DEP-Depression; GID-
Gastrointestinal Disease; GUD-Genitourinary Disease; DM-Diabetes Mellitus; RESP-
Respiratory Disease; HEMATO-Hematologic Disease; ONCO-Oncology Disease; NEURO-
Neuropathologies; ALCOHOL-Alcohol Excessive Use. ∗ Statistical test: χ2-Chi square test. 
The superscript letters: a,b,c the same subscript letter denotes a subset of categories whose 
column proportions do not differ significantly from each other at the 0.05 level. Different 
subscript letters denote column proportions which differ significantly from each other at 
the 0.05 level. In bold, the p-value<0.05. NOTE: % is expressed as a function of the total in 
each of the CDR groups (CDR 0 N=301, CDR 0.5 N=199, CDR ≥ 1 N=68). 
 
  
Given the high correlation with GID, this was evaluated in more detail (Table 
11). The individual clinical records of the 151 clinically referenced GID positive 
participants were consulted. Thus, it was possible to determine the specific GID 
pathologies affecting the patients (Table 11) but also that 4 of the patients diagnosed 
with Glucose Intolerance were classified as DM in this study. Clearly particular 
attention should be paid to the number of patients diagnosed with gastrointestinal 
tract disease.  
 
 
 
 
 
Comorbidities 
pcb-Cohort 
N=568 
CDR=0 
N=301 
CDR=0.5 
N=199 
CDR≥1 
N=68  
p-value* 
HYP 351 (61.8%) 185
a 
(61.5%) 122
a
 (61.3%) 44
a
 (64.7%) 0.870 
DYL 333 (58.6%) 175
a
 (58.1%) 119
a
 (59.8%) 39
a
 (57.4%) 0.910 
OA 305 (53.7%) 150
a
 (49.8%) 124
b
 (62.3%) 31
a
 (45.6%) 0.008 
CDV 302 (53.2%) 154
a
 (51.2%) 112
a
 (56.3%) 36
a
 (52.9%) 0.532 
DEP 182 (32.0%) 83
a
 (27.6%) 73
a
 (36.7%) 26
a
 (38.2%) 0.052 
GID 151 (26.6%) 61
a
 (20.3%) 73
b
 (36.7%) 17
a,b
 (25.0%) <0.001 
GUD 122 (21.5%) 63
a
 (20.9%) 44
a
 (22.1%) 15
a
 (22.1%) 0.944 
DM 115 (20.2%) 66
a
 (21.9%) 36
a
 (18.1%) 13
a
 (19.1%) 0.562 
RESP 93 (16.4%) 41
a
 (13.6%) 43
b
 (21.6%) 9
a
 (13.2%) 0.047 
HEMATO 60 (10.6%) 39
a
 (13.0%) 16
a
 (8.0%) 5
a
 (7.4%) 0.142 
ONCO 32 (5.6%) 18
a
 (6.0%) 11
a 
(5.5%) 3
a 
(4.4%) 0.877 
NEURO 22 (3.9%) 2
a
 (0.7%) 8
b 
(4.0%) 12
c
 (17.6%) <0.001 
ALCOHOL 14 (2.5%) 10
a
 (3.3%) 3
a
 (1.5%) 1 (1.5%) 0.376 
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Table 11 Breakdown of conditions included in gastrointestinal diseases 
 
Abbreviation: GID=Gastrointestinal Disease; GERD=Gastroesophageal Reflux disease 
 
In the pcb-Cohort the GID that most affects participants are dyspepsia (116 out 
of 151), this is followed by gastritis (8 out of 151) but in much lower numbers (Table 
11). Affecting only 5 individuals are diverticulosis and hepatic steatosis. The other 
conditions affected 1 to 3 individuals. 
 
4.1.1.3 Correlation between CDR status and APOE genotyping 
Apolipoprotein E (APOE) is a cholesterol carrier supporting lipid transport and 
the highest genetic risk factor for dementia thus far identified [190–193]. The gene has 
three alleles;ε2,ε3, andε4. For the pcb-Cohort blood was collected, but only possible 
for 508 individuals. The pcb-Cohort genotypes areε2ε3 (N=31; 6.1%),ε2ε4 
(N=7;1.4%),ε3ε3 (N=381;75.0%),ε3ε4 (N=82;16.1%) andε4ε4 (N=7;1.4%). The most 
common allele in the pcb-Cohort isε3 (Table 12), found in more than half of the 
general population, and the most abundant (97.2%). The allele frequency was then 
considered as a function of the CDR score. Relativelyε4 carrier percentages increase 
significantly with increasing CDR; 15.6% at CDR=0, almost doubling to 29.7% for CDR 
≥1. Thus, theε4 allele represents a significant risk factor. In contrast theε2 allele 
carriers are more represented in CDR=0 than in CDR≥1, consistent with its protective 
role. 
 
Types of Gastrointestinal disease Total 
No GID 417 
Dyspepsia 116 
Gastritis 8 
Diverticulosis 5 
Hepatic Steatosis 5 
Esophagitis / GERD / Hernia 3 
Anusite 3 
Esophagitis / GERD / Hernia + Gastritis 2 
Diverticulosis + Gastritis 2 
Intestinal polyp 1 
Cancer 1 
Others 5 
Intestinal Inflammatory  disease 0 
Total 568 
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Table 12 Correlation of CDR groups and APOE allele’s carriers 
 
Abbreviations: CDR-Clinical Dementia Rate; APOE ε2,ε3,ε4: Apolipoprotein E alleleε2,ε3,ε4, respectively; 
APOE genotyping was carried out for 508 voluntaries (from which the blood was available). Statistical test: 
*χ2-Chi square test. a,b,c the same subscript letter denotes a subset of categories whose column 
proportions do not differ significantly from each other at the 0.05 level. Different subscript letters denote 
column proportions that differ significantly from each other at the 0.05 level. In bold, the p-value<0.05. 
NOTE: For the pcb-Cohort column % is expressed as a function of the total sample size, 508 volunteers. 
Data in the other columns are represented as a function of each of the CDR group. 
 
 
4.1.1.4 Multivariate Analyses based on CDR status  
 For an overall analysis, an all-in-one multivariate data analysis was employed 
Table 13 shows multivariate analysis to identify risk factors. Literacy, Age, Gender, ADL, 
IADL, GID, NEURO and APOE ε2, contribute significantly to the multinomial regression 
and therefore to cognitive performance (Likelihood Ratio Test-Table 14). The reference 
CDR=0 group was compared to CDR=0.5 and CDR≥1 groups (Table 11). Whereas some 
parameters/risk factors are sustained in both analyses, others are more relevant in 
only one of the sets. For instance, comparing CDR=0 to CDR=0.5 individuals, the APOE 
ε2 carriers, have a 64% (% of 1-0.36; OR=0.36; CI 0.15-0.88; p=0.025) less chance of 
scoring CDR=0.5 compared to the non-APOE ε2 carries. This is not so for CDR=0 against 
CDR≥1. In fact, being anε2 carrier is no longer significant, but rather, significance is 
associated withε4 carriers. APOE ε4 carriers, compared to APOE ε4 non-carriers, have a 
2.30 greater chance of scoring CDR≥1.  
Some parameters are significant in only one of the multinomial regressions 
(Table 13). Age is not significant in the CDR=0 vs CDR=0.5 but is for CDR≥1. For the 
latter, in the age group 50-64, there is an 87% (% of 1-0.13; OR=0.13; CI: 0.040-0.39; 
p=0.000) less chance of scoring CDR≥1, compared to the older age group. This 
percentage falls to 51% (% of 1-0.49; OR=0.49; CI: 0.225- 1.08; p=0.078) when the age 
APOE allele carriers pcb-Cohort 
CDR=0 
N=256 
CDR=0.5 
N=188 
CDR≥1 
N=64  
p-value* 
ε2 
Non ε2  470 (92.5%) 233
a 
(91.0%) 176
a 
(93.6%) 61
a 
(95.3%) 
0.390  
ε2 38 (7.5%) 23
a 
(9.0%) 12
a
 (6.4%) 3
a 
(4.7%) 
ε3 
Non ε3 14 (2.8%) 4
a 
(1.6%) 7
a
 (3.7%) 3
a 
(4.7%) 
0.234 
ε3 494 (97.2%) 252
a 
(98.4%) 181
a
 (96.3%) 61
a 
(95.3%) 
ε4 
Non ε4 412 (81.1%) 216
a 
(84.6%) 151
a, b
 (80.3%) 45
b 
(70.3%) 
0.035 
ε4 96 (18.9%) 40
a 
(15.6%) 37
a, b 
(19.7%) 19
b 
(29.7%) 
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groups compared are 65-74 versus 75-90. In other words, higher age groups correlate 
significantly with higher CDR scores. ADL also varies between the two multinomial 
regressions. In the CDR=0 vs the CDR=0.5 there is no correlation, but in the CDR=0 vs 
the CDR≥1, dependent patients are 19.36 times more likely to score CDR≥1. Gender, 
likewise, did not produce the same results across both analyses. No significance was 
detected in CDR=0 vs CDR≥1, but gender is significant for CDR=0 vs CDR=0.5. In fact, 
females have a 1.70 greater chance of scoring CDR=0.5, compared to males. 
Unexpectedly this finding is not sustained in CDR≥1, this may be linked to the fact that 
life expectancy in Portugal is around 75 years [194]. Thus, the older age group, which is 
75-90 years old, is highly impacted by life expectancy. 
Other significant parameters in both multinomial regressions are Literacy, IADL, 
NEURO and GID. Literacy correlates with dementia [195,196]. In the CDR=0 vs the 
CDR=0.5, patients with low literacy (0-2 years) are around 7.40 times more likely, than 
those with relatively higher literacy (>7 year), to score CDR=0.5; and patients with 3-6 
years of literacy are 2.50 times more likely. This correlation is even more accentuated 
in the CDR=0 vs the CDR≥1 multinomial regression analyses. Patients with low literacy 
(0-2 years) have 35.28 times more chance of scoring CDR≥1, compared to the higher 
literacy group (>7 years). Likewise, patients with 3-6 years of literacy have 3.95 times 
more chance of scoring CDR≥1 (Table 13). With increasing dementia, patients become 
more dependent. In the CDR=0 vs CDR=0.5, volunteers who are dependent (IADL), 
have a 2.24 greater chance of scoring CDR=0.5 compared to independent volunteers. 
This rises to 3.47 in the CDR≥1 group. A similar trend is evident with respect to NEURO. 
Participants with a neuropathology are at a 5.06 times greater risk of scoring CDR=0.5 
and 17.52 times of scoring CDR≥1. 
Completely unexpected, and to our knowledge, hitherto unreported, is the 
association between cognitive performance as determined by CDR scores and GID. In 
the CDR=0 vs CDR=0.5 or CDR≥1 regression analyses, patients with GID, have a 2.55 or 
2.29 greater risk of scoring the respective higher CDR score. 
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Table 13 Multivariate analyses to identify risk factors 
 
Abbreviations: OR-risk or protective values in each parameter studied (CI-
confidential Interval of OR; APOE: Genotypingε2/ε3/ε4 alleles; ADL: Activity 
daily of life; IADL: Instrumental Activity daily life; HYP-Hypertension; OA-
Osteoarthicular disease; DEP-depression; GID-Gastrointestinal disease; DM-
Diabetes Mellitus; NEURO-Neuropathologies. The superscript letter: 
the
 
reference category is: CDR=0 or Normal Cognitive Performance; (---) This 
parameter is set to zero because it is redundant. It is the reference class into 
the parameter studied. For the other categories it is as indicated in the 
previous tables, i.e. male for female. If the number 1 is not within the CI, there 
is statistical significance. Other abbreviations are as previously indicated. In 
bold, the p-value<0.05. 
 
 
Parameters 
CDR=0.5
a
 CDR≥1
a
 
OR (CI 95%) p-value OR (CI 95%) p-value 
Intercept 
 
0.413 
 
0.105 
APOE ε2 carriers 0.36 (0.15-0.88) 0.025 0.25 (0.04-1.45) 0.130 
APOE ε3 carriers 0.28 (0.06-1.20) 0.087 0.37 (0.03-4.03) 0.412 
APOE ε4 carriers 1.20 (0.68-2.13) 0.522 2.30 (0.98-5.39) 0.055 
Female 1.70 (1.01-2.84) 0.044 1.06 (0.46-2.42) 0.890 
50-64 years 1.00 (0.55-1.82) 0.992 0.13 (0.04-0.39) <0.001 
65-74 years 1.16 (0.66-2.04) 0.615 0.49 (0.23-1.08) 0.078 
75-90 years --- --- --- --- 
0-2 years of Literacy 7.41 (2.64-20.82) <0.001 35.28 (7.25-171.70) <0.001 
3-6 years of Literacy 2.50 (1.4-4.46) 0.002 3.95 (1.10-14.20) 0.035 
≥ 7 years of Literacy --- --- --- --- 
Dependent ADL 4.01 (0.73-22.85) 0.108 19.36 (3.22-116.60) 0.001 
Dependent IADL 2.24 (1.37-3.67) 0.001 3.47 (1.62-7.45) 0.001 
HYP 0.80  (0.51-1.26) 0.343 1.05 (0.48-2.28) 0.905 
OA 1.15  (0.74-1.79) 0.529 0.70 (0.33-1.46) 0.333 
DEP 1.10 (0.69-1.77) 0.679 1.92 (0.88-4.20) 0.101 
GID 2.55 (1.56-4.16) <0.001 2.29 (1.01- 5.20) 0.047 
DM 0.68  (0.39-1.16) 0.155 0.83 (0.35-1.95) 0.670 
NEURO 5.06 (0.99-25.62) 0.050 17.52 (2.8-108.70) 0.002 
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Table 14 Internal model of the multinomial regression of cognitive performance based on 
CDR scores  
 
Abbreviations: OR-risk or protective values in each parameter studied (CI-confidential Interval of OR; APOE-
Genotypingε2/ε3/ε4 alleles; ADL-Activity daily of life; IADL-Instrumental Activity daily life; HYP-Hypertension; OA-
Osteoarthicular disease; DEP-depression; GID-Gastrointestinal disease; DM-Diabetes Mellitus; NEURO-
Neuropathologies. 
 
 
As is clearly evident the model used for the multivariate analysis is a good fit.  
The reduced model is formed by omitting an effect from the final model. The null 
hypothesis is that all parameters of that effect are 0. This reduced model is equivalent 
to the final model given that omitting the effect does not increase the degrees of 
freedom. The variables that contribute significantly to the final model are those 
identified in bold (Table 14). The APOE allele carriers, Age group, Literacy, ADL, IADL, 
GID and NEURO contribute significantly to the cognitive performance of individuals 
(based on the CDR test). The chi-square test statistic is the difference in-2 log-
likelihoods between the final model and a reduced model. 
 
4.1.2 Cognitive Evaluation Based on Applying the DSM-5 Criteria 
In order to give further clinical relevance to the data, the DSM-5 criteria were 
applied to the pcb-Cohort. Thus, the data obtained, from the participants, was 
subsequently evaluated as detailed in table 1 in the Introduction (Chapter 1). All the 
criteria listed in the above mentioned table 1 were applied as well as the exclusion of 
Effect 
Model Fitting Criteria Likelihood Ratio Tests 
AIC of Reduced 
Model 
BIC of Reduced 
Model 
-2 Log Likelihood of 
Reduced Model 
Chi-
Square 
df Sig. 
Intercept 705.673 849.510 637.673
a
 0.000 0 --- 
APOE ε4 
carriers 
705.219 840.595 641.219 3.546 2 0.170 
APOE ε3 
carriers 
704.767 840.142 640.767 3.094 2 0.213 
APOE ε2 
carriers 
707.966 843.342 643.966 6.293 2 0.043 
Gender 706.147 841.523 642.147 4.474 2 0.107 
Age Group 716.139 843.053 656.139 18.465 4 0.001 
Literacy  731.027 857.941 671.027 33.353 4 <0.001 
ADL 716.895 852.270 652.895 15.222 2 <0.001 
IADL 717.093 852.469 653.093 15.420 2 <0.001 
HYP 702.789 838.165 638.789 1.116 2 0.572 
OA 703.634 839.009 639.634 1.960 2 0.375 
DEP  704.364 839.739 640.364 2.691 2 0.260 
GID 716.569 851.944 652.569 14.895 2 0.001 
DM 703.730 839.105 639.730 2.056 2 0.358 
NEURO 712.906 848.281 648.906 11.233 2 0.004 
 
_______________________________________________________________________ 
_______________________________________________________________________ 
Departamento de Ciências Médicas/UA- 2017/201886 86 
 
all possible cases of depression. All the questionnaires (CDR, MMSE and GDS) 
employed in this study are internationally validated; further questions necessary to 
implement the DSM-5 for depressive disorders were not included. Thus, to reliably 
apply the DSM-5 criteria regarding depressive disorders; depression cases considered 
were; all those individuals who had a clinical depression diagnosis, as well as those 
who scored positive in the GDS screening test.  
The pcb-Cohort includes 286 individuals with normal depression evaluation 
(without depressive disorder plus GDS15 negative) and 282 with depressive possible 
cases (74 individuals with depressive disorder, 106 patients with GDS15 positive, but 
without definitive diagnosis of depression, plus 102 patients with history of depression 
but it is not possible to confirm of the diagnosis). The figure below (Figure 6) shows the 
methods used to select the patients for subsequent analyses.  
 
  
 
Figure 6 Selection procedure to apply the DSM-5 criteria 
Abbreviations: CDR-Clinical Dementia Rate. DSM-The Diagnostic and Statistical Manual of Mental Disorders; NCD-
neurocognitive disorder; NCD-normal: performance cognitive normal; NCD-mild: neurocognitive disorder mild; 
NCD-major: neurocognitive disorder major.  
 
pcb-Cohort 
568 volunteers 
Applying inclusion and exclusion criteria 
 
CDR evalua on 
301 CDR =0 
199 CDR =0.5 
68 CDR= 1 
 
DSM-5 
189 NCD-normal 
61 NDC-mild 
36 NCD-major 
282 Possible cases of depression  
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According to the DSM-5 criteria, as described in Chapter 1, cases of cognitive 
alteration considered cannot be explained by other mental illnesses such as major 
depression and schizophrenia. To obey this precept, the possible cases of depression 
were excluded from the neurocognitive disorder (NCD) group, but were nonetheless 
considered during the analyses, as explained below. The DSM-5 criteria are sub-
dividing NCD into mild (NCD-mild) and major (NCD-major) cases. 
Regarding depression, there are a total of 182 patients with a history of 
depression and a total of 174 patients with GDS positive. Of the 182 patients with 
depression, 108 are GDS- this may be due to medication usage and positive response 
to the therapeutic strategy used. Of the 174 patients with GDS-positive, for 100 
subjects it was not possible to confirm that they fulfil the DSM-5 criteria for depressive 
disorder. Considering the 182 and 174 above mentioned putative depression cases 
only 74 individuals have a confirmed diagnosis and a positive GDS.  
Taking all these aspects into consideration, four groups result (Figure 6); NCD-
normal, NCD-mild, NCD-major and possible cases of depression (PCD).  
 
4.1.2.1 Correlating DSM-5 based cognitive performance and 
sociodemographic characteristics  
The pcb-Cohort was thus analysed taking into consideration the DSM-5 criteria 
for cognitive performance and the impact of sociodemographic characteristics 
addressed. The results are presented below (Table 15).  The analysis shows the 
correlation of the individuals without cognitive impairment, those with NCD-mild, 
NCD-major patients, and PCD. Significant differences were evident for gender, age, 
living arrangement and literacy. The results (Table 15) clearly show that NCD-mild have 
a greater proportion: females, age group 65-74 years old, cases of patients that live 
alone and patients with fewer years of literacy, relative patients with NCD-normal. In 
cases of NCD-major, it is possible see that there is prevalence of patients who are 
older, (≥ 75 years old), and with fewer years of literacy (Table 15).For PCD, there are 
more women (82.3%) compared to men and regarding age the greatest proportion of 
depressed individuals is found in the age group 65-74. Other significant contributors to 
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depression are low monthly family income (p=0.037), living arrangement and literacy 
(Table 15). 
Table 15 Correlation of DSM-5 based neurocognitive disorders with sociodemographic 
characteristics in pcb-Cohort 
 
Abbreviation: NCD-Neurocognitive disorder; PCD-Possible cases of depression; MW-Minimum Wage. Statistical test: 
*χ2-Chi square test. Values in the same row and not sharing the same superscript are significantly different at 
p<0.05 in the two-sided test of equality for column proportions. Tests assume equal variances. Tests are adjusted 
for all pairwise comparisons within a row of each innermost using the Bonferroni correction. Superscripts letters 
a, b
: 
The same subscript letter denotes a subset of categories whose column proportions do not differ significantly from 
each other at the 0.05 level. Different subscript letters denote column proportions which differ significantly from 
each other at the 0.05 level. In bold, the p-value less than 0.05.  
 
 
With respect to ageing, as expected, increasing NCD deficits are clearly evident 
in the older age groups (Table 15). In the younger age group, 50 to 64 years old, 42.3% 
exhibited NCD-normal performance and these falls to 23.3% for individuals aged 75 
years old. In contrast, for the 50 to 64-year-old group, 27.8% exhibited NCD-major, 
whereas in the 75-year-old or more groups, this increased to 41.7% (for more details 
Characteristics  
N=568 
(%) 
NCD-normal 
N=189 
NCD-mild 
N=61 
NCD-major 
N=36 
PCD 
N=282 
p-value 
Gender  
 Male 
 Female 
 
113(39.5%) 
173 (60.5%) 
 
82
a 
(43.4%) 
107
a 
(56.6%) 
 
13
b
 (21.3%) 
48
b
 (78.7%) 
 
18
a
 (50.0%) 
18
a
 (50.0%) 
 
50
b
 (17.7%) 
232
 b
 (82.3%)
<0.001 
 
Age Group 
 50-64 
 65-74 
 >=75 
 
 
103 (36.0%) 
112 (39.2%) 
71 (24.8%) 
 
 
80
a
 (42.3%) 
65
a
 (34.4%) 
44
a
 (23.3%) 
 
 
13
b
 (21.3%) 
36
b
 (59.0%) 
12
a 
(19.7%) 
 
 
10
a,b
 (27.8%) 
11
a
 (30.6%) 
15
b
 (41.7%) 
99
 a.b
 (35.1%)
117
 a.b
 (41.5%)
66
 a
 (23.4%)
 
0.003 
 
Age 
 <65 
 >=65 
 
 
103 (36.0%) 
183 (64.0%) 
 
 
80
a
 (42.3%) 
109a (57.7%) 
 
 
13
b 
(21.3%) 
48
b
 (78.7%) 
 
 
10
a,b
 (27.8%) 
26
a,b
 (72.2%) 
99
 a.b
 (35.1%)
183
 a.b
 (64.9%)
 
 
0.017 
 
Marital Status 
 Living with  
 partner 
 Others 
 Situations 
 
 
 
218 (76.2%) 
 
68 (23.8%) 
 
 
 
146
a 
(77.2%) 
 
43
a
 (22.8%) 
 
 
 
42
a
 (68.9%) 
 
19
a 
(31.1%) 
 
 
 
30
a
 (83.3%) 
 
6
a
 (16.7%) 
182
 a.b
 (64.5%)
100
 b
 (35.5%)
 
0.008 
 
Living Arrangement 
 Alone 
 Accompanied 
 
 
42 (14.7%) 
244 (85.3%) 
 
 
25
a 
(13.2%) 
164
a
 (86.8%) 
 
 
15
b 
(24.6%) 
46
 b
  (75.4%) 
 
 
2
c
 (5.6%) 
34
c
 (94.4%) 
54
 a
 (19.1%)
228
 a
 (80.9%)
 
 
0.034 
 
Professional Status  
 Active  
 Reformed 
 Unemployed 
 
 
84 (29.4%) 
192 (67.1%) 
10 (3.5%) 
 
59
a
 (31.2%) 
122
a
 (64.6%) 
8
a 
(4.2%) 
 
19
a
 (31.1%) 
41
a
 (67.2%) 
1
a
 (1.6%) 
 
6
a
 (16.7%) 
29
a
 (80.6%) 
1
a
 (2.8%) 
92
 a
 (32.6%)
169
 a
 (59.9%)
21
 b
 (7.4%)
 
 
0.139 
 
Monthly Family Income  
 <=1 MW 
 >1 MW 
 
 
 
74 (25.9%) 
212 (74.1%) 
 
 
 
45
a 
(23.8%) 
144
a
 (76.2%) 
 
 
 
17
a 
(27.9%) 
44
a
 (72.1%) 
 
 
 
12
a
 (33.3%) 
24
a
 (66.7%) 
102
 b
 (36.2%)
180
 b
 (63.8%)
 
 
0.037 
 
Literacy  
 0-2 years 
 3-6 years  
 >=7 years 
 
 
18 (6.3%) 
203 (71.0%) 
65 (22.7%) 
 
 
3
a
 (1.6%) 
133
a
 (70.4%) 
53
a
 (28.0%) 
 
 
7
b
 (11.5%) 
46
a
 (75.4%) 
8
a 
(13.1%) 
 
 
8
b
 (22.2%) 
24
a
 (66.7%) 
4
a
 (11.1%) 
33
 b
 (11.7%)
199
 a
 (70.6%)
50
 a
 (17.7%)
 
<0.001 
 
_______________________________________________________________________ 
 
_______________________________________________________________________ 
Characterization of the pcb-Cohort in the Aveiro region of Portugal 89 
 
see Table 15). The highest group however was 59% exhibiting NCD-mild in the 65-74 
age groups, clearly indicating that this group should be closely followed. The 
proportion of cognitive impairment is higher in patients that are living with someone. 
In patients who are accompanied, a higher proportion of cognitive impairment is also 
observed. This proportion is even higher in the more NCD-major. 
With respect to education, three groups were considered, 0-2 years formal 
education, 3-6 years formal education and more than 7 years (Table 15). The most 
striking, significant difference was observed in the 0-2 years literacy. In other words, 
22.2% of individuals with NCD-major have 0-2 years formal education, and this 
percentage falls to 11.5% in NCD-mild and 1.6% in NCD-normal. 
 
4.1.2.2 Association between cognitive performance based on DSM-5 and 
clinical characteristics  
Comorbidity bivariate correlations with cognitive deficits, as determined by 
applying the DSM-5 neurocognitive criteria, were subsequently investigated (Table 16). 
As explained above, 286 individuals fulfil the DSM-5 criteria and the fourth group 
includes patients with depression or possible depression. However, for comparative 
purposes the prevalence of the original pcb-Cohort group (N=568) is also included in 
the table. 
As is evident (Table 16), cognitive performance correlates with OA and RESP 
related disorders. This is consistent with the results when the DSM-5 criteria are not 
implemented (presented in 4.1.1.2). Contrary to this however GID and NEURO do not 
correlate with NCD when DSM-5 criteria are applied. Rather suggesting that these 
individuals who previously were associated with poor CDR scores are now included in 
the PCD group. Thus, GID in the PCD group is significantly more represented when 
compared to the NCD-normal (p=0.001). 
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Table 16 Comorbidities and cognitive performance based on DSM-5 classification for 
neurocognitive disorders  
 
Abbreviations: HYP-Hypertension arterial; DYS-Dyslipidaemia; OA-Osteoarthicular disease; CVD-Cardiac and vascular 
Disease; DEP-Depression; GID-Gastrointestinal Disease; GUD-Genitourinary Disease; DM-Diabetes Mellitus; RESP-
Respiratory Disease; HEMATO-Hematologic Disease; ONCO-Oncology Disease; NEURO-Neuropathologies; ALCOHOL-
Alcohol Excessive Use. Statistical test: *χ2-Chi square test. Values in the same row and not sharing the same 
superscript are significantly different at p<0.05 in the two-sided test of equality for column proportions. N=568 
patients of pcb-Cohort). Superscripts letters 
a, b
: The same subscript letter denotes a subset of categories whose 
column proportions don not differ significantly from each other at the 0.05 level. Different subscript letters denote 
column proportions which differ significantly from each other at the 0.05 level. In bold, the p-value less than 0.05. 
Tests assume equal variances. Tests are adjusted for all pairwise comparisons within a row of each innermost using 
the Bonferroni correction. 
 
 
4.1.2.3 Correlating DSM-5 based cognitive performance and APOE genotype 
Table 17 depicts cognitive performance, based on DSM-5 criteria, with 
Apolipoprotein E (APOE) genotyping. Of the 508 individuals in the pcb-Cohort, 286 
fulfil the DSM-5 criteria for NCD, of theε4 carriers 14.7% (N=24) exhibit normal 
cognitive performance, 24.6% (N=18) NCD-mild, 8.6% (N=3) NCD-major 21.7% (N=54) 
PCD. Unlike the correlation shown in table 12 there is no significant correlation 
between cognitive performance and APOE genotype. However, it must be noted that 
some of the groups in table 17 are too small for meaningful statistical analysis (groups 
with 0 or 1), this was nonetheless done for the sake of carrying out complete analyses 
for comparison. Therefore, care must be taken when determining conclusions. 
  
Comorbidities N=568 
NCD-normal 
N=189 
NCD-mild 
N=61 
NCD-major 
N=36 
PCD 
N=282 
p-value* 
HYP 351 (61.8%) 115a (60.8%) 41
a (67.2%) 20a (55.6%) 175a (62.1%) 0.698 
DYS 333 (58.6%) 111
a 
(58.7%) 38
a 
(62.3%) 19
a 
(52.8%) 165
a 
(58.5%) 0.838 
OA 305 (53.7%) 86
a 
(45.5%) 30
a,b 
(49.2%) 20
a,b 
(55.6%) 169
b 
(59.9%) 0.018 
CVD 302 (53.2%) 101a (53.4%) 34a (55.7%) 21a (58.3%) 146a (51.8%) 0.856 
GID 151 (26.2%) 34
a 
(18.0%) 16
a,b 
(26.2%) 6
a,b 
(16.7%) 95
b 
(33.7%) 0.001 
GUD 122 (21.5%) 40
a 
(21.2%) 12
a 
(19.7%) 8
a 
(22.2%) 62
a 
(22.0%) 0.980 
DM 115 (20.2%) 42a (22.2%) 14a (23.0%) 5a (13.9%) 54a (19.1%) 0.605 
RESP 93 (16.4) 24
a 
(12.7%) 9
a,b 
(14.8%) 12
b 
(33.3%) 48
a.b 
(17.0%) 0.022 
HEMATO 60 (10.6%) 24
a 
(12.7%) 5
a 
(8.2%) 4
a 
(11.1%) 27
a 
(9.6%) 0.655 
ONCO 32 (5.6%) 9
a 
(4.8%) 6
a
(9.8%) 0(0.0%) 17
a 
(6.0%) 0.210 
NEURO 22 (3.9%) 2a (1.1%) 4a(6.6%) 1a(2.8%) 15a (5.3%) 0.075 
AlCOHOL 14 (2.5%) 6
a
(3.2%) 2
a
(3.3%) 1
a
(2.8%) 5
a 
(1.8%) 0.767 
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Table 17 Correlation between cognitive performance based on DSM-5 criteria and APOE 
genotyping 
 
Abbreviations: NCD-Neurocognitive disorder; NCD-mild- Neurocognitive disorder mild; NCD-major-Neurocognitive 
disorder major. NCD normal: performance cognitive normal. PCD-Possible cases of depression; APOE- 
apolipoprotein. Statistical test: *χ2-Chi square test. N=259 because there are patients that blood is not available. 
Values in the same row not sharing the same superscript are significantly different at p<0.05 in the two-sided test of 
equality for column proportions. Cells with no subscript are not included in the test. Tests assume equal variances. 
Tests are adjusted for all pairwise comparisons within a row of each innermost using the Bonferroni correction. 
More than 20% of cells in this table have expected cell counts less than 5. Chi-square results may be invalid. 
 
 
4.1.2.4 Multivariate analyses of cognitive performance based on DSM-5 
The reference Normal cognitive performance group was compared to NCD-
mild, NCD-major and Depressive possible cases groups (Table 18). Multivariate data 
analysis was consequently carried out to again identify risk factor(s) in patients with 
NCD as identified upon applying the DSM-5 neurocognitive criteria (Table 18). Age, 
gender, literacy, GID and ADL correlate significantly.  
 
 
APOE 
allele 
carriers 
N=508 
NCD-normal 
N=163 
NCD-mild 
N=61 
NCD-major 
N=35 
PCD 
N=249 
p-value 
ε2 Non-ε2 (N=240) 149
a 
(91.4%) 59
a 
(96.7%) 32
a 
(91.4%) 230
a
 (92.4%) 
0.590 
ε2 (N=19) 14
a 
(8.6%) 2
a 
(3.3%) 3
a 
(8.6%) 19
a
 (7.6%) 
ε3 Non-ε3  (N=3) 0
1 (0.0%) 2a (3.3%) 1a (2.9%) 11a (4.4%) 
0.064 
ε3 (N=256) 163(100.0%) 59
a 
(96.7%) 34
a 
(97.1%) 238
a
 (95.6%) 
ε4 Non-ε4  (N=217) 139
a 
(85.3%) 46
a 
(75.4%) 32
a 
(91.4%) 195
a
 (78.3%) 
0.077 
ε4 (N=42) 24
a 
(14.7%) 15
a 
(24.6%) 3
a
 (8.6%) 54
a
 (21.7%) 
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Table 18 Multivariate analyses to identify risk factors based on DSM-5 classification  
 
Abbreviations: OR-risk or protective values in each parameters studied (CI-confidential Interval of OR); NCD-
Neurocognitive disorder; NCD-mild- Neurocognitive disorder mild; NCD-major-Neurocognitive disorder major; NCD-
normal-performance cognitive normal; PCD-Possible cases of depression; APOE- Genotypingε2/ε3/ε4 alleles; ADL- 
Activity daily of life; IADL- Instrumental Activity daily life; HYP-Hypertension; OA-Osteoarthicular disease; DEP-
depression; GID-Gastrointestinal disease; DM-Diabetes Mellitus; NEURO-Neurodegenerative pathologies. The 
reference category is: NCD-normal or Normal Cognitive Performance; (---) This parameter is set to zero because it is 
redundant. It is the reference class into the parameter studied. For the other categories it is as indicated in the 
previous tables, i.e. male for female. If the number 1 is not within the CI, there is statistical significance. Other 
abbreviations are as previously indicated. In bold, the p-value<0.05. 
 
 
APOE ε2 non-carriers do not have statistical significance as a risk factor with 
respect to NCD-mild or NCD-major or even PCD. APOE ε4 carriers have 2.1 times 
greater chance of scoring NCD-mild and 1.7 times greater chance of scoring PCD, with 
moderate statistical significance (p-value=0.053 and p-value=0.068 respectively). 
 Gender is significant for NCD-mild. In fact, females have 3.7 times greater 
chance of scoring NCD-mild and 3.6 times greater chance of possible depressive cases 
(Table 18), compared to males (OR 3.7, CI 95% 1.7-7.8, p-value=0.001). In contrast, 
women are about 55% less likely to have NCD-major, compared to men (OR 0.447, CI 
95% 0.186-1.078, p-value 0.073). Women have 3.6 times greater chance of scoring 
depressive possible cases (OR 3.6 CI 95% 2.2-5.8, p-value<0.001). 
Age is likewise significant for the risk of NCD-mild, but age is not significant in 
NCD-Major and PCD. For the latter, in the age group 65-74, there is a 2.3 times greater 
 Parameters 
NCD-mild NCD-major PCD 
Sig OR CI Sig OR CI Sig OR CI 
APOEε2 
non carriers 
0.100 3.877 (0.771-19.499) 0.788 1.211 (0.300-4.899) 0.241 1.629 (0.721-3.681) 
APOEε4 
carriers 
0.053 2.133 (0.991-4.590) 0.059 0.234 (0.052-1.058) 0.068 1.700 (0.962-3.005) 
Female 0.001 3.709 (1.761-7.813) 0.073 0.447 (0.186-1.078) <0.001 3.591 (2.205-5.846) 
50-64 Years old 0.524 0.735 (0.284-1.898) 0.737 0.838 (0.300-2.343) 0.910 0.966 (0.532-1.755) 
65-74 years old 0.050 2.291 (1.001-5.244) 0.767 0.862 (0.321-2.310) 0.339 1.330 (0.741-2.388) 
≥75 years old* --- --- --- 
0-2 years of  
education 
0.005 10.783 (2.083-55.812) <0.001 44.435 (6.646-297.099) 0.003 7.339 (1.934-27.856) 
3-6 years of  
educations 
0.239 1.721 (0.698-4.246) 0.024 4.698 (1.223-18.049) 0.127 1.533 (0.886-2.654) 
≥7 years of 
education* 
--- --- --- 
HTA 0.624 1.192 (0.590-2.409) 0.360 0.676 (0.292-1.564) 0.799 0.940 (0.587-1.508) 
OA 0.419 1.316 (0.676-2.563) 0.075 0.457 (0.193-1.082) 0.479 0.847 (0.536-1.340) 
GID 0.389 1.396 (0.653-2.986) 0.937 0.959 (0.336-2.737) 0.017 1.905 (1.121-3.236) 
DM 0.801 0.906 (0.422-1.948) 0.176 0.457 (0.147-1.420) 0.252 0.723 (0.416-1.259) 
NEURO 0.087 4.980 (0.793-31.264) 0.333 0.247 (0.015-4.183) 0.212 2.825 (0.553-14.424) 
ADL 0.843 1.345 (0.072-25.209) 0.001 58.117 (5.851-577.243) 0.035 9.562 (1.170-78.116) 
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chance of scoring NCD-mild compared with patients 75 years old or more (reference 
class to age group) (OR=2.291, %CI:1.001-5.244).  
Years of the study are significant with respect to NCD, based on multivariate 
analysis. Patients with 0-2 years of education have about 10 times greater chance of 
scoring NCD-mild, 44 times greater chance of scoring MCD-major, and 7.3 greater 
chance of scoring PCD (OR=10.783, %CI=2.083-55.812, p-value=0.005; OR=44.435, 
%CI=6.646-297.099, p-value<0.001; OR=7.339, %CI=1.934-27.856, p-value=0.003, 
respectively). 
Relative to comorbidities, special attention is necessary regarding GID. These 
patients have about 1.9 times greater chance of scoring PCD, compared to NCD-normal 
(OR=1.905, CI=(1.121-3.236, p-value=0.017). 
Another variable that presents statistical significance with respect to cognitive 
performance is ADL.  For the latter, there is a 58 times greater chance of scoring NCD-
major and 9.5 time greater chance to score PCD, relative the NCD-normal performance 
(OR=58.117, CI=5.851-577.243, p-value<0.001; OR=9.562, CI=1.170-78.116, p-
value=0.035). 
 
Relative to the performance of the statistical model in multivariate analysis, it 
is necessary to identify the important variables to predict the model. The-2log 
likelihood decreases relative to the model only with the constant (from 826.561 to 
679.292) but the model significantly improved (p<0.05) with the introduction of 
predictive variables. Goodness-of-fit tests the adjustment of the variables to the 
model, if p>0.05 then the variables fits the model well. In this model, the Goodness-of-
fit (Deviance 505.975, df(663), p-value=1.000) means that the variable fits to the model. 
Table 19 shows the variables that contributed with statistical significance to final 
model in this statistical analysis. 
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Table 19 Internal model of the multivariate analyses of the pcb-Cohort for NCD 
 
Abbreviation: HYP-Hypertension arterial; OA-Osteoarthicular disease; GID-Gastrointestinal Disease; DM-Diabetes 
Mellitus; NEURO-Neuropathologies; ADL-Basic Activities daily of Life. The chi-square statistic is the difference in -2 
log-likelihoods between the final model and a reduced model. The reduced model is formed by omitting an effect 
from the final model. The null hypothesis is that all parameters of that effect are 0.  This reduced model is 
equivalent to the final model because omitting the effect does not increase the degrees of freedom. 
 
The model used for the multivariate analysis is a good fit conforming to the 
variables as previously described. The variables that contribute significantly to the final 
model are those identified in bold (Table 19). The APOE allele carriers, age group, 
literacy, ADL, IADL and NEURO contribute significantly to the cognitive performance of 
individuals. The chi-square test is the difference in-2 log-likelihoods between the final 
model and a reduced model. 
 
  
Effect 
Model Fitting Criteria Likelihood Ratio Tests 
AIC of 
Reduced 
Model 
BIC of 
Reduced 
Model 
-2 Log 
Likelihood 
of Reduced 
Model 
Chi-
Square 
df Sig. 
Intercept 763.292 940.973 679.292a .000 0 . 
APOEε2 non carrier 760.923 925.912 682.923 3.631 3 0.304 
APOEε4 carrier  771.085 936.074 693.085 13.793 3 0.003 
Female 802.271 967.260 724.271 44.979 3 <0.001 
Age Group 762.026 914.323 690.026 10.734 6 0.097 
Literacy 774.499 926.796 702.499 23.206 6 0.001 
HTA 758.682 923.671 680.682 1.390 3 0.708 
OA 762.461 927.450 684.461 5.169 3 0.160 
GID 764.159 929.147 686.159 6.866 3 0.076 
DM 760.017 925.006 682.017 2.725 3 0.436 
NEURO 766.077 931.066 688.077 8.785 3 0.032 
ADL 780.865 945.853 702.865 23.572 3 0.000 
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4.2 Depression Evaluation of the pcb-Cohort 
Depression affects many individuals in the pcb-Cohort. As described in the 
methods section the GDS (Geriatric Depression Scale) was applied to participants. The 
prevalence of depression, based on the clinical history, is 32% (N=182). Depression 
prevalence based on the GDS15 questionnaire (174) is 30.6% (Figure 7). However, 
when GDS4Lit (GDS4 based on the literature [197]) was applied, unexpectedly, only 46 
(8.1%) patients obtained scores consistent with the absence of a depressive status and 
522 scored above 2 points, that is a score consistent with possible cases of depression. 
These results are represented in figure 7. 
 
Figure 7 GDS scales applied to the pcb-Cohort 
Of the 590 volunteers, 568 were within the inclusion criteria. Distinct analyses of the GDS were applied to the study 
population as explained in the materials and methods. The number of individuals scoring negative or positive for 
depression changed with respect to the analysis implemented. 
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4.2.1 Comparing the Geriatric Depressive Scale (GDS) with 15 Items and GDS 
with 4 Items as Reported in the Literature 
In the pcb-Cohort, applying GDS15 and GDS4Lit resulted in significantly 
different numbers of potentially depressed patients (Figure 7), 174 and 522 positive 
cases respectively. Given this difference each of the questions of GDS15 was evaluated 
independently. That is, each question was scored as positive if answered in a manner 
consistent with depression. The percentage was then calculated as a function of the 
total number of patients with depression, as determined by the GDS15 (N=174) (Figure 
7). There is a marked difference in the top responses denoting positivity for depressive 
symptoms when comparing the GDS15 with the short version GDS4Lit. In other words, 
the top responses denoting positivity for depression to GDS4Lit are not the same as 
the top ones for GDS15 (Figure 8). 
 
Figure 8 Frequency of answers consistent with depression in the GDS15 for the pcb-Cohort 
The number in front of GDS corresponds to the number of the question in the original GDS15 questionnaire (see 
methods). Stripped columns represent the four questions in the short version of GDS4Lit described in the literature. 
That is questions: GDSQ1, GDSQ3, GDSQ6 and GDSQ7 [186]. The percentage referred is based in individuals scoring 
in a pattern consistent with depression for each of the questions. Values are shown as a percentage of the total 
number of individuals scoring positive for Depression N=174 (GDS15). 
88.5%
71.3%
69.0%
66.7%
64.4% 63.2% 62.1%
46.0%
41.4% 40.8% 39.1% 37.9% 37.4%
27.0%
10.9%
%
 o
f 
In
d
iv
id
u
al
 in
 G
D
S 
q
u
es
ti
o
n
s
Questions in Geriatric Depression Scale with 15 questions
_______________________________________________________________________ 
_______________________________________________________________________ 
Departamento de Ciências Médicas/UA- 2017/201898 98 
 
4.2.2 Applying Alternative Shorter GDS Versions 
Since there was a significant discrepancy in the number of possible cases of 
depression using GDS4Lit compared to GDS15, other shorter versions of the GDS were 
evaluated. Thus, in the shorter versions, and respecting the order of most frequent 
questions where “yes” or “no” response denoted an association with depression 
(Figure 8), GDS scales with fewer questions were considered. The number of questions 
included was progressively increased, from the top four to the top eight. The top eight 
questions considered had around 50% depressed people (N=174) responding in a 
pattern consistent with depression (Figure 8). The top 4 questions in GDS4 (questions 
4, 6, 3 and 9) most answered are different from those used in the previous publication 
GDS4Lit (these questions are: 6, 3, 7 and 1). For the shorter versions tested, the top 
five questions included in the GDS5 (questions 4, 6, 3, 9 and 2), the top six questions in 
GDS6 (questions 4, 6, 3, 9, 2 and 5), the top seven questions in GDS7 (questions 4, 6, 3, 
9, 2, 5 and 7) and the top eight in the GDS8 (questions 4, 6, 3, 9, 2, 5, 7 and 1). 
 
4.2.3 Determining cut-off Points for the Shorter GDS Versions 
Cut-off points for each of the scales tested were determined, as explained in 
the methodology (3.11.2.3). For each point, sensitivity and specificity is identified. The 
best cut-off point is the one with the best correlation between these two parameters. 
The ROC curve and the coordinates of the curves are represented in figure 9. These 
coordinates are expressed in table 20. 
. 
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Figure 9 ROC curves for shorter GDS scales 
The number of questions in each of the different GDS analyses is as previously explained and based on the top 
incorrect answers of the GDS15. The AUC (Area Under Curve) for GDS8 is 0.961 (CI (Confidential Interval) 95% 
0.946-0.976); for GDS7 it is 0.772 (95%CI 0.731-0.813); for GDS6 it is 0.974 (CI 95% 0.845 – 0.903); for GDS5 it is 
0.937 (CI 95% 0.918-0.956); for GDS4 it is 0.922 (95%CI 0.900-0.944); and for GDS4Lit it is 0.782 (95%CI 0.739-
0.826). The curves with the best discriminating power are GDS8 and GDS6. The null hypothesis: true area=0.5. 
 
Looking at the coordinates that are shown in table 20 one can see that a 
patient with a positive result presents a result consistent with "depression" if the cut-
off points are those highlighted in the table (Table 20). Therefore, the best cut offs for 
the different short versions are: GDS8 ≥ 3; GDS7 ≥ 4; GDS6 ≥ 3; GDS5 ≥ 3; GDS4 ≥ 2.  
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Table 20 ROC curve to determine cut-off points for the shorter GDS versions 
 
The test result variable(s): GDS8, GDS7, GDS6, GDS5, GDS4, GDS 4Lit 
question has at least one tie between the positive actual state group 
and the negative actual state group. The smallest cut-off value is the 
minimum observed test value minus 1. And the largest cut-off value is 
the maximum observed test value plus 1. All the other cut-off values 
are the averages of two consecutive ordered observed test values. 
 
 
Since we have the questions that best indicate depression in the study 
population, it follows that the cut-off points for the new scales here proposed should 
be identified (Table 20). As explained in the methods, the ROC Curve provides 
important information on the accuracy of the scales. The area under the curve shows 
Short Version 
Positive if 
Greater Than or 
Equal To 
Sensitivity Specificity 
GDS8 
-1.0 1.000 0.000 
0.5 1.000 0.365 
1.5 0.983 0.683 
2.5 0.902 0.896 
3.5 0.741 0.982 
4.5 0.454 0.997 
5.5 0.195 0.997 
6.5 0.098 1.000 
7.5 0.029 1.000 
9.0 0.000 1.000 
GDS7 
0.0 1.000 0.000 
1.5 1.000 0.020 
2.5 0.937 0.322 
3.5 0.793 0.662 
4.5 0.454 0.876 
5.5 0.132 0.980 
6.5 0.029 1.000 
8.0 0.000 1.000 
GDS6 
-1.0 1.000 0.000 
0.50 1.000 0.003 
1.5 1.000 0.307 
2.5 0.920 0.647 
3.5 0.701 0.876 
4.5 0.310 0.977 
5.5 0.034 1.000 
7.0 0.000 1.000 
GDS5 
-1.0 1.000 0.000 
0.5 1.000 0.302 
1.0 0.994 0.632 
2.5 0.862 0.871 
3.5 0.575 0.977 
4.5 0.167 0.997 
6.0 0.000 1.000 
GDS4 
-1.0 1.000 0.000 
0.5 1.000 0.376 
1.5 0.954 0.726 
2.5 0.736 0.924 
3.5 0.264 0.997 
5.0 0.000 1.000 
GDS4Lit 
-1.0 1.000 0.000 
0.5 0.977 0.018 
1.5 0.839 0.604 
2.5 0.431 0.952 
3.5 0.063 0.997 
5.0 0.000 1.000 
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that the use of the test is better than chance alone but, in addition, the coordinates of 
the curve are very useful because they provide guidelines to help determine the best 
cut-off points for the shorter versions proposed for the pcb-Cohort population.  Along 
with the curve, the coordinate points of the curve are also available in the statistical 
program. For each point, one has the sensitivity and specificity. The best cut-off point 
is the one with the best correlation between these two parameters.  
 
4.2.4 Evaluating the Predictive Values to Shorter GDS Versions  
Subsequently the following question was asked: Given that the diagnostic test with our 
proposed short versions showed a positive (or negative) result, what is the probability 
that the patient is putatively positive or negative for depression? This test attribute is 
known as Predictive Value (PV) and may be positive (PPV) or negative (NPV), and it is 
determined by the interaction of three variables: the sensitivity and specificity of the 
test and the prevalence of the disease in the study group [177,198]. PPV is the 
proportion of patients (with disease) among all the individuals with a positive result by 
the test. NPV is the proportion of healthy (without the disease) individuals among the 
negative ones. These tests (PPV and NPV) are important to show the validity of the 
proposed shorter versions. 
As explained above shorter versions with specific cut-off points were 
proposed. These results were compared with the gold standard, the GDS15. PPV is 
calculated based on patients who have both positive tests divided by the total positive 
of the gold standard GDS15 (N=174). NPV is calculated based on the patients without 
depression in the proposed test, divided by the total of negative in the gold standard 
test.  
Table 21 shows the correlation between the positive and negative results of 
the shorter GDS versions compared to GDS15, the calculated value of positive and 
negative predictive values for all versions is also shown. All proposed shorter versions 
present a statistically significant correlation with GDS15, except for the version with 
four questions already described in the literature (GDS4Lit). 
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Table 21 Measure of positive predictive value and negative predictive value 
 
Abbreviation: GDS: Geriatric Depression Scale; -: negative test; +: positive test; GDS8 is short 
version with eight questions; GDS7 is short version with seven questions; GDS6 is short version 
with six questions; GDS5 is short version with five questions; GDS4 is short version with four 
questions; GDS4Lit is short version with four questions in literature. S-Sensibility; SP-
Specificity; PPV-Positive predictive value; NPV-Negative predictive value; Statistical test: *χ2-
Chi square test. Superscripts letters: 
a,b
 the same subscript letter denotes a subset of GDS 
categories whose column proportions do not differ significantly from each other at the 0.05 
level. Different subscript letters denote column proportions which differ significantly from 
each other at the 0.05 level. In bold, p-value<0.05. 
 
 
4.2.5 Depression Characterization in the pcb-Cohort as a Function of 
Different GDS Versions 
Having established the shorter GDS versions, a comparison of the socio-
demographic, clinical and cognitive characteristics of all versions was carried out. One 
of the ways to validate the veracity of the information proposed by the short versions 
is to verify if the correlations observed with the GDS15 gold standard are also observed 
with the proposed short GDS versions. 
 
 
 
Short Versions N% 
GDS15 
p-value S SP PPV NPV 
GDS15- 
N=374 
69.4% 
GDS15+ 
N=174 
30.6% 
GDS8 
GDS8- 
370 
65.1% 
353
a 
89.6% 
17
b 
9.8% 
0.001 90.2 89.6 79% 95% 
GDS8+ 
198 
34.9% 
41 a 
10.4% 
157 b 
90.2% 
GDS7 
GDS7- 
297 
52.3% 
261
 a
 
66.2% 
36
 b
 
20.7% 
0.001 79.3 66.2 51% 88% 
GDS7+ 
271 
47.7% 
133
 a
 
33.8% 
138
 b
 
79.3% 
GDS6 
GDS6- 
269 
47.4% 
255 a 
64.7% 
14 b 
8.0% 
<0.001 92 64.7 54% 95% 
GDS6+ 
299 
52.6% 
139
 a
 
35.3% 
160
 b
 
92.0% 
GDS5 
GDS5- 
367 
64.6% 
343 a 
87.1% 
24 b 
13.8% 
<0.001 86.2 87.1 75% 93% 
GDS5+ 
201 
35.4% 
51
 a
 
12.9% 
150
 b
 
86.2% 
GDS4 
GDS4- 
294 
51.8% 
286
 a
 
72.6% 
8
 b
 
4.6% 
<0.001 95.4 72.6 61% 97% 
GDS4+ 
274 
48.2% 
108 a 
27.4% 
166 b 
95.4% 
GDS4Lit 
GDS4Lit- 
46 
8.1% 
16
 a
 
4.1% 
30
 b
 
17.2% 
0.070 83.9 60.4 28% 35% 
GDS4Lit+ 
522 
91.9% 
378
 a
 
95.9% 
144 
82.8% 
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4.2.5.1 Sociodemographic characterization 
Tables 22 and 23 show correlations of sociodemographic characteristics 
compared to GDS15 or the different GDS versions: 4Lit, 4, 5, 6, 7 and 8 questions. 
There is a statistically significant correlation with age (for GDS5), gender (for GDS5, 6, 
7, 8 and 15), marital status (for GDS15), monthly family income (for GDS8 and 15), 
living arrangement (all GDS cut offs tested including GDS4Lit), level of education (for 
GDS8 and 15) and professional status (for GDS4, 5, 6, 7, 8 and 15). Depressive status is 
highest in women, individuals living alone, in lower monthly income situations (less 
than 1 minimum wage) and with lower literacy levels. It is observed that the scale that 
presents results most like GDS15 is the short version with 8 questions. It is also evident 
that the GDS4Lit does not effectively characterize the pcb-Cohort population, when 
compared to the GDS15. 
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Table 22 Correlation of sociodemographic characteristics with GDS15  
 
Abbreviation: GDS: Geriatric Depression Scale; -: negative test; +: positive test; Statistical test: χ
2
 (Chi Square). 
MW=Minimum Wage; Superscripts letters: 
a,b
 the same subscript letter denotes a subset of GDS categories whose 
column proportions do not differ significantly from each other at the 0.05 level. Different subscript letters denote 
column proportions which differ significantly from each other at the 0.05 level. In bold, p-value<0.05. 
 
 Sociodemographic  
Characteristics 
N=568 
GDS 
p-value GDS15- 
394(69.7%) 
GDS15+ 
174 (30.3%) 
Gender 
 Male 163 (28.7%) 128 a (32.5%) 35 b (20.1%) 
0.003 
 Female 405 (71.3%) 266 a (67.5%) 139 b (79.9%) 
Age group 
 50-64 years old 202 (35.6%) 148 a (37.6%) 54 a (31.0%) 
0.160  65-74 years old 229 (40.3%) 159 a (40.4%) 70 a (40.2%) 
 ≥ 75 years old 137 (24.1%) 87 a (22.1%) 50 a (28.7%) 
Marital Status 
 Living with the partner 400 (70.4%) 291 a (73.9%) 109 b (62.6%) 
0.007 
 Others situations 168 (29.6%) 103 a (26.1%) 65 b (37.4%) 
Living Arrangement 
 Alone 96 (16.9%) 56 a (14.2%) 40 b (23.0%) 
0.010 
 Accompanied 472 (83.1%) 338 a (85.8%) 134 b (77.0%) 
     
Professional Status 
 Active 176a (31%) 125 a (37.1%) 51 a (29.3%)  
 Reformed 362 a (63.7 %) 254 a (64.2%) 108 b (62.1%) 0.010 
 Desemployed 31 a (5.3) 16 a (4.1%) 15b (8.6%)  
Monthly Family Income     
  ≤1 MW 176 (31.0%) 106 a (26.9%) 70 b (40.2%) 
0.002 
 >1 MW 392 (69.0%) 288 a (73.1%) 104 b (59.8%) 
Literacy 
 0-2 years of Literacy 51 (9.0%) 23 a (5.8%) 28 b (16.1%) 
<0.001  3-6 years of Literacy 402 (70.8%) 282 a (71.6%) 120 a (69.0%) 
 ≥7 years of Literacy 115 (20.2%) 89 a (22.6%) 26 b (14.9%) 
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4.2.5.2 Clinical evaluation of pcb-Cohort patients based on shorter GDS 
versions  
As with the sociodemographic characteristics, the clinical characteristics were 
correlated with GDS15, as well as with the shorter GDS versions (Table 24). 
There are statistical significant correlations with GDS15+ and patients with OA, 
that have a diagnosis of DEP and as well as being diagnosed with GID. Regarding the 
shorter versions GDS6, GDS7, GDS8 all have the same correlations for comorbidities as 
those seen for GDS15. The GDS4 and GDS5 versions, in addition to the same 
correlations already mentioned above, include a correlation with HYP. However, the 
GDS4Lit version does not reveal any correlation with the comorbidities tested for the 
pcb-Cohort. 
Hypertensive patients do not present a positive correlation with the scales 
studied here, except in GDS4 and 5. Patients with DYP, CVD, GUD, DM, RESP and 
NEURO do not exhibit statistically significant correlations with any of the GDS versions 
tested. As already mentioned above, GDS4Lit fails to reveal any significant correlations.  
Taken together one can deduce that the worst performer in the pcb-Cohort is 
GDS4Lit and that the shorter versions GDS4 and 5 duplicate the results obtained with 
GDS15. The remaining shorter versions GDA 6, 7 and 8 behave in a manner like that 
seen for GDS15.  
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4.2.5.3 Correlation of shorter GDS versions with cognitive performance  
Since forgetfulness correlates with depression and since depression has, in 
other studies, been correlated with the poor cognitive performance [15], the present 
study evaluated how the shorter GDS versions and GDS15 behave relative to cognitive 
performance. Cognitive assessment is based on the CDR and MMSE and the results are 
presented in table 25. There is a good significant correlation with almost all the shorter 
GDS versions tested, except for GDS4Lit with respect to the CDR results. Results are 
similar when the MMSE data is considered, although in the latter GDS7 exhibits a 
lower level of significance with a p-value=0.074. To summarize there is a high 
correlation between low cognitive performance and positive GDS scores, even when 
fewer questions are considered.  
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Table 25 Correlation of shorter GDS versions and cognitive evaluation based on CDR and MMSE 
Abbreviations: GDS: Geriatric Depression Scale; -: negative test; +: positive test; GDS4Lit- 4 questions in 
questionnaire in the literature; GDS4-4 questions more frequent in pcb-Cohort; GDS5-5 more frequent questions in 
pcb-Cohort;  GDS6-6 more frequent questions in pcb-Cohort; GDS7-7 more frequent questions in pcb-Cohort; GDS8-
8 more frequent questions in pcb-Cohort; Statistical test: χ
2
 (Chi Square).  Superscripts letters: 
a.b
 the same subscript 
letter denotes a subset of GDS categories whose column proportions do not differ significantly from each other at 
the 0.05 level. Different subscript letters denote column proportions which differ significantly from each other at 
the 0.05 level. In bold, the p-value<0.05.  
 
 
4.2.5.4 APOE Genotyping and shorter GDS versions 
Subsequently the different GDS versions were compared to the APOE genotype 
(Table 26). This is particularly relevant as APOE genotype has been reported to be the 
highest risk factor for dementia, in particular AD [57,192,199] and given that GDS has a 
strong correlation with poor cognitive performance [132] this analysis was carried out. 
GDS 
version 
N (%) 
568 
CDR 
p-value 
MMSE 
p-value CDR=0 
N=301 
CDR=0.5 
N=199 
CDR≥1 
N=68 
MMSE- 
N=436 
MMSE+ 
N=132 
GDS15 
GDS15- 
394 
69.4% 
250
a 
83.1% 
112
b 
56.3% 
32
 b
 
47.1% 
<0.001 
 
370
a
 
72.0% 
24
b
 
44.4% 
<0.001 
GDS15+ 
174 
30.6% 
51
 a
 
16.9% 
87
 b
 
43.7% 
36
 b
 
52.9% 
144
a
 
28.0% 
30
b
 
55.6% 
GDS8 
GDS8- 
370 
65.1% 
231
 a
 
76.7% 
105
 b
 
52.8% 
34
 b
 
50.0% 
<0.001 
344a 
66.9% 
26b 
48.1% 
0.006 
GDS8+ 
198 
34.9% 
70
 a
 
23.3% 
94
 b
 
47.2% 
34
 b
 
50.0% 
170
a
 
33.1% 
28
b
 
51.9% 
GDS7 
GDS7- 
297 
52.3% 
182
 a
 
60.5% 
90
 b
 
45.2% 
25
 b
 
36.8% 
<0.001 
275
a
 
53.5% 
22
a
 
40.7% 
0.074 
GDS7+ 
271 
47.7% 
119 a 
39.5% 
109 b 
54.8% 
43 b 
63.2% 
239
a
 
46.5% 
32
a
 
59.3% 
GDS6 
GDS6- 
269 
47.4% 
169
 a
 
56.1% 
79
 b
 
39.7% 
21
 b
 
30.9% 
<0.001 
251
a
 
48.8% 
18
b
 
33.3% 
0.030 
GDS6+ 
299 
52.6% 
132
 a
 
43.9% 
120
 b
 
60.3% 
47
 b
 
69.1% 
263a 
51.2% 
36b 
66.7% 
GDS5 
GDS5- 
367 
64.6% 
229
 a
 
76.1% 
106
 b
 
53.3% 
32
 b
 
47.1% 
<0.001 
342
a
 
66.5% 
25
b
 
46.3% 
0.003 
GDS5+ 
201 
35.4% 
72 a 
23.9% 
93 b 
46.7% 
36 b 
52.9% 
172
a
 
33.5% 
29
b
 
53.7% 
GDS4 
GDS4- 
294 
51.8% 
190
 a
 
63.1% 
80
 b
 
40.2% 
24
 b
 
35.3% 
<0.001 
275
a
 
53.5% 
19
b
 
35.2% 
0.010 
GDS4+ 
274 
48.2% 
111
 a
 
36.9% 
119
 b
 
59.8% 
44
 b
 
64.7% 
239a 
46.5% 
35b 
64.8% 
GDS4Lit 
GDS4Lit- 
46 
8.1% 
19
 a
 
6.3% 
20
 a
 
10.1% 
7
 a
 
10.3% 
0.253 
40
a
 
7.8% 
6
a
 
11.1% 
0.394 
GDS4Lit+ 
522 
91.9% 
282
 a
 
93.7% 
179
 a
 
89.9% 
61
 a
 
89.7% 
474a 
92.2% 
48a 
88.9% 
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Of the different GDS cut-offs here tested the GDS15 and GDS8 gave the best 
correlation with the APOE Ε4.  
The proportion of patients who are GDS15+ is higher inε4 carriers than non-
carriers, with statistical significance (p-value=0.041). Similar results are observed for 
the GD8 version (p-value=0.004). The other GDS versions tested have no significant 
statistical relationship with any of the APOE alleles. 
_______________________________________________________________________ 
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Table 26 Correlation of shorter GDS versions and APOE genotype 
 
Abbreviations: GDS: Geriatric Depression Scale; -: negative test; +: positive test; SD=Standard Deviation; GDS-
Geriatric Depression State; GDS4Lit- 4 questions in questionnaire in the literature; GDS4-4 questions more frequent 
in pcb-Cohort; GDS5-5 more frequent questions in pcb-Cohort; GDS6-6 more frequent questions in pcb-Cohort; 
GDS7-7 more frequent questions in pcb-Cohort; GDS8-8 more frequent questions in pcb-Cohort; APOE-
Apolipoprotein E. Number of allele carriers are indicatedε2/ε3/ε4. Data presented as N (%) and % is expressed % as 
a function of the total in each of the APOE allele. Statistical test used: χ2=Chi square test; Superscripts letters: 
a.b
 the 
same subscript letter denotes a subset of GDS categories whose column proportions do not differ significantly from 
each other at the 0.05 level. Different subscript letters denote column proportions which differ significantly from 
each other at the 0.05 level. In bold, the p-value<0.05. 
 
 
GDS 
Versions 
N (%) 
 APOE  
Non ε2 
carriers 
N=470 
ε2 
carriers 
N=38 
p-value 
Non ε3 
carriers 
N=14 
ε3 
carriers 
N=494 
p-value 
Non ε4 
carriers 
N=412 
ε4 
carriers 
N=96 
p-value  
GDS15 
GDS15- 
351 
69.1% 
323
a 
68.7% 
28
 a
 
73.7% 
0.524 
9
 a
 
64.3% 
342
 a
 
69.2% 
0.693 
293
 a
 
71.1% 
58
b 
60.4% 
0.041 
 GDS15+ 
157 
30.9% 
147
 a
 
31.3% 
10
 a
 
26.3% 
5
 a
 
35.7% 
152
 a
 
30.8% 
119
 a
 
28.9% 
38
b 
39.6% 
GDS8 
GDS8- 
333 
65.6% 
308
 a
 
65.5% 
25
 a
 
65.8% 
0.974 
10
 a
 
71.4% 
323
 a
 
65.4% 
0.639 
282
 a
 
68.4% 
51
b 
53.1% 
0.004 
GDS8+ 
175 
34.4% 
162 a 
34.5% 
13 a 
34.2% 
4 a 
28.6% 
171 a 
34.6% 
130 a 
31.6% 
45b 
46.9% 
GDS7 
GDS7- 
273 
53.7% 
247
 a
 
52.6% 
26
 a
 
68.4% 
0.059 
10
 a
 
71.4% 
263
 a
 
53.2% 
0.178 
226
 a
 
54.9% 
47
 a
 
49.0% 
0.297 
GDS7+ 
235 
46.3% 
223
 a
 
47.4% 
12
 a
 
31.6% 
4
 a
 
28.6% 
231
 a
 
46.8% 
186
 a
 
45.1% 
49
 a
 
51.0% 
GDS6 
GDS6- 
247 
48.6% 
225
 a
 
47.9% 
22
 a
 
57.9% 
0.234 
9
 a
 
64.3% 
238
 a
 
48.2% 
0.234 
206
 a
 
50.0% 
41
 a
 
42.7% 
0.198 
GDS6+ 
261 
51.4% 
245
 a
 
52.1% 
16
 a
 
42.1% 
5
 a
 
35.7% 
256
 a
 
51.8% 
206
 a
 
50.0% 
55
 a
 
57.3% 
GDS5 
GDS5- 
327 
64.4% 
300
 a
 
63.8% 
27
 a
 
71.1% 
0.371 
11
 a
 
78.6% 
316
 a
 
64.0% 
0.261 
273
 a
 
66.3% 
54
 a
 
56.3% 
0.065 
GDS5+ 
181 
35.6% 
170 a 
36.2% 
11 a 
28.9% 
3 a 
21.4% 
178 a 
36.0% 
139 a 
33.7% 
42 a 
43.8% 
GDS4 
GDS4- 
264 
52.0% 
243
 a
 
51.7% 
21
 a
 
55.3% 
0.673 
10
 a
 
71.4% 
254
 a
 
51.4% 
0.139 
217
 a
 
52.7% 
47
 a
 
49.0% 
0.512 
GDS4+ 
244 
48.0% 
227
 a
 
48.3% 
17
 a
 
44.7% 
4
 a
 
28.6% 
240
 a
 
48.6% 
195
 a
 
47.3% 
49
 a
 
51.0% 
GDS4Lit 
GDS4Lit- 
43 
8.5% 
39
 a
 
8.3% 
4
 a
 
10.5% 
0.635 
2
 a
 
14.3% 
41
 a
 
8.3% 
0.427 
34
 a
 
8.3% 
9
 a
 
9.4% 
0.722 
GDS4Lit+ 
465 
91.5% 
431
 a
 
91.7% 
34
 a
 
89.5% 
12
 a
 
85.7% 
453
 a
 
91.7% 
378
 a
 
91.7% 
87
 a
 
90.6% 
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4.2.5.5 Multivariate analyses of the shorter GDS versions  
In the light of all the results presented above, a bivariate evaluation of all the 
characteristics was carried out for all the GDS versions tested. The model was validated 
to determine the factors that contribute to a significant model to determine the 
parameters that behave as a risk factor; protective factor or not. 
When determining the validity of the model, the optimal logistic model 
involved integration of: APOE carriers, sociodemographic characteristics, comorbidities 
and cognitive evaluation. This specific model was further analysed to evaluate 
statistical support for data integration in the evaluation of the best GDS short version. 
The Hosmer–Lemeshow statistic, the GDS15 had a p-value of 0.737; in the GDS8, a p-
value of 0.699; in the GDS7, a p-value of 0.632; in the GDS6, p-value of 0.583; in the 
GDS5 p-value is 0.940; GDS4, p-value is 0.807 and to GDS4Lit, p-value is 0.780. The 
model fits the data, except for the GDS4Lit version, which features an Omnibus test of 
Model coefficients with p>0.05. All other versions have p-value<0.05. 
Table 27 shows the multivariate analysis based on the Logistic regression 
enter methods to determine the possible risk factor(s) for depression with respect to 
the different GDS versions tested. Relative to GDS4Lit, it did not reveal a valid model, 
and furthermore no statistically significant correlation, at least for the pcb-Cohort.  
Relative to GDS5, it is possible to see that APOE ε4, Female, CDR=0.5, IADL 
and depression history are important risk factors to determine possible depressive 
disorders. For the GDS6, the risk factors include: being female, scoring CDR=0.5, and a 
history of IADL and depression. For the GDS7, the risk factors are: being female, 
CDR=0.5, CDR≥1, literacy 3-6 years and depression history. For the GDS8, APOE ε4 
appears as a risk factor for depression, as well as being female, suspected cognitive 
impairment and a history of IADL and depression. 
To GDS-15, the important factors with significance are: APOE ε4, being 
female, cognitive impairment based on the CDR, IADL, and a history of depression. 
These factors represent an increased risk, about twice as high, of having depression 
compared to individuals who do not have these characteristics. 
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4.2.6 Optimizing Criteria to Define Cases of Depression in the pcb-Cohort 
Relative to depressive disorders, DSM-5 criteria for these pathologies was not 
applied. This is because the original questionnaire used was GDS, but this does not 
have all the items necessary to apply DSM-5 for depressive disorders. Because of this, 
depression was considered for individuals diagnosed with depression but also had to 
have confirmation in their respective clinical file from a psychiatric consultation.  
This means that in this stage of the work, the patients excluded were:  
1) Patients diagnosed in the clinical file without confirmation and 
2) Patients with GDS15 positive without confirmation. 
 
The results are explained in figure 10. Thus, for the subsequent studies in this 
section the cases of individuals with depression considered were 74 (herein referred to 
as TrueDEP/True depression cases). 
 
 
 
Figure 10 Workflow to identify cases of depression 
A total of 208 patients were excluded because it was not possible to confirm the diagnostic of depression based on 
DSM-5. 286 patients did not have depression and the GDS is negative. 74 patients have a depression diagnostic 
confirmed by a specialist doctor and the GDS15 is positive. 
 
 
 
568
pcb-Cohort
282
Normal
74
TrueDEP
208
Excluded
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4.2.7 Comparing the GDS15 and GDS4Lit for the True Depression Cases in 
the pcb-Cohort  
Comparing the data here obtained with that of figure 8, it is immediately 
obvious that there is great consistency in the frequency and order of the top questions 
when considering each individual response of the GDS15. Again, for the TrueDEP the 
GDS4Lit does not perform well. 
In detail, the top 8 most frequent depression positive questions are the same 
whether all the GDS15 positive cases (Figure 8) are considered or only the TrueDEP 
(Figure 11), with only one minor alteration; the order of question 5 and 7 (GDSQ5 and 
GDSQ7). That is the top 8 questions for GDS15 positive are (4, 6, 3, 9, 2, 5, 7 and 1) and 
for the TrueDEP (4, 6, 3, 9, 2, 7, 5 and 1). For the remaining 7 questions the overall 
order is consistent, although some minor alterations in the order of relative 
frequencies. Thus, for GDS15 the order is: 8, 14, 13, 15, 10, 12 and 11 and for the 
TrueDEP: 8, 13, 15, 10, 14, 12, and 11 (Figure 11). 
 
Figure 11- Frequency of answers consistent with depression in the GDS15 in patients with depression 
diagnostic in pcb-Cohort.  
The number in front of GDS corresponds to the number of the question in the original GDS15 questionnaire (see 
methods); GDSQ4=question 4 in the GDS15. Stripped columns represent the four questions in the short version of 
GDS4Lit described in the literature. That is questions: GDSQ1. GDSQ3. GDSQ6 and GDSQ7 [186]. The percentage of 
individuals scoring in a pattern consistent with Depression, for each of the questions, is shown as a percentage of 
the total number of individuals with Depression (N=74). 
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4.2.8 Determining cut-off points for the Shorter GDS Versions Using the 
TrueDEP Cases 
As above, the cut-off points for the shorter GDS versions were calculated but 
the TrueDEP cases were used as the reference for depression (Figure 12 and Table 28). 
Results are like those obtained when GDS15 is the reference for depression (Figure 9 
and Table 20). The best cut offs for the different shorter GDS versions when TrueDEP 
cases are considered are: GDS8TrueDEP≥3; GDS7TrueDEP≥4; GDS6TrueDEP≥3; 
GDS5TrueDEP≥ 3; GDS4TrueDEP≥2. These are the same as those previously 
determined for the GDS15+, namely: GDS8≥3; GDS7≥4; GDS6≥3; GDS5≥3; GDS4≥2.  
 
Figure 12 ROC Curve to GDS with short version based on TrueDEP cases 
The number of questions in each of the GDS scales is as previously explained and based on the top incorrect 
answers of the GDS15. The AUC for GDS8 is 0.965 (CI 95% 0.945-0.985); for GDS7 it is 0.806 (95%CI 0.757-0.861); for 
GDS6 it is 0.904 (CI 95% 0.870 – 0.938); for GDS5 it is 0.947 (CI 95% 0.925-0.970); for GDS4 it is 0.934 (95%CI 0.906-
0.961); and for GDS4Lit it is 0.812 (95%CI 0.762-0.874). The curves with the best discriminating power are GDS8 and 
GDS6. The null hypothesis: true area=0.5. Abbreviation: AUC=Area Under Curve; CI=Confidential Interval. 
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Table 28 ROC curve to determine cut-off points for the shorter GDS short versions based on 
TrueDEP 
 
The test result variable(s): GDS8TrueDEP, GDS7TrueDEP, GDS6TrueDEP, GDS5TrueDEP, GDS4TrueDEP, GDS4Lit has 
at least one tie between the positive actual state group and the negative actual state group. The smallest cut-off 
value is the minimum observed test value minus 1. The largest cut-off value is the maximum observed test value 
plus 1. All the other cut-off values are the averages of two consecutive ordered observed test values. 
Test Result 
Variable(s) 
Positive if 
Greater 
Than or 
Equal To 
Sensitivity Specificity 
GDS8 
TrueDEP 
-1.0000 1.000 0.000 
0.5000 1.000 0.371 
1.5000 0.986 0.682 
2.5000 0.905 0.902 
3.5000 0.730 0.986 
4.5000 0.486 1.000 
5.5000 0.216 1.000 
6.5000 0.095 1.000 
7.5000 0.014 1.000 
9.0000 0.000 1.000 
GDS7 
TrueDEP 
0.00 1.000 0.000 
1.50 1.000 0.014 
2.50 0.959 0.332 
3.50 0.865 0.682 
4.50 0.486 0.874 
5.50 0.135 0.979 
6.50 0.054 1.000 
8.00 0.000 1.000 
GDS6 
TrueDEP 
-1.00 1.000 0.000 
0.50 1.000 0.003 
1.50 1.000 0.311 
2.50 0.959 0.668 
3.50 0.784 0.874 
4.50 0.351 0.979 
5.50 0.054 1.000 
7.00 0.000 1.000 
GDS5 
TrueDEP 
-1.00 1.000 0.000 
0.50 1.000 0.311 
1.50 1.000 0.647 
2.50 0.878 0.874 
3.50 0.622 0.979 
4.50 0.189 1.000 
6.00 0.000 1.000 
GDS4 
TrueDEP 
-1.00 1.000 0.000 
0.50 1.000 0.395 
1.50 0.959 0.748 
2.50 0.743 0.934 
3.50 0.311 1.000 
5.00 0.000 1.000 
GDS4Lit 
-1.00 1.000 0.000 
0.50 1.000 0.021 
1.50 0.878 0.615 
2.50 0.459 0.958 
3.50 0.054 0.997 
5.00 0.000 1.000 
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4.2.8.1 Determining the positive and negative predictive value of short 
versions by considering TrueDEP  
 The concept is as explained before, N=74 for patients with TrueDEP. Table 29 
shows the correlation of the shorter GDS version and TrueDEP, as well as the 
sensibility (S), specificity (SP), positive predictive value (PPV) and negative predictive 
value (NPV). To recall (Table 21), all proposed shorter GDS versions compared to GDS 
15 present a statistically significant correlation with the latter, except for the version 
with four questions already described in the literature (GDS4Lit). Comparing to the 
TrueDEP based analysis (Table 29), results are similar except that GDS4Lit is also 
significant although the specificity level is very low (3.1). 
To summarize all shorter GDS versions compared to TrueDEP exhibit similar 
statistical parameters (to distinguish from the above mentioned GDSn shorter 
versions, these are designated as GDSnTrueDEP). Thus, shorter GDS versions may be 
valuable tools, but of course this would have to be further validated. 
 
_______________________________________________________________________ 
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Table 29 Predictive values to shorter GDS versions based on TrueDEP 
 
Abbreviation: GDS: Geriatric Depression Scale; -: negative test; +: positive test; GDS8TrueDEP is short version with 
eight questions pcb-Cohort; GDS7TrueDEP is short version with seven questions pcb-Cohort; GDS6TrueDEP is short 
version with six questions pcb-Cohort; GDS5TrueDEP is short version with five questions pcb-Cohort; GDS4TrueDEP 
is short version with four questions pcb-Cohort; GDS4Lit is short version with four questions in literature. S: 
Sensibility; SP: Specificity; PPV: Positive Predictive Value; NPV: Negative Predictive value. PPV is the division of the 
true positives by the sum of patients. NPV-Negative predictive value is the division of true negatives by not ill.  
Statistical test: Statistical test used: χ2=Chi square test. Superscripts letters: 
a.b
. The same superscript letter denotes 
a subset of GDS categories whose column proportions do not differ significantly from each other at the 0.05 level. 
Different superscript letters denote column proportions which differ significantly from each other at the 0.05 level. 
Tests are adjusted for all pairwise comparisons within a row of each innermost table using the Bonferroni 
correction.  
 
 
4.2.8.2 Correlation of sociodemographic characteristics and shorter GDS 
versions based on TrueDEP  
 Sociodemographic characteristics in patients with shorter GDS versions based 
on TrueDEP (Table 30 and Table 31). For the TrueDEP group, there is a statistically 
significant correlation with all the parameters, except age: that is gender, marital 
status, living arrangement, professional status, monthly family income and level of 
education. These results are the same as when the GDS15+ was used as the control 
group (Tables 22 and 23). 
Short Versions 
N (%) 
360 
  No Depression 
N=286 
Depression 
N=74 
p-value S SP PPV NPV 
GDS8 
TrueDEP 
GDS8 
TrueDEP - 
265 
(73.6%) 
258a 
90.2% 
7b 
9.5% <0.001 90.5 90.2 69.4 97.4 
GDS8 
TrueDEP + 
95 
(26.4%) 
28
a
 
9.8% 
67
b
 
90.5% 
GDS7 
TrueDEP 
GDS7 
TrueDEP - 
205 
(56.9%) 
195
a
 
68.2% 
10
b
 
13.5% <0.001 86.5 68.2 64.7 95.1 
GDS7 
TrueDEP + 
155 
(43.1%) 
91
a
 
31.8% 
64
b
 
86.5% 
GDS6 
TrueDEP 
GDS6 
TrueDEP - 
194 
(53.9%) 
191
a
 
66.8% 
3
b
 
4.1% <0.001 95.9 66.8 71.7 98.5 
GDS6 
TrueDEP + 
166 
(46.1%) 
95a 
33.2% 
71b 
95.9% 
GDS5 
TrueDEP 
GDS5 
TrueDEP - 
259 
(71.9%) 
250a 
87.4% 
9b 
12.2% <0.001 87.8 87.4 66.8 96.5 
GDS5 
TrueDEP + 
101 
(28.1%) 
36a 
12.6% 
65b 
87.8% 
GDS4 
TrueDEP 
GDS4 
TrueDEP - 
217 
(60.3%) 
214a 
74.8% 
3b 
4.1% <0.001 95.9 74.8 72.0 98.6 
GDS4 
TrueDEP + 
143 
(39.7%) 
72
a
 
25.2% 
71
b
 
95.9% 
GDS4Lit 
GDS4Lit- 
19 
(5.3%) 
9
a
 
3.1% 
10
b
 
13.5% <0.001 86.5 3.1 64.2 47.4 
GDS4Lit+ 
341 
(94.7%) 
277a 
96.9% 
64b 
86.5% 
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Table 30 Sociodemographic characteristics and depression based on TrueDEP 
 
Abbreviation: GDS: TrueDEP- 74 patients with confirmed diagnostic to depressive disorder; (-) negative cases for 
depressive disorder; (+) the true positive cases for depressive disorder. 
 
In Table 31, the shorter GDSnTrueDEP versions were compared to TrueDEP. To 
summarize the results were as follows, significant correlations with: 
• GDS4Lit and monthly income; 
• GDS4TrueDEP and monthly income, years of literacy and gender; 
• GDS5TrueDEP and gender, living arrangement, monthly wage and years 
of literacy; 
• GDS6TrueDEP and gender, monthly wage and years of literacy; 
• GDS7TrueDEP and gender, marital status, living arrangement, monthly 
wage and years of literacy; 
• GDS8TrueDEP and gender, marital status, living arrangement,  monthly 
wage and years of literacy. 
 
Therefore, GDS4Lit does not effectively characterize depression in the 
Portuguese pcb-Cohort. The short versions however do show similar results compared 
with TrueDEP, particularly so for GDS7TrueDEP and GDS8TrueDEP. These results are in 
line with those obtained with GDS15+ was employed for base line comparisons. 
Sociodemographic Characteristics TrueDEP 
p-value 
(-) (+) 
Gender  
  
 Male 113
a
 (39.5%) 7
b 
(9.5%) 
<0.001 
 Female 173
a
 (60.5%) 67
b 
(90.5%) 
Age Group    
 50-64 103
a
 (36.0%) 28
a 
(37.8%) 
0.714  65-74 112
a
 (39.2%) 31
a 
(41.9%) 
 ≥ 75 71
a
 (24.8%) 15
a 
(20.3%) 
Marital Status    
 Living with partner 218
a 
(76.2%) 41
b 
(55.4%) 
<0.001 
 Others Situations 68a (23.8%) 33b (44.6%) 
Living Arrangement    
 Alone 42
a 
(14.7%) 20
b 
(27.0%) 
0.012 
 Accompanied 244
a 
(85.3%) 54
b 
(73.0%) 
Professional Status    
 Active 84
a 
(29.4%) 26
a 
(35.1%) 
0.001  Reformed 192a (67.1%) 38b (51.4%) 
 Unemployed 10
a 
(3.5%) 10
b 
(13.5%) 
Monthly Family    
 ≤1MW 74
a
 (25.9%) 31
b 
(41.9%) 
0.007 
 >1 MW 212
a
 (74.1%) 43
b 
(58.1%) 
Years of Literacy    
 0-2 years of Literacy 18a (6.3%) 11b (14.9%) 
0.021  3-6 years of Literacy 203a (71.0%) 53a (71.6%) 
 >= 7 years of Literacy 65a (22.7%) 10a (13.5%) 
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4.2.8.3 Correlation of shorter GDS versions based on TrueDEP and 
comorbidities 
Table 32 shows the correlation of clinical characteristics and TrueDEP cases of 
depressive disorder. The comorbidities that show correlation are OA and GID, both 
with statistical significance. As explained before, N=356 patients from the pcb-Cohort 
(286 negative cases and 74 positive cases). 
 
Table 32 Correlation comorbidities with TrueDEP 
 
Abbreviations: TrueDEP-74 patients with confirmed diagnostic to depressive disorder; (-) negative cases for 
depressive disorder; (+) the true positive cases for depressive disorder. HYP-Hypertension arterial; DYS-
Dyslipidaemia; OA-Osteoarthicular disease; CVD-Cardiac and vascular Disease; DEP-Depression; GID-Gastrointestinal 
Disease; GUD-Genitourinary Disease; DM-Diabetes Mellitus; RESP-Respiratory Disease; HEMATO-Hematologic 
Disease; ONCO-Oncology Disease; NEURO-Neuropathologies; ALCOHOL-Alcohol Excessive Use. Statistical test: *χ2-
Chi square test. Values in the same row and not sharing the same superscript are significantly different at p<0.05 in 
the two-sided test of equality for column proportions. N=356 patients of pcb-Cohort. Superscripts letters 
a, b
: The 
same subscript letter denotes a subset of categories whose column proportions don not differ significantly from 
each other at the 0.05 level. Different subscript letters denote column proportions which differ significantly from 
each other at the 0.05 level. In bold, the p-value less than 0.05. Tests assume equal variances. Tests are adjusted for 
all pairwise comparisons within a row of each innermost using the Bonferroni correction. 
 
In Table 33 the correlations of the shorter version based on TrueDEP cases with 
comorbidities are shown. For GDS4Lit, there are not correlations, but for all the other 
Comorbidities 
N (%) 
356 
TrueDEP 
p-value (-) 
N=286 
(+) 
N=74 
HTA 223 (61.9%) 176
a
 (61.5%) 47
a
 (63.5%) 0.755 
DYS 214 (59.4%) 168
a
 (58.7%) 46
a
 (62.2%) 0.593 
OA 188 (52.2%) 136
a
 (47.6%) 52
b
 (70.3%) <0.001* 
CVD 196 (54.4%) 156
a
 (54.5%) 40
a
 (54.1%) 0.940 
GID 90 (25.0%) 56
a
 (19.6%) 34
b
 (45.9%) <0.001* 
GUD 76 (21.1%) 60
a
 (21.0%) 16
a
 (21.6%) 0.904 
DM 75 (20.8%) 61
a
 (21.3%) 14
a
 (18.9%) 0.649 
RESP 60 (16.7%) 45
a
 (15.7%) 15
a
 (20.3%) 0.351 
HEMATO 42 (11.7%) 33a (11.5%) 9a (12.2%) 0.882 
NEURO 10 (2.8%) 7
a
 (2.4%) 3
a
 (4.1%) 0.4541 
ALCOHOL 10 (2.8%) 9
a
 (3.1%) 1
a
 (1.4%) 0.4021 
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cases the correlations with OA and GID are confirmed, with statistical significance. This 
is consistent with the results seen when GDS15+ cases were taken as the depressed 
participants (Table 24). 
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4.2.8.4 Correlation of TrueDEP shorter GDS versions and cognitive evaluation 
with CDR and MMSE 
True depression cases (TrueDEP) were correlated with CDR and MMSE scores. 
In both cases no correlations occurred with GDS4Lit. Regarding all the other cases 
GDSnTrueDEP correlations are significant in all cases except for MMSE and 
GDS7TrueDEP (Table 34). The results are like those shown in the GDS15 correlations 
(Table 21). Taken together one can deduce that there is a strong correlation with 
cognitive impairment and depression. 
 
Table 34 Correlation of depressive disorders and TrueDEP shorter GDS versions  
Abbreviation: GDS: Geriatric Depression Scale; GDSnTrueDEP-short version with “n” questions based in 74 patients 
with confirmed diagnosis of depression in pcb-Cohort; -: negative test; +: positive test. -: negative test; +: positive 
test; GDS4Lit is short version with four questions in literature. CDR-Clinical Dementia Rate; MMSE-Mini Mental 
Status Examination. Superscripts letters: 
a.b
. The same superscript letter denotes a subset of GDS categories whose 
column proportions do not differ significantly from each other at the 0.05 level. Different superscript letters denote 
column proportions which differ significantly from each other at the 0.05 level. Tests are adjusted for all pairwise 
comparisons within a row of each innermost table using the Bonferroni correction. 
 
 
GDS 
version 
N (%) 
CDR 
p-value 
MMSE 
p-value CDR=0 
N=301 
CDR=0.5 
N=199 
CDR≥1 
N=68 
MMSE- 
N=436 
MMSE+ 
N=132 
TrueDEP  
Dep- 
N=282 
189
a
 
89.6% 
76
b
 
67.3% 
21
b
 
58.3% 
<0.001 
270
a
 
82.1% 
16
b
 
51.6% 
<0.001 
Dep+ 
N=74 
22
a
 
10.4% 
37
b
 
32.7% 
15
b
 
41.7% 
59
a
 
17.9% 
15
b
 
48.4% 
GDS8 
TrueDEP 
GDS8PCB- 
N=265 
171
a
 
81.0% 
73
b
 
64.6% 
21
b
 
58.3% 
<0.001 
247
a
 
75.1% 
18
b
 
58.1% 
0.040 
GDS8PCB+ 
N=95 
40
a
 
19.0% 
40
b
 
35.4% 
15
b
 
41.7% 
82
a
 
24.9% 
13
b
 
41.9% 
GDS7 
TrueDEP 
GDS7PCB- 
N=205 
137
a
 
64.9% 
56
b
 
49.6% 
12
b
 
33.3% 
<0.001 
192
a
 
58.4% 
13
a
 
41.9% 
0.077 
GDS7PCB+ 
N=155 
74a 
35.1% 
57b 
50.4% 
24b 
66.7% 
137a 
41.6% 
18a 
58.1% 
GDS6 
TrueDEP 
GDS6PCB- 
N=194 
131
a
 
62.1% 
52
b
 
46.0% 
11
b
 
30.6% 
<0.001 
183
a
 
55.6% 
11
b
 
35.5% 
0.032 
GDS6PCB+ 
N=166 
80
a
 
37.9% 
61
b
 
54.0% 
25
b
 
69.4% 
146
a
 
44.4% 
20
b
 
64.5% 
GDS5 
TrueDEP 
GDS5PCB- 
N=259 
171
a
 
81.0% 
68
b
 
60.2% 
20
b
 
55.6% 
<0.001 
243
a
 
73.9% 
16
b
 
51.6% 
0.008 
GDS5PCB+ 
N=101 
40
a
 
19.0% 
45
b
 
39.8% 
16
b
 
44.4% 
86
a
 
26.1% 
15
b
 
48.4% 
GDS4 
TrueDEP 
GDS4PCB- 
N=217 
148
a
 
70.1% 
55
b
 
48.7% 
14
b
 
38.9% 
<0.001 
204
a
 
62.0% 
13
b
 
41.9% 
0.029 
GDS4PCB+ 
N=143 
63
a
 
29.9% 
58
b
 
51.3% 
22
b
 
61.1% 
125
a
 
38.0% 
18
b
 
58.1% 
GDS4Lit 
GDS4Lit- 
N=19 
8a 
3.8% 
10a 
8.8% 
1a 
2.8% 
0.118 
17a 
5.2% 
2a 
6.5% 
0.760 
GDS4Lit+ 
N=341 
203
a
 
96.2% 
103
a
 
91.2% 
35
a
 
97.2% 
312
a
 
94.8% 
29
a
 
93.5% 
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4.2.8.5 Correlation of TrueDEP shorter GDS versions and APOE genotyping 
APOE and depression have previously been correlated in literature [200]. 
Subsequently the different TrueDEP shorter versions were compared to the APOE 
genotype (Table 35). There are no correlations with statistical significance, in any of 
the shorter version based on TrueDEP cases. This is strikingly different to the results 
obtained in the GDS15, when in fact APOEe4 correlated with a depressive condition as 
determined by GDS15+ and GDS8+ (Table 26). 
Table 35 Correlation of depressive disorders based on TrueDEP shorter GDS versions and 
APOE genotyping 
 
Abbreviation: GDS: Geriatric Depression Scale; GDSnTrueDEP-short version with “n” questions based in 74 patients 
with confirmed diagnosis of depression in pcb-Cohort; -: negative test; +: positive test. -; APOE-Apolipoprotein E. 
Number of allele carriers are indicatedε2/ε3/ε4. Data presented as N (%) and % is expressed % as a function of the 
total in each of the APOE allele.  Superscripts letters: a.b. The same superscript letter denotes a subset of GDS 
categories whose column proportions do not differ significantly from each other at the 0.05 level. Different 
superscript letters denote column proportions which differ significantly from each other at the 0.05 level. Tests are 
adjusted for all pairwise comparisons within a row of each innermost table using the Bonferroni correction. 
 
 
GDS 
Versions 
N (%) 
 APOE  
Non ε2 
carriers  
N=303 
ε2 
carriers 
N=23 
p-value 
Non ε3 
carriers 
N=4 
ε3 
carriers 
N=322 
p-
value 
Non ε4 
carriers 
N=271 
ε4 
carriers 
N=55 
p-value  
TrueDEP 
GDS15- 
N=259 
240
a
 
79.2% 
19
a
 
82.6% 
0.697 
3
a
 
75.0% 
256
a
 
79.5% 
0.825 
217
a
 
80.1% 
42
a
 
76.4% 
0.535 GDS15+ 
N=67 
 
63
a
 
20.8% 
4
a
 
17.4% 
1
a
 
25.0% 
66
a
 
20.5% 
54
a
 
19.9% 
13
a
 
23.6% 
GDS8 
 TrueDEP 
GDS8- 
N=241 
224
a
 
73.9% 
17
a
 
73.9% 
0.999 
3
a
 
75.0% 
238
a
 
73.9% 
0.961 
205
a
 
75.6% 
36
a
 
65.5% 
0.117 GDS8+ 
N=85 
 
79
a
 
26.1% 
6
a
 
26.1% 
1
a
 
25.0% 
84
a
 
26.1% 
66
a
 
24.4% 
19
a
 
34.5% 
GDS7 
 TrueDEP 
GDS7- 
N=190 
 
174
a
 
57.4% 
16
a
 
69.6% 
0.255 
2
a
 
50.0% 
188
a
 
58.4% 
0.735 
163
a
 
60.1% 
27
a
 
49.1% 
0.129 
GDS7+ 
N=136 
 
129
a
 
42.6% 
7
a
 
30.4% 
2
a
 
50.0% 
134
a
 
41.6% 
108
a
 
39.9% 
28
a
 
50.9% 
GDS6 
TrueDEP 
GDS6- 
179 
164
a
 
54.1% 
15
a
 
65.2% 
0.303 
2
a
 
50.0% 
177
a
 
55.0% 
0.843 
154
a
 
56.8% 
25
a
 
45.5% 
0.122 
GDS6+ 
147 
139
a
 
45.9% 
8
a
 
34.8% 
2
a
 
50.0% 
145
a
 
45.0% 
117
a
 
43.2% 
30
a
 
54.5% 
GDS5 
TrueDEP 
GDS5- 
N=234 
215
a
 
71.0% 
19
a
 
82.6% 
0.231 
3
a
 
75.0% 
231
a
 
71.7% 
0.885 
198
a
 
73.1% 
36
a
 
65.5% 
0.253 
GDS5+ 
N=92 
88
a
 
29.0% 
4
a
 
17.4% 
1
a
 
25.0% 
91
a
 
28.3% 
73
a
 
26.9% 
19
a
 
34.5% 
GDS4 
TrueDEP 
GDS4- 
N=197 
182
a
 
60.1% 
15
a
 
65.2% 
0.626 
3
a
 
75.0% 
194
a
 
60.2% 
0.549 
165
a
 
60.9% 
32
a
 
58.2% 
0.709 
GDS4+ 
N=129 
121
a
 
39.9% 
8
a
 
34.8% 
1
a
 
25.0% 
128
a
 
39.8% 
106
a
 
39.1% 
23
a
 
41.8% 
GDS4Lit 
GDS4Lit- 
N=19 
16
a
 
5.3% 
3
a
 
13.0% 
0.126 
0
1
 
0.0% 
19
a
 
5.9% 
0.617 
15
a
 
5.5% 
4
a
 
7.3% 
0.616 
GDS4Lit+ 
N=307 
287
a
 
94.7% 
20
a
 
87.0% 
4
1
 
100.0% 
303
a
 
94.1% 
256
a
 
94.5% 
51
a
 
92.7% 
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4.2.8.6 Logistic Regression to determine risk factors for depressive status 
based on GDSnTrueDEP 
 In the light of all these results, a bivariate evaluation of all the characteristics 
was carried out for depressive cases and for all the GDSnTrueDEP scales tested. The 
model was validated. To determine the factors that are important to a significant 
model and of these factors, which behave as a risk factor, protective factor, or as a 
factor not bearing a statistically significant contribution, through the odds ratio. The 
optimal logistic model involved integration of: APOE carriers, sociodemographic 
characteristics, comorbidities and cognitive evaluation. This specific model was further 
analysed to evaluate statistical support for data integration in the evaluation of the 
best GDS short version. The Hosmer–Lemeshow statistic, in the depressive disorder 
cases, had a p-value of 0.401; in the GDS8TrueDEP, a p-value of 0.184; in the 
GDS7TrueDEP, a p-value of 0.385; in the GDS6TrueDEP, p-value of 0.358; in the 
GDS5TrueDEP, p-value is 0.421; in GDS4 TrueDEP, p-value is 0.139 and to GDS4Lit, p-
value is 0.338. The model fits the data, except for the GDS4Lit version, which features 
an Omnibus test of Model coefficients with p>0.05. All other versions have p-
value<0.05. The Logistic Regression was performed to find important risk factors in 
different GDSnTrueDEP versions. Table 36 shows all OR and p-values. 
 Significant correlations were seen with gender, cognitive impairment based on 
the CDR, IADL, and age. These factors represent an increased risk, about twice as high, 
with respect to having depression (Table 36). The shorter versions GDSnTrueDEP 
behave in a similar fashion but with GDS4Lit there are no significant correlations. 
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4.3.1 APOE Genotype Frequency in the pcb-Cohort 
Several genetic risk factors have been associated with AD, but as mentioned in 
the introduction APOE is the best studied risk factor. Specifically, the presence of the 
APOE alleleε4 is a known risk factor for AD. Thus, the pcb-Cohort was genotyped for 
APOE (Figure 13). The most prevalent APOE genotype is theε3ε3, expressed in 75% of 
the individuals,ε3ε4 in 16.1% andε2ε3 in 6.1%. Noε2ε2 individuals are evident and 
lower percentages of 1.4% can be seen for bothε2ε4 andε4ε4.  
 
 
Figure 13 APOE genotype in the pcb-Cohort 
The more frequent genotype isε3ε3. There are noε2ε2. The prevalence ofε2ε4 andε4ε4 is 1.4%. 
 
4.3.2 APOE Polymorphisms Correlations with Ageing and Cognitive 
Decline 
Relevant characteristics, namely socio-demographic and cognitive decline 
within the pcb-Cohort and corresponding associations with APOE ε4,ε3 andε2 carriers 
were carried out. No significant associations are evident for alleleε3 carriers (data not 
shown), with respect to APOE ε4 andε2 alleles (Table 35). No statistically significant 
gender related associations were found. However, for the younger age group in the 
pcb-Cohort population (age group from 50-64 years old) there is a significant 
correlation with the APOE ε2 carriers (p=0.042). 
75.0%
16.1%
6.1%
1.4% 1.4%
0,0
10,0
20,0
30,0
40,0
50,0
60,0
70,0
80,0
ε3ε3 ε3ε4 ε2ε3 ε4ε4 ε2ε4
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Regarding the associations between APOE genotype and cognition, the 
percentage of individuals with moderate to severe cognitive decline based on the CDR 
scores is greater in ε4 carriers (p=0.035) [201]. This is consistent with other literature 
reports. None of the APOE genotypes associate with instrumental activities of life, IADL 
or with ADL. Of note, no correlations between APOE genotype and MMSE are 
observed. Another aspect monitored includes geriatric depression determined by 
applying the GDS scale (GDS≥5); high GDS scores associate significantly (Table 35) with 
APOE ε4 carriers (p-value=0.041). With the application of DSM-5 criteria for 
neurocognitive disorders, no significant correlations with APOE are evident. It could be 
that the N is relatively small. 
 
4.3.3 Association of APOE Alleles with Comorbidities 
 
All volunteers were scored for the presence of other diseases; the most 
representative are shown in table 36. APOE ε4 carriers significantly associate with 
dyslipidaemia (p<0.05). With moderate statistical significance, there is a correlation 
with respiratory disease and APOE ε4 and CVD and DM with APOE ε2. None of the 
other comorbidities investigated significantly associated with APOE ε2 andε4 carriers 
or non-carriers. 
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Patients with DYS are APOE4 carriers, in a higher statistical significance 
percentage (57.0% vs 69.8%), compared to non-APOE4 carriers (p=0.022). Regarding 
patients with RESP, APOE4 carrier patients are in a lower proportion than non-carriers 
with statistical significance (17.5% vs 9.4%. p=0.051).  
For patients with CVD, APOE2 carriers have a statistically higher percentage 
(55.7% vs 39.5%), compared to non-APOE2 carriers (p=0.053). It is also noted that, in 
relation to patients with DM, APOE2 carriers have a higher percentage (20.6% vs 7.9%), 
compared to non-APOE2 carriers, with moderate statistical significance (p=0.057). 
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4.4 Inappropriate Medication in the pcb-Cohort 
As briefly discussed in the introduction, polypharmacy is the concurrent use of 
multiple medications and it can be a problem particularly relevant in the older 
populations. Thus, medication usage was addressed in this study; relevant data was 
available for 361 participants. Within the pcb-Cohort, the total number of medications 
used is 2306. The average number is 6.39±3.55; with a minimum=0 and a 
maximum=19. For men the average is 4.96±2.80 and for women 7.04±3.60 (p<0.001). 
Only 5.5% (N=20) of patients are classified as no polypharmacy; 28 % (N=101) are 
classified as polypharmacy minor (using 2 to 4 chronic medications) and 66.5% (N=240) 
are polypharmacy major (using more than 5 chronic medications). 
 
4.4.1 Potentially Inappropriate Medication  
4.4.1.1  Table 1 Beers Criteria: Potentially Inappropriate Medication Use in 
Older Adults in the pcb-Cohort 
The data collected was organized bearing in mind the Beers Criteria (Annex I-
Supplementary table 1- Table I of the Beers Criteria AGS Beers Criteria for Potentially 
Inappropriate Medication Use in Older Adults – PIM1). It is evident that, in the pcb-
Cohort, 190 (52.6%) patients 65 years old or more, are not using any medication from 
the list of PIMs. The 171 break down as follows: 104 (29.6%) patients using one PIM1; 
53 (14.7%) patients using two PIM1; 9 (2.5%) patients using three PIM1 and 2 patients 
(0.6%) using four PIM1. The prevalence of medication classified as PIM1 (Table I- Beers 
Criteria) is shown in table 39. The most frequently used medications include 
Benzodiazepines (short and intermediate acting) 19.4% (N=70); other Benzodiazepines 
16.1% (N=58); Benzodiazepines (long-acting) 8.6% (N=31); conventional and atypical 
Antipsychotics 6.0% (N=22); and Non-steroidal Anti-inflammatory drugs (oral) 6.0% 
(N=22).  
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Table 39 Frequency of Potentially Inappropriate Medication Use in Older Adults in the pcb-
Cohort 
 
 
Relative to PIM1 there are some medications with a low number of users the 
cardiovascular drug of low usage in the pcb-Cohort is Spironolactone>25mg/day, 
N=2. The low usage pain medication (Meperidine, Indomethacin, Ketorolac, 
Pentazocine) has N=2 and the first-generation Antihistamines N=1 and the 
antiparkinsonian agents (Benztropine) has an N=1. The other classes of 
medications of the Table one of Beers Criteria do not have any cases. The other 
drugs not included in the table, because they do not constitute PIM are (although 
the patient was taking the medication, it had no criteria for PIM): Barbiturates 
(Phenobarbital) N=1 (0.3%), Amiodarone N=8 and Sotalol N=5, and Endocrine 
Drugs (estrogens with or without progestin N=2 (0.6%) and insulin as sliding scale 
N=7 (1.9%)). The other classes of medications of the Table one of Beers Criteria do 
not have any cases. 
 
4.4.1.2  Table 2 Beers Criteria: Potentially Inappropriate Medication Use in 
Older Adults Due to Drug-Disease or Drug-Syndrome Interactions That 
May Exacerbate the Disease or Syndrome 
Beers Table 2 (see Annex I) addresses the interactions of the drugs with 
diseases or with syndromes: Beers Criteria for PIM Use in Older Adults Due to Drug-
Drugs PIM1 N % 
Benzodiazepines Short- and intermediate-acting 70 19.4% 
Other Benzodiazepines 58 16.1% 
Benzodiazepines Long-acting 31 8.6% 
Non-COX-selective (NSAIDs oral) 22 6.0% 
No benzodiazepine Hypnotics 18 5.0% 
Antipsychotics. first(conventional) and second(atypical) generation 16 4.4% 
Antithrombotic   15 4.2% 
Antiarrhythmic drugs (Class Ia. Ic. III)  14 3.9% 
Tertiary TCAs. alone or in combination  11 3.1% 
Others Cardiovascular disease drugs  2 0.6% 
Pain medications 2 0.6% 
First-generation antihistamines  1 0.3% 
Antiparkinson agents (Benzitropine) 1 0.3% 
Abbreviations: COX-cyclooxygenases; NSAIDs-Non steroids anti-inflammatory drugs; TCAs-tricyclic antidepressants. The medications classified in Table I 
of Beers Criteria (PIM1) are presented in decreasing order of usage. % is relative to total number of patients (N=361). In the class of Benzodiazepines 
Short and intermediate acting the drugs are: Alprazolam N=31 (8.6%). Estazolam N=1 (0.3%). Lorazepam N=35 (9.7%). Oxazepam N=1 (0.3%) and 
association among these medications N=2 (0.6%); In the class of Benzodiazepines Long-acting drugs are: Chlorazepate N=6 (1.7%). Clonazepam N=1 
(0.3%). Diazepam N=21 (5.8%). Flurazepam N=3 (0.8%); Other Benzodiazepines are: Bromazepam N=23 (6.4%). Cloxazolam N=8 (2.2%). Mexazolam 
N=10 (2.8%). Brotizolam N=1 (0.3%). Midazolam N=1 (0.3%). Ethyl Loflazepate N=5 (1.4%). Clobazam N=7 (1.9%).  
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Disease or Drug-Syndrome Interactions That May Exacerbate the Disease or Syndrome 
(PIM2). The pathologies that must be considered from Table 2 Beers Criteria (see 
Annex 1 – Supplementary Table 2) are:  
• Cardiovascular: heart failure and syncope;  
• Central Nervous System: seizures or epilepsy, delirium, dementia 
syndrome, falls, insomnia, Parkinson's disease;  
• Gastrointestinal Tract: constipation, gastric or duodenal ulcer; and 
Urinary Tract / Kidney: chronic renal failure stage IV or V. or urinary 
tract symptoms/benign prostatic hyperplasia stress urinary 
incontinence. 
 
Table 40 describes the application of Table 2 of the Beers Criteria in patients 
of the pcb-Cohort. In the pcb-Cohort, the total number of patients in this study is 361. 
There are 27 patients with heart failure diagnosis; 78 patients with cognitive 
impairment/dementia based on DSM-5; 6 with Parkinson disease; 46 with a history of 
gastric or duodenal ulcers and 4 with chronic kidney disease stages IV or V (see Table 
40). 
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Table 40 Beers Criteria for PIM use in older adults due to drug-disease or drug-syndrome 
interactions that may exacerbate the disease or syndrome (PIM2) applied to the pcb-cohort 
PIM2 Medication N % 
 
Heart  failure (N=27) 
 
Not medicated with PIM 
 
20 
 
74% 
Diltiazem 5 18.5% 
Verapamil 2 7.5% 
Dementia & Cognitive Impairment 
 
 NCD-mild (N=48) 
 
 
Not medicated with PIM  
 
44 
 
91.7% 
Benzodiazepines 3 6.2% 
Combination 1 2.1% 
  
 NCD-major (N=25) 
   
Not medicated with PIM 20 80% 
Benzodiazepines 1 4.0% 
Zolpidem 1 4.0% 
Antipsychotics  3 12.0% 
Parkinson's disease (N=6)  
Not medicated with PIM  
 
4 
 
66.6% 
All antipsychotics 1 16.7% 
Antiemetic (metoclopramide, 
prochlorperazine, promethazine) 
1 16.7% 
History of gastric or duodenal ulcers 
(N=87) 
 
Not medicated with PIM  
 
65 
 
74.7% 
Non-COX2 selective NSAIDs 22 25.3% 
Chronic Kidney disease stages IV or V 
(N=4) 
 
Not medicated with PIM  
 
3 
 
75% 
NSAIDs 1 25% 
Abbreviations: PIM-Potentially Inappropriate medication use; NCD-Neurocognitive disorder (mild or major); 
DSM-5- DSM-The Diagnostic and Statistical Manual of Mental Disorders; COX2-Cyclooxygenase 2; NSAIDs-
Non-steroids anti-inflammatory drugs; Note: % is based in subtotal indicate in first columns. 
 
In the first group (heart failure), there are 5 patients using Diltiazem and 2 are 
using Verapamil. These two drugs are considered inappropriate when used in patients 
have heart failure pathology. These drugs must be avoided because they have a 
potential to promote fluid retention and/or exacerbate heart failure.  
Table 40 also shows the results relative the patients with cognitive 
impairment/dementia. In patients above 65 years older, regarding dementia, a total of 
108 (29.9%) no have syndrome or disease and patients have normal cognitive 
performance based in DSM-5, and 73 have history of neurocognitive disorder (NCD-
mild=48 and NCD-major=25). Of these, 64 (44NCD-mild + 22NCD-major) (87.6%) 
patients are not using PIM2; 1 patient with NCD-major use Benzodiazepines; 1 NCD-
major is using Zolpidem; 3 NCD-major is using combinations of the different classes 
already referred. There are 3 NCD-mild use benzodiazepines and 1 NCD-mild is using 
combinations of the different classes already referred. Relative to these drugs, 
antipsychotics should be avoided in patients with cognitive impairment because they 
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increase the risk of stroke and increase the mortality among patients. They can only be 
administered if non-pharmacological options for treating behavioural changes of 
dementia are unsuccessful and the patient poses a threat to her/himself and others  
In the pcb-Cohort there are 6 patients with a diagnosis of Parkinson's disease 
(prevalence of Parkinson disease is of 1.7% in patients above 65 years old). 4 (1.1%) 
who have no reports of PIM. 1 (0.3%) using Antipsychotics and 1 (0.3%) using an 
Antiemetic (Table 40). These drugs must be avoided because they are dopamine 
receptor antagonists with the potential to worsen parkinsonian symptoms. 
In pcb-Cohort, 87 patients above 65 years old have a history of gastric or 
duodenal ulcers. These patients 22 (0.6%) are using non-COX2 selective NSAIDs (Table 
40). These drugs should also be avoided given that they may exacerbate existing ulcers 
or cause new/additional ulcers. Alternative drugs can be considered and if these are 
not effective a gastro protective agent (proton-pump inhibitor or misoprostol) may be 
considered. In case of chronic diagnosis of Kidney disease, there are 4 patients. And 1 
(25%) is using NSAIDs (Table 40). These drugs must be avoided because they may 
increase the risk of kidney injury. 
Some information is not represented in Table 40, essentially because there are 
no cases of PIM. These include: 
• Lower urinary tract symptoms or benign prostatic conditions, with 31 
cases of hyperplasia): anyone use PIM  
• Chronic seizures or epilepsy: 20 cases, no use PIM;  
• Insomnia: 14 cases, no use PIM;  
• stress or mixed urinary incontinence in women: 8 cases, no use PIM; 
• Chronic constipation: 6 cases, no use PIM; 
• Urinary incontinence in women: 5 cases, no use PIM; 
• Syncope: 1 case, no use PIM 
• Delirium: anyone with this diagnostic 
•  History of fall or fractures: anyone with this diagnostic. 
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4.4.1.3 Table 3 Beers Criteria: Potentially Inappropriate Medications to Be 
Used with Caution in Older Adults 
Table 3 of the Beers Criteria (Annex 1 – Supplementary table 3) for Potentially 
Inappropriate Medications addresses medications to be used with Caution in Older 
Adults (PIM3), it is designed for individuals that are more than 75 or 80 years old 
(depends on the drug). The drugs with which doctors should be particularly vigilant are 
Aspirin, Dabigatran, Prasugrel, Antipsychotics, Carbamazepine, Carboplatin and 
Cisplatin, Mirtazapine and Serotonin, Noradrenalin reuptake inhibitors, Selective 
Serotonin Reuptake Inhibitors, Tricyclics antagonists, Vincristine and Vasodilators.  To 
apply Table 3 of the Beers Criteria, it is necessary to remember that we are dealing 
with patients that are more than 75 or 80 years older. In the pcb-Cohort there are 137 
individuals over 75 years and 61 individuals over 80 years. 
Aspirin for primary prevention of cardiac events should be used with caution in 
adults’ ≥80 years old; there is a lack of evidence of benefit versus risk in individuals ≥80 
years old. Likewise, Dabigatran must be used with caution in adults ≥75 years old, in 
cases where individuals have a Creatinine Clearance (CrCl) rate less than 30 mL/min. In 
these cases, the risk of bleeding is greater in comparison to Warfarin. Furthermore, 
there is a lack of evidence for efficacy and safety in patients with CrCl rate<30 mL/min. 
Prasugrel must also be used with caution in adult’s ≥75 years old, because it presents a 
greater risk of bleeding in older adults; risk may be offset by benefit in highest risk 
older patients (e.g. those with prior myocardial infarction or diabetes). Also, 
vasodilators must be used with caution given that they may exacerbate episodes of 
syncope in individuals with a history of syncope.  
Care must also be taken with drugs that may exacerbate or cause SIADH 
(Secretion Inappropriate Anti Diuretic Hormone) or hyponatremia. A good 
recommendation is to monitor sodium levels closely when starting or changing 
medication dosages in older adults and to bear in mind that these individuals have 
increased risks of suffering adverse drug effects. Drugs deserving attention are: 
Antipsychotics, Carbamazepine, Carboplatin, Cisplatin, Mirtazapine, SNRIs, SSRIs, TCAs 
and Vincristine. Thus, these drugs are included in Table 3 of the Beers Criteria. and 
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referred to as drugs that should be used with caution in patients above 80 or 75 years 
old as they may cause SIADH [165].  
 Relative to patients over 80 years, 8 (13.2%) are taking Aspirin to prevent 
cardiac events (see Table 3 Beers Criteria – Annex I- Supplementary table 3). Regarding 
Dabigatran, in 2012, patients were not using this drug, as in Portugal it had not yet 
been approved for use by the national regulatory agency. In the pcb-Cohort Prasugrel 
is also not being taken by any of the participants. 
The other drugs from Table 3 of the Beers Criteria (Annex I – Supplementary 
table 3) are psychiatric drugs that may exacerbate or cause SIADH or Hyponatremia. 
Table 41 show the results of Table 3 of Beers Criteria in pcb-Cohort. 
Table 41 Table 3 of Beers Criteria applied to the pcb-Cohort 
 
*Patients 80 years old or more (N=61). In this case, % is based 
in N=61 **Patients 65 years old or more (N=361). % is based in 
N=361. Abbreviations: SNRIs-Serotonin Noradrenalin Receptors 
Inhibitors; SIAHD-Secretion Inappropriate of Antidiuretic 
Hormone; SSRIs-Serotonin Selective Receptors Inhibitors; TCA-
Tricyclics Antidepressant; Association-Association of at least 
two drugs in this group of the drugs that cause SIAHD or 
Hyponatremia; There are no cases of other drugs that can 
cause SIAHD: Carbamazepine, Carboplatin, Cisplatin and 
Vincristine. 
 
 In the study sample, and about 250 (69.3%) patients are not using any of these 
drugs and 111 (30.7%) are (Table 41).  Additionally, 7 (1.9%) patients are using 
Medication N % 
Aspirin*  
(N=62) 
Not 
medicated 
with PIM  
53 86.8% 
Use  8 13.2% 
Cause 
SIAHD/Hyponatremia**   
(N=111) 
Not 
medicated 
with PIM  
250 
69.3 
Antipsychotics 7 1.9 
SNRIs 2 0.6 
SSRIs 57 15.8 
TCAs 19 5.3 
Combinations 26 7.2 
Vasodilators** (N=92) 
Not 
medicated 
with PIM  
269 74.5% 
Use 92 25.5% 
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Antipsychotics (Table 37). 2 (0.6%) are using SNRIs (Serotonin Noradrenalin Receptors 
Inhibitors), 57 (15.8%) are using SSRI (Serotonin Selective Receptors Inhibitors), 19 
(5.3%) are using TCAs (TCA=Tricyclic’s Antidepressants) and 26 (7.2%) patients are 
using combinations of these psychiatric drugs. Curiously in the pcb-Cohort the greater 
use of PIM3 is vasodilators, where 269 (74.5%) patients do not take it while 92 (25.5%) 
patients do. 
 
4.4.2 Association between Sociodemographic Characteristics with 
Polypharmacy and PIM1 
PIM1 prevalence with respect to sociodemographic characteristics was 
analysed (Table 42). In the pcb-Cohort (N=361 have medication related information 
available), the prevalence of polypharmacy is 66.5% (240/361) in patients over 65 
years of age. The polypharmacy affected 73.4 (182/248) % of women and 51.3% 
(58/113) of men; these differences are statistically significant (p<0.001). The 
prevalence of non-polypharmacy is greater in the comparatively younger age group; of 
65-74 years: 37.6% (85/226) when compared to the age group over 75, 73.3% 
(99/135). Regarding individuals with or without polypharmacy there is a statistical 
difference between mean of age (71.5 vs 73.9, Table 38).  
Non-polypharmacy patients have higher monthly incomes: the proportion of 
non-polypharmacy is higher in patients who earn more than the minimum wage, while 
the polypharmacy ratio is lower in patients who earn more than a minimum wage 
(37% versus 63%). These differences have statistical significance; patients with 
polypharmacy have a lower average number of years of education. The other 
sociodemographic characteristics did not have statistical significance. 
Regarding the use of inappropriate medication, based on Beers Criteria for 
PIM1 (Table 42), the proportion of women using PIM1 is significantly higher (p-value 
0.004). Other significantly different characteristics with respect to PIM1 are monthly 
income and years of study p-value=0.039 and p-value=0.045, respectively. The other 
socio-demographic characteristics did not present significant differences between the 
two groups (use or not of PIM1).  
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Table 42 Sociodemographic characteristics in polypharmacy and PIM1 
 
 
 
4.4.3 Association between Comorbidities with Polypharmacy and PIM1 
The results of comparing comorbidities, polypharmacy and PIM1 are shown in 
Table 39. In the pcb-Cohort the mean number of co-morbidities is higher in both cases 
of polypharmacy and in cases of PIM1. Patients with polypharmacy have a higher 
average number of comorbidities namely Hypertension, Dyslipidaemia, Cardiac and 
vascular disease, Osteoarticular disease, Depression, Gastrointestinal disease and 
Haematology pathology.  
Patients using inappropriate medication, based on PIM1, are mostly those with 
a history of Depression, Cardiac and vascular Disease and Gastrointestinal disease; the 
latter are statistically significant. Remember that we have 366 patients over 65 years, 
but the medication data were only possible at 361. The table percentages are based on 
the 361 individuals of the pcb-Cohort, as explained above (Table 43). 
 
Superscripts letters: 
a.b
 The same subscript letter denotes a subset of categories whose column proportions do not differ significantly from each other at 
the 0.05 level. Different subscript letters denote column proportions which differ significantly from each other at the 0.05 level. 
Abbreviations: SD-Standard Deviation; PP- use less than 5 medications; PP+ Polypharmacy (≥5 medications). 
NOTE: 
1. Data presented as N (%) and % is expressed % as a function of the total in each of the PIM or Polypharmacy group or mean ± standard 
deviation. 
2. Statistical test: χ2 = Chi square test 
3. Statistical test: Test t student; 
Demographics 
Characteristics 
N (%) 
Polypharmacy PIM1 
PP- 
(N=120)1 
PP+ 
(N=241)1 
p-value PIM1- 
(N=190)1 
PIM1+ 
(N=171)1 
p-value 
Gender 
 Male 
 Female 
 
113 (31.3%) 
248 (68.7%) 
 
55a (45.5%) 
66 a (54.5%) 
 
58 b (24.2%) 
182 b (75.8%) 
<0.0012 
 
72 a (37.9%) 
118 a(62.1%) 
 
41 a (28.0%) 
130 a (72.0%) 
0.0042 
Age 
 [65-74] 
 [≥ 75] 
 
226 (62.6%) 
135 (37.4%) 
 
85 a (70.2%) 
36 a (29.8%) 
 
141b (58.8%) 
99 b (41.3%) 
0.0332 
 
122a (64.2%) 
68 a (35.8%) 
 
104a (60.8%) 
67 a (39.2%) 
0.5062 
 
Age (years)  
 Mean ± SD  
73 ± 6.2 71.5 ± 5.4 a  73.9 ± 6.4 b  0.0013 73 ± 6.3 a 73.2 ± 6 b 0.7063 
 
Marital Status 
 Partner
4 
 Other  
 
241
a 
66.8%) 
120 33.2%) 
 
87
 a 
(71.9%) 
34 a (28.1%) 
 
154
a 
64.2%) 
86 a (35.8%) 
 
0.141
2
 
 
131
a 
(68.9%) 
59 a (31.1%) 
 
110
a 
(64.5%) 
61(35.5%) 
0.1412 
 
Living Arrangement 
 Alone  
 Accompanied  
80 (22.2%) 
281 77.8%) 
26 a (21.5%) 
95 a(78.5%) 
54 a (22.5%) 
186 a (77.5%) 
 
 
0.8272 
36 a (16.8%) 
154 a (83.2%) 
44a (28%) 
127 a (72%) 
 
 
0.1212 
 
Professional Status 
 Active 
 Retired 
 Unemployed 
58 (16.1%) 
300 83.1%) 
3 (0.8%) 
13 a (10.7%) 
107
a 
(88.4%) 
1 a (0.8%) 
45 a (18.8%) 
193
a 
(80.4%) 
2 a (10.8%) 
 
0.1472 32
 a (55.2%) 
158 
a 
(52.7%) 
0 a (0.0%) 
26 (13.1%)  
142 (86.0%) 
3 (0.9%) 
 
0.1752 
 
Monthly Income 
 ≤ 1 5 
 > 1 5 
126 34.9%) 
235 65.1%) 
34 a (27.0%) 
87 a (37.0%) 
92 b (73.0%) 
148 b (63.0%) 
0.0542 
57 a (30%) 
133 a (70%) 
69 (36.4%) 
102 (63.6%) 
0.0392 
 
Education Level 
 0-2 6 
 3-6 6 
 ≥ 7 6 
41 (11.4%) 
272 75.3%) 
48 (13.3%) 
12 a (29.3%) 
83 a (30.5%) 
26 a (54.2%) 
29 a (12.1%) 
189a (78.8%) 
22 a (9.2%) 
0.0052 17 a (8.9%) 
142 a (74.7%) 
31 a (16.3%) 
24 (10.2%) 
130 (78.5%) 
17 (10.3%) 
0.0902 
Years of Studies 
 (Mean ± SD ) 
4.5 ± 3.4 5.2 ±3.8 a 4.1 ± 3.1 b 0.0063 4.8 ± 3.5 4.1 ± 3.1 b 0.0453 
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4.4.4 Association among PIM1 and PP with Cognitive Evaluation 
 
This session describes the correlation between the cognitive performance of 
pcb-Cohort users with PIM1 and Polypharmacy. Table 44 shows these correlations. 
Regarding CDR, patients with no cognitive impairment showed a lower proportion of 
polypharmacy and PIM1, with statistical significance (p<0.05). Patients with CDR=0.5, 
on the other hand, already present a higher proportion of polypharmacy and PIM, 
although still with no statistical significance. Patients with cognitive impairment clearly 
show a higher proportion of PIM1 and polypharmacy with statistical significance. 
When DSM-5 is applied, identical behaviour is observed. Patients without 
cognitive impairment have a lower proportion of polypharmacy and PIM (Table 40). 
Statistical significance is not observed for NCD-mild and NCD-major. However, it is 
observed that patients classified as possible cases of depression, present a higher 
proportion of use of PIM and polypharmacy. 
 
Table 44 Correlation of cognitive performance with PIM1 and polypharmacy in the pcb-
Cohort 
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4.4.5 Multivariate Analyses: Factors Associated with Polypharmacy and PIM1 
Multivariate analysis was subsequently carried out (Table 41), using the 
Logistic Regression Model. Relative to Logistic Regression for polypharmacy to validate 
the model, the R2 measure was as proposed by Nagelkerkethe [202]; has a score of 
0.346 (Model Summary-2 log Likelihood=356.836), it has the Omnibus test χ2  (df 
18)=103.650, p<0.001 and it has Hosmer and Lemeshow test χ2  (df 8)=4.403, p-
value=0.819. The values validating the model for PIM1 are:  the R2 has a score of 0.253 
(Model Summary-2 log Likelihood =423.641), the Omnibus test χ2 (df 18)=75.811, 
p<0.001 and Hosmer and Lemeshow test χ2 (df 8)=16.143, p-value=0.040. Relative to 
polypharmacy, the factors that were statistically significant in the multivariate analysis 
by logistic regression were (table 32): age over 75 with OR 1.9 (CI 95% 1.084-3.471, p-
value 0.026); being female 2.042 (CI 95% 1.130-3.390, p-value 0.018); 3-6 years of 
education OR 2.6 (CI 95% 1.061-6.486, p-value 0.037); Gastrointestinal disease OR 1.6 
(CI 95% 0.936-2.768, p-value 0.085); Cardiac and vascular disease OR 2.09 (CI 95% 
1.155-3.788, p-value=0.015); and potentially inappropriate medication use OR 4.5 (CI 
95% 2.587-8.038, p-value<0.001). 
Relative to results of Logistic Regression to PIM1, the factors that significantly 
contribute to potentially inappropriate medication use are: Dyslipidaemia OR 1.6 
(95%CI 0.935-2.962, p-value=0.083); Cardiac and vascular diseases OR 1.6 (95%CI 
0.942-2.919, p-value=0.080); Respiratory diseases OR 1.6 (95%CI 0.930-3.098, p-
value=0.085); cognitive impairment based DSM-5 (neurocognitive disorder major and 
mild) OR 2.6; 95% CI 1.245-5.561, p-value=0.011; and with the additional presence of 
polypharmacy (OR 4.5; 95% CI 2.623-8.053, p-value<0.001). 
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Table 45 Multivariate analyses based on logistic regression to polypharmacy and PIM1 
Abbreviations: OR-Odds Ratio; CDR-Clinical Dementia Rate; PIM1: Potentially Inappropriate Medication based in table 1 of Beers 
Criteria. HYP- Hypertension; DYS-Dyslipidemia; OA-Osteoarthicular; CVD-Cardiac and vascular disease; GID-Gastrointestinal 
disease; DM-Diabetes Mellitus; RESP- Respiratory disease. In bold, the p-value with statistical significance. * reference Class to 
calculate OR to variable literacy and CDR. Variable(s) entered in Logistic Regression ENTER methods: Age (group), Gender, Literacy, 
Diabetes Mellitus, Hypertension, Dyslipidemia, Gastrointestinal disease, Cardiac and vascular disease, Respiratory disease, 
Neurodegenerative, Osteoarthicular, CDR, MMSE, polypharmacy, Neurocognitive disorder and depressive cases. 
 
 
Therefore, polypharmacy is well associated with patients with more quality, 
with less literacy, and with cardiac or vascular disease as well as with the presence of 
inappropriate medication use. Regarding PIM1, this is well associated with NCD, and 
with moderate significance to cardiac and vascular and respiratory diseases. 
 
 
Characteristics 
Polypharmacy PIM1 
p-value OR CI (95%) p-value OR CI (95%) 
≥75 years old 0.026 1.940 1.084 3.471 0.742 1.090 0.652 1.823 
Female 0.018 2.042 1.130 3.690 0.333 1.319 0.753 2.312 
0-2 years of Literacy*
 0.008    0.724    
3-6 years of Literacy 0.037 2.623 1.061 6.486 0.421 0.719 0.322 1.605 
≥7 years of Literacy 0.955 0.969 0.328 2.869 0.581 0.751 0.271 2.079 
DM 0.862 1.062 0.540 2.087 0.483 1.230 0.689 2.195 
HYP 0.444 0.812 0.476 1.384 0.460 1.199 0.741 1.939 
DYS 0.130 1.594 0.872 2.916 0.083 1.664 0.935 2.962 
GID 0.085 1.610 0.936 2.768 0.686 1.106 0.678 1.804 
CVD 0.015 2.092 1.155 3.788 0.080 1.658 0.942 2.919 
RESP 0.185 1.619 0.794 3.300 0.085 1.697 0.930 3.098 
OA 0.449 1.250 0.701 2.229 0.478 0.826 0.486 1.402 
CDR=0* 0.708    0.752    
CDR=0.5 0.828 1.088 0.509 2.325 0.673 1.153 0.595 2.233 
CDR≥1 0.407 2.487 0.288 21.449 0.456 1.761 0.398 7.798 
NCD 0.980 1.010 0.448 2.280 0.011 2.643 1.245 5.610 
Depressive cases 0.402 1.512 0.575 3.974 0.188 1.638 0.786 3.413 
Polypharmacy     <0.001 4.596 2.623 8.053 
PIM1 <0.001 4.560 2.587 8.038     
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5.1 Establishing the Study Group 
At the onset of this thesis it was important to establish a study group. Bearing 
in mind that the fundamental concern was to contribute to identifying putative 
dementia and depression related cases in primary health care centres, a cohort based 
on individuals attending local health care facilities was established. The pcb-Cohort is 
an observational longitudinal study and represents an important contribution in the 
Aveiro region, at the level of primary health care centres. As previously mentioned, the 
Aveiro region has around 75.000 habitants. To determine the size of the study sample 
[176] for the Aveiro region, the number necessary is at least 480 individuals. In fact, 
the pcb-Cohort includes 590 individuals.  
The main goal is to test tools to characterize the functional capacity and the 
prevalence of dementia and depression at the primary point of care. Given the 
pathologies involved participants recruited had to be at least 50 years old. Often the 
cut-off is 65 years for this type of study but given the intent to identify putative cases 
early on and to carry follow up studies participants recruited had to be at least 50 
years old. Furthermore, information regarding medication usage in the study group 
was also collected. Other data collected included sociodemographic characteristics and 
clinical, information. Blood was collected to permit genotyping for the APOE. 
It was the intent of this study to identify putative poor cognitive performance 
as early as possible. Also, for subsequent follow up studies, envisaged in the future, 
there will be increased opportunities to see how ageing affects cognitive capacities. 
Cognitive capacities were evaluated using the CDR and MMSE tests but to add further 
clinical relevance to the data collated the DSM-5 criteria were applied as already 
described in the results. It is not the intent of this study to profile the Portuguese 
population as addressed in other studies [180] or to accurately diagnose depression 
and dementia cases like AD. Dementia is a growing problem in modern societies so if 
putative cases can be identified early on and subsequently referred to specialised 
consultations this would contribute to efficiently dealing with such pathologies. 
Dementia impacted 46.8 million people worldwide in 2015, and this number is 
expected to almost double every 20 years [203].  
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5.1 Cognition based on CDR and DSM-5 in the pcb-Cohort 
The CDR evaluation of the pcb-Cohort identified 12% (N=68) of the participants 
as having mild-to-severe cognitive deficits. Of these, 7 (10.3%) are <65 years old. These 
7 participants have a high CDR score and are particularly young, they should therefore 
be closely monitored. With respect to cases of suspected cognitive deficits, scoring 0.5 
on the CDR, there were another 64 subjects, again in the younger age group of 50–64 
years. This also highlights the importance of including younger participants in the 
study. Overall, it is relevant to note that by applying the CDR, even in a primary care 
setting it is indeed possible to identify putative cases of cognitive deficits (Table 8) in 
both the younger and older participants.  
In this study CDR scores were correlated with comorbidities in gender specific 
and in absolute terms. In both cases significant differences are evident between 
cognitive results and OA and GID. With women correlations were more evident with 
depression and hematologic diseases, whereas for men correlations are more evident 
with GUD and excessive use of alcohol (Tables 8 and 9). As with many other disease 
states, the concern with risk factors is paramount and the multivariate analysis 
characterizing cognitive alteration based on CDR, revealed the following to be risk 
factors: being female, having few years of literacy, exhibiting a degree of dependence, 
having a neuropathology, or a disease of the gastrointestinal tract and being a non 
APOE ε2 carrier. 
 
When applying the DSM-5 criteria for neurodegenerative disorders, results 
were like those obtained when considering only the CDR data. Of all the participants, 
189 have normal cognitive performance, 61 have NCD-mild, 36 have NCD-major and 
282 were excluded because they are possible or confirmed cases of depression. The 
latter represents a prevalence of 12% cases (N=36) of dementia in the study 
population (NCD-major). Of the 36 individuals with NCD-major, around 28% are 
between 50-64 years old, 30% are 65-74 years old and 42% more than 75 years old. 
The percentage in the younger age group is only marginally lower when compared to 
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older individuals. This is a strong indicator for monitoring these younger individuals 
with respect to putatively developing dementia. 
As with the CDR data, applying the DSM-5 criteria revealed that the risk factors 
associated with NCD are: the female gender, increasing age, few years of literacy, and 
being dependent. OA and GID still correlate although the latter in NCD-mild and 
neither hold in the multivariate analysis. The difference was investigated by comparing 
the data based on CDR and DSM-5 criteria (Table 46 below).  
It can be observed that patients with normal performance in both assessment 
methods are 189. Also 9 patients with mild, moderate to severe cognitive impairment 
(CDR based) are assessed as NCD-mild because their IADL was not compromised. 
Encouragingly, there is an overlap of 12 patients with the same degree of severity in 
both methods. Also 24 users, although suspected, for the CDR, are already classified as 
NCD-major because they already have the IADL compromised.  
 
Table 46 Correlation between number of patients with CDR and DSM-5 criteria 
 DSM-5 Total 
NCD-Normal NCD-mild NCD-major PCD 
CDR CDR=0  189 0 0 112 301 
CDR=0.5 0 52 24 123 199 
CDR>=1 0 9 12 47 68 
Total 189 61 36 282 568 
Abbreviation: DSM-5- ; CDR-Clinical Dementia Rate; CDR=0- cognitive performance is normal; 
CDR=0.5-cognitive performance suspect; CDR≥1-cognitive performance mild, moderate, 
severe; NCD-Neurocognitive disorder; PCD-Possible cases of depression. 
 
It is noteworthy that the number of patients classified as possible cases of 
depression, strongly impacts the results. Of the total group with depression (282), 123 
scored CDR=0.5 and 47 cases with CDR≥1, this is a total of 170 participant lost from the 
study and of these although depressed they appear to also be cognitively 
compromised, particularly true for the 47 cases with CDR≥1. Nonetheless these 
patients were excluded to diminish selection bias when applying the DSM-5 criteria for 
NCD. 
Regarding the application of CDR test as the main screening test, there are 
studies in Portugal that also use it for characterizing dementia. By consulting the 
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literature, it is possible to compare these results with studies that are ongoing. 
Namely, a prevalence study of dementia and depression at a national level: this is 
carried out by the 10/66 Dementia Research Group [204]. In this study evaluations 
include, cognitive deficit profiling based on a formal test, corroboration of cognitive 
and functional decline (by an informer), and a clinical interview, determining if a high 
probability of being a case of dementia exists. The methodologies used in this thesis 
are similar thus it will be interesting to compare the forthcoming data with that 
presented in this thesis. 
When analyzing the determinant factors in the characterization of patients by 
both CDR and DSM-5, there is a clear overlap. Special attention should be given to the 
presentation of pathology of the gastrointestinal tract as a risk factor for cognitive 
impairment. This feature is statistically significant in the CDR assessment and with an 
increased proportion in the NCD-mild group; this will be further explored below. 
 
5.1.1 Sociodemographic Risk Factors in Cognitive Impairment  
Many of the risk factors for cognitive impairment identified above have already 
been reported in the literature. 
Regarding age as a risk factor, in Portugal, there is a study called the Study of 
the Aging Profile of the Portuguese Population. In it the authors describe a statistically 
significant association between cognitive evaluation score and the age group, p<0.001. 
Namely in the 65-74 age group exhibits the lowest percentage of individuals with 
cognitive impairment (3.6%), followed by the age group of 55-64 years (3.9%), and the 
oldest age group of 75 years or older, present the highest percentage of individuals in 
an unfavorable situation (12.0%) [180]. This same study shows that the age group ≥ 75 
years of age has a functional dependence about 2 times higher than the other age 
groups. The values in the work here presented are superior (globally CDR based 
prevalence 12% and NCD-major 12%) but this can be explained by the fact that the 
study group was based in primary health care centres. Of note studies have shown that 
Dementia prevalence can range from 5 to 10% among those aged≥65 years 
[8,206,207]. Regarding the CDR's performance in identifying these risk factors, the CDR 
can identify dementia conversion rates with age [37,208]. 
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Another factor involved in cognitive change is literacy [84]. In the study of 
ageing in Portugal, it is reported that only 7.7% have completed school education for 
more than 12 years. These results are in line with national figures showing that about 
23% have schooling of less than 3 years [180]. Having more years of literacy is 
described as a protective factor for dementia [84]; this holds true for the pcb-Cohort.  
Another important factor in cognitive change is gender. Regarding the 
difference in the proportion of cases of dementia in women, the literature shows that, 
due to menopause and the consequent decline in estrogen levels, there is an increased 
risk of cognitive impairment and the prevalence of other diseases [190]. This is also 
reflected in the pcb-Cohort where women are 3.7 times more likely to have dementia 
compared to men (Table 18). 
 
5.1.2 Comorbidities as Risk Factor in Cognitive Impairment  
Dementia has previously been associated with several comorbid conditions 
[207]. For instance, diabetes is associated with an increased rate of cognitive decline 
[208]. There are several factors that may contribute to the increased risk for dementia 
in patients with diabetes: macrovascular and microvascular disease, genetic 
predisposition, hypertension, hypoglycaemia and hyperglycaemia, insulin resistance 
and hyperinsulinemia, chronic inflammation, dysregulation of the hypothalamic 
pituitary axis [209]. However, this correlation was not found in the pcb-Cohort. 
 Other comorbidities associated with dementia are hypertension. Likewise, 
many studies have shown that midlife hypertension is associated with increased 
dementia risk in later life [210]. A previous study in the Aveiro district [211] on patients 
in long-term facilities found that hypertension had a lower prevalence than that 
reported in the study here presented (41.3% vs 61.8%) [211] for the pcb-Cohort. The 
association between dementia and hypertension can be explained because blood 
pressure values: a high systolic BP (≥160 mm Hg) are associated with a greater 
dementia risk in the youngest group (65–74 years) [212]; a high diastolic BP (>90 mm 
Hg) is associated with a lower risk of developing dementia 6 to 9 years later [213]. In 
the pcb-Cohort the blood pressure was not performed. In future follow up studies, 
information regarding this parameter will be collected.  
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To our knowledge GID was correlated with high CDR scores for the first time 
in the pcb-Cohort. In the Aveiro district, a prevalence of GID 10% [211] has previously 
been described in an independent study. In the pcb-Cohort there are a 26.6% of GID 
cases, this is higher than that previously reported. In the pcb-Cohort these individuals 
with GID exhibit a higher risk of poor cognitive performance; there is a highly 
significant correlation between CDR≥0.5 and GID+. 
It will be important to monitor these cases and address the issue of whether 
GID is a confounding factor, of relevance. GID has been associated with poor diet 
[214]. Hence, by analogy, the association of GID with high CDR scores supports the 
finding that a Mediterranean diet can be a protective factor for dementia [214,215]. In 
fact, the diet may affect the molecular basis for AD [22,215] including processes 
leading to plaque deposition [216]. Furthermore, GID is associated with ageing 
populations [217]. However, one cannot dismiss the possibility that medications used 
by the elderly patients may contribute to GID, and, in fact, an association between 
proton pump inhibitors (PPI study) and cognitive impairment has recently been 
reported [218,219]. The study design of this association of the use of proton inhibitory 
pump medications is different from the design of our study. In the PPI study, it is 
believed that the association may be due to inhibition of vitamin B12 absorption and 
increased deposition of beta-amyloid. It is true that the molecular nature of the 
association of gastrointestinal pathologies and cognitive impairment deserves further 
attention. However, this biomolecular study was not the focus of the study of this 
thesis. Nonetheless, it is particularly noteworthy that the enteric nervous system is as 
important as the central nervous system [217], since it is equally enervated and 
subject to the same neurotransmitter signalling cascades. 
In pcb-Cohort the correlation between cognitive performance and disease of 
the respiratory tract was shown.  In the above mentioned study in the Aveiro region, a 
prevalence of 6.4% of respiratory pathologies was observed [211]. Asthma in midlife 
and in late life appears to increase the risk of developing dementia and AD, but the 
physiopathology is as yet uncertain [220]. Another study showed that Chronic 
Obstructive Pulmonary Disease (COPD) is associated with cerebral small-vessel disease, 
stroke and cognitive decline and showed that smoking, oxidative stress and 
inflammation can cause vascular brain damage in COPD [221]. In the pcb-Cohort there 
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is a negative correlation between APOE ε4 carriers and respiratory disease. This 
deserves further clarification in other future studies. 
Other notable risk factors are depression and APOE and these will be 
discussed in the following sections.  
 
5.2 Depression 
Depression affects modern populations and can be a heavy burden in the 
elderly. Thus, depression was addressed in the pcb-Cohort and will be discussed 
bearing in mind the following aspects: 
• Evaluating depression and possible risk factors.  
• Correlating depression with dementia in pcb-Cohort. 
 
5.2.1 Depression in the pcb-Cohort and Possible Risk Factors 
GDS15 is a validated tool to screen for, but not diagnose, possible cases of 
depression and adequate for use in primary care [155]. It is a quick application scale, 
with a yes/no response format. There is a validation study of the Portuguese version 
and this was applied [98,222]. The procedure involved applying the GDS15 but also 
evaluating how a previously published shorter version with only 4 questions (GDS4Lit) 
performed. The 568 patients in the pcb-Cohort were included in the data analysis. Of 
these 174 are classified as GDS15+. The number of the cases detect based in GDS4Lit is 
much higher (522) and did not prove to be a particularly useful tool in our hands, thus 
it will not be further discussed. Nonetheless shorter GDS versions (GDS4 to GDS8) were 
tested as described in the results. 
Relative to sociodemographic factors associated with patients with depressive 
cases, the GDS15+ are mostly women, living alone, separated, retired or unemployed, 
low income and low literacy levels. These results are concordant with previous 
publications [221, 222]. Globally, the same parameters are equally relevant in the 
shorter versions, with the GDS4 showing a slight deviation (Table 23). In GDS15+ cases, 
relevant comorbidities are osteoarticular diseases, gastrointestinal tract and 
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dyslipidaemia (moderate significance). The short versions based on GDS15+ cases 
show the similar correlations (Table 24).  
In literature, depression is associated with chronic somatic diseases [225]. 
Table 47 shows a literature review of the main comorbidities associating with 
depression. Mechanisms proposed for these associations are also briefly explained. 
 
Table 47 Summary of comorbidities associating with depression 
Comorbidity Result 
Cardiovascular 
disease 
• Depression is exceedingly common in CVD patients and contributes to worse 
patient outcomes, including mortality, recurrent CVD events and health status 
[226]; 
• Mechanisms: Lifestyle (Smoking, Excessive alcohol use, Physical inactivity, 
Unhealthy diet, Lower treatment compliance and worse medical care); 
Pathophysiology: Metabolic deregulations, Immune-inflammatory 
deregulations, Autonomic deregulations, HPA-axis deregulations [227]; 
• Depression results in a 80–90% increased risk of cardiovascular disease [228]; 
• Depressed persons are at increased risk for peripheral atherosclerosis as 
indicated through e.g. coronary or aortic calcification, impaired endothelial 
function and increased arterial stiffness [229]; 
Gastrointestinal 
disease 
 
• Anxiety, depression, panic attacks, posttraumatic stress disorders, and other 
somatization disorders are frequently detected prior to or simultaneously 
with the occurrence of functional gastrointestinal disorders [230]; 
• Depressive mood was significantly related to Functional Dyspepsia and 
Functional Dyspepsia + irritable bowel syndrome (IBS) overlap but not to IBS 
based on Rome III criteria. FD-IBS overlap patients have worse quality of life 
than FD-alone and IBS-alone patients [231]; 
• Anxiety is associated with uninvestigated and functional dyspepsia (Rome III 
criteria) in a Swedish population-based study [232]; 
Osteoarticular 
disease  
• In the case of osteoarticular conditions, depression was associated with this 
somatic disease [225]; 
Diabetes Mellitus • The prevalence of type 2 diabetes in major depression is 21.19%. Multivariate 
logistic regression analysis revealed that male gender, high blood pressure, 
Hypertriglyceridemia, Body Mass Index ≥30 kg/m², age ≥50 years, sleep 
duration <6.5 hours, C-reactive protein ≥4.5 mg/L, beck depression inventory 
>12, and apnea-hypopnea index ≥5/hour were significant risk factors of type 2 
diabetes in major depression [233]; 
• Glycaemic control seem to influence the severity of depressive symptoms 
[146]; 
Dementia • Depression is common in Alzheimer disease and other neuropathologies 
[234,235]; 
• MCI and dementia were associated with significantly higher rates of 
depression. Efforts to effectively engage and treat older adults with dementia 
will need also to address co-occurring depression [236]; 
• Depression being an independent risk factor in developing dementia 
[237,238]; 
• Depression affecting the threshold for manifesting dementia [238,239]; 
• Dementia or cognitive impairment being a feature of depression [238,240];  
• The notion of depression being a prodromal of dementia [238,241]; 
• Depression being a reaction to cognitive decline [137,238]; 
• Dementia and depression sharing common risk factors explaining the 
increased prevalence of both in this population and why they are frequently 
comorbid [238,242] 
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Furthermore, to add further clinical relevance the DSM-5 for depression was 
not directly applied, as already explained, but rather patients with a diagnosis of 
confirmed depression (patients who were evaluated by psychiatry) were taken as true 
cases and designated as TrueDEP (74 cases, see Figure 11). Shorter versions of the GDS 
were likewise tested whereby the TrueDEP group was taken as the individuals with 
confirmed depression. 
 
Relative to factors associated with the TrueDEP group, results are like those 
obtained using the GDS15+ group. Namely, gender, marital status, living arrangement, 
monthly family income and literacy, OA, GID and cognitive impairment appear to be 
risk factors. Likewise, the shorter GDS versions compared against the TrueDEP group 
revealed the same correlations. Thus, putatively validating the shorter versions. These 
will nonetheless have to be further validated. 
 
Taken together the results for both the GDS15+ cases and TrueDEP groups are 
in agreement with the Portuguese study the Mental Health Report in Portugal [243]. 
This study shows that women present a greater risk than men of suffering from 
depressive disorders (OR=2.30) and anxiety disorders (OR=2.89), while men are more 
likely to suffer from disorders affecting the control of impulses and disturbances by 
substance abuse. Also in this study [243], the older group is less likely to suffer from 
depressive disorders, anxiety and substance abuse than younger age groups. The 
group of previously married (separated/divorced/widowed) persons is at a higher risk 
of suffering from depressive disorders and substance abuse, whereas those who have 
never been married are associated with a greater risk of substance abuse and impulse 
control disorders. Regarding the influence of the level of education, there is an 
association between the medium-low level and the disorders of impulse control and 
substance abuse disorders. The level of income, as estimated in the study, does not 
show significant associations with the variables of psychiatric morbidity. Overall 
conclusions are like those obtained for the pcb-Cohort. 
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5.2.2 Correlating Depression and Dementia  
Depression and dementia are common in older individuals and their 
association is very complex, further, the coexistence of both has emerged as a 
significant public health problem leading to increased health care utilization and costs 
[173]. The question ‘Are depressed people also in an early stage of dementia?’ is of 
some concern. Depression has been described to be a risk factor for dementia [152]. It 
is a condition that reduces the quality of life for the patients [244]. Demented patients 
can also exhibit a depressed state [138,209]  
In the pcb-Cohort, the number of patients with both conditions is striking 
(Table 48). Specifically, 87 and 36 patients with suspected cognitive disorder, based on 
the CDR evaluation are GDS15+. Comparatively in the TrueDEP equivalent numbers fall 
to 37 and 15 for CDR=0.5 and CDR>=1 respectively. Reports in the literature, indicate 
that rates of depression are significantly higher in subjects with MCI and dementia 
when compared to those with normal cognition [236].  
 
Table 48 Correlating patients with GDS results and cognitive evaluation 
Cognitive Evaluation 
GDS Depressive case 
GDS15- GDS15+ Normal TrueDEP Inconclusive 
CDR 
CDR=0  250 51 189 22 90 
CDR=0.5 112 87 76 37 86 
CDR>=1 32 36 21 15 32 
Total 
 
394 174 286 74 208 
NCD 
NCD=0 189 0 189 0 0 
NCD-mild 61 0 61 0 0 
NCD-major 36 0 36 0 0 
PCD 108 174 0 74 208 
Total   394 174 286 74 208 
Abbreviations: GDS-Geriatric Depression Scale; (-) negative cases; (+) positive cases; 
TrueDEP: confirmed cases of depressive disorder bases in DSM-5; Inconclusive-cases that 
not conclude the diagnostic of depressive disorder; CDR-Clinical Dementia Rate; NCD-
Neurocognitive disorder; PCD-Possible cases of depression; N total= 568 patients in pcb-
Cohort 
 
  Consistently in the pcb-Cohort, dementia and depressive conditions 
show an association (Tables 25 and 34). Not surprisingly depressive symptoms have in 
the past been correlated to neuropsychological variables, MMSE, cognitive profiles, 
daily life activities and age of onset [135]. 
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5.3  APOE Genotyping in pcb-Cohort 
The APOE genotype is an important determinant of the risk of dementia 
[192,245], AD and depression [200]. Apolipoprotein E has three alleles:ε2/ε3/ε4 [199], 
where epsilon4 is the major genetic risk factor for AD [245].  In the pcb-Cohort,ε3ε3 
(75%) was the most common polymorphism, andε2ε4 (1.4%) was the rarest. Theε2ε4 
genotyping is represented in 1.4%. There was noε2ε2 individual [201], (Figure 13). 
Carriers of ε4 represent 96 in 508 (18.9%) patients in pcb-Cohort.  
Relative to sociodemographic characteristics associating with APOE ε4, no 
significant associations between APOE ε4 allele and gender was found in the pcb-
Cohort. The proportion of patients with dementia carrying the ε4 allele was estimated 
to be 20%, but at a population level, it must be born in mind that factors other than 
the APOE genotype play an important role in dementia onset [193]. The risk APOE ε4 
association with dementia has been shown in developed countries and in Asia, but not 
in Africa or in Latin America [89]. In the pcb-Cohortε4 also appears to be a risk factor 
(Tables 13 and 18) with respect to CDR≥1 and NCD-mild, curiously no such relationship 
was found for NCD-major; due to the exclusion of patients with depression. In fact, 
there are reports showing a correlation between depression and APOE ε4 allele 
[199,200]. In pcb-Cohort, this correlation is also found; GDS15+ cases are in higher 
proportion inε4carriers (p-value=0.041). 
Furthermore, APOE ε4 has been related to other disorders. In fact APOE ε4 
has been reported to associate with increased cardiovascular risk [200,246] and 
dyslipidaemia [246]. In the pcb-Cohort a correlation between APOE ε4 carriers and 
dyslipidaemia is evident (Table 37). It is also worthwhile noting that a high risk APOE ε4 
genotype can be counterbalanced by high-density lipoproteins (HDL) [246]. 
Additionally, data from the pcb-Cohort revealed a higher prevalence of 
chronic respiratory diseases in non-ε4 carriers. The mechanism by which APOE ε4 non-
carrier´s contribute to the pathogenesis of respiratory disease remains to be 
elucidated. 
Relative to APOE ε2 carriers, this allele has been associated to a protective 
role to cognitive impairment [193]. In the pcb-Cohort, theε2 carriers and prevalence 
appears to increase in the age range of 50-64 years. Relative to NCD evaluation, no 
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correlation with this allele was found (Table 37). But it is possible to see that the 
proportion of the normal cognitive performance is marginally higher in APOE ε2 
carriers (73.7% vs 62.1% non ε2 carrier). 
Dyslipidaemia, cardiac and vascular disease and Type 2 diabetes are tightly 
linked. APOE ε2 carriers in the pcb-Cohort show a negative association with both 
dyslipidaemia (p-value=0.009) and cardiac and vascular disease (p-value=0.053). 
Further, in the pcb-Cohort, it is possible to see that DM is in a higher proportion in 
APOE ε2 non-carrier (20.6% vs 7.9% of APOE ε2 carrier, p-value=0.057).  Other reports 
have shown that in healthy patients, APOE ε2 carriers are associated with reduced 
cardiovascular disease [199], and that Type 2 diabetes individuals have increased risk 
of developing AD [195]. So, in a primary care setting the screening and control of the 
above-mentioned three pathologies may aid in dementia prevention. 
 
5.4  Considerations when Working in Primary Health Care Settings 
Considering the limited access to specialized health care that particularly 
affects the elderly, primary care providers are usually on the front line in the diagnosis 
and care of these patients [247]. Depression is common across the population, and 
imposes social, financial, and medical costs to patients and their families [248]. 
Screening for depression can be useful in the primary care setting if reliable systems 
are in place to ensure adequate treatment and follow-up [248]. Use of collaborative 
care models for depression in the primary care setting have been shown to be a cost-
effective means of providing depression-related care, but economic and cultural 
barriers continue to slow down widespread acceptance [248]. The fact that older 
adults seek treatment for depression in primary care settings led to the development 
of collaborative care interventions for depression. These interventions have 
consistently demonstrated clinically meaningful effectiveness in the treatment of late-
life depression [158].  
Relative to dementia, this pathology still does not have the same evolution in 
primary health care as hypertension, diabetes and diseases of the cardiovascular 
system. It is fact that the training, the dedication in weekly working hours is greater for 
the latter pathologies. There is perhaps a deficit in recognizing dementia ([110]. In 
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practice, this means that there is perhaps a lower dementia recognition rate, and it 
would be important for potential cases to be identified as early as possible and 
referred to a specialist (neurologist or psychiatrist). As with other pathologies, the 
family doctor does not substitute other specialists, but they complement each other. 
The norms of the General Directorate of Health (Direção-Geral da Saúde) already have 
guidelines for diagnosis and therapy of many pathologies like DM and HYP [249]. 
Currently the family doctor suspects, applies a quick test and recommends the patient 
to specialized consultations. It would be important to include dementia in this 
workflow. 
In the above-suggested scenario, brief cognitive tests could be implemented 
for the identification of cognitive deficits at the community and primary health care 
levels. In addition, these tests are useful in monitoring the progression of cognitive 
deficits and evaluating the efficacy of anti-dementia drugs or other intervention 
strategies. There are several short cognitive assessment tests, but only a few are 
adapted for use in Portugal [98]. The Mini-Mental State Examination (MMSE) is a good 
tool for detecting dementia, but it is not usually altered in the early stages of cognitive 
decline, such as a mild cognitive defect [112]. Several other instruments have been 
proposed to detect early stages of cognitive decline. The Montreal Cognitive 
Assessment (MOCA) test [250] has recently been translated, adapted and validated for 
Portugal [251] and can be recommended. The MOCA shows sensitivity values of 84% 
and specificity of 79% for detection of mild cognitive impairment, and sensitivity values 
of 77% and specificity of 80% for detection of Alzheimer's disease [252].  
In the pcb-Cohort the use of a quick test the MMSE was employed but also 
the ‘gold standard’ CDR. This permitted comparing a more complete test with one that 
is quicker to employ. However given that the CDR is more complete than the MMSE, it 
was chosen to be used primarily in this study, furthermore it has already been 
validated in the Portuguese version [253]. It has also been shown to be a very effective 
tool in evaluating various forms of dementia [254] and has cross-cultural validity 
[112,183,233].  
Previous studies have shown that the CDR has a diagnostic accuracy of 96% in 
patients with mild cognitive disturbance, 97.1% in patients with AD and a CDR≥0.5 and 
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an accuracy of 87.2% in AD patients with a CDR≥1 [98]. Clearly attention should be 
given to patients with CDR=0.5. This is a heterogeneous group where CDR=0.5 
incorporates several conditions: questionable dementia, incipient or very mild 
dementia and still Alzheimer's type dementia [135,234]. Therefore, in the results from 
the first part of the thesis, patients with CDR=0.5 represent in fact this heterogeneous 
group, which needs to be re-evaluated later to better define the group. 
Another methodology that could have been used is the sum of the scores 
obtained in each category (or box), with an amplitude of 0 to 18, in which the highest 
scores correspond to the greatest severity [105,183]. It also has validity in clinical 
practice and research. We chose not to use it once we detected people with a score of 
0.5 and who had changes in orientation for example, not memory, and that did not 
match the overall score. 
In this phase of the study, we have not yet been able to completely re-
evaluate the pcb-cohort. Thus, we have an idea of cognitive deficit prevalence but not 
incidence. A re-evaluation is ongoing, and the results should be forthcoming. In the 
future it will be interesting to identify how many new confirmed cases occurred, what 
therapy was used, and the impact of starting treatment on the evolutionary 
performance of dementia in our region. This is feasible because the individuals’ data 
obtained for each patient during the study here presented was made available to the 
respective family doctor. 
This thesis has the advantage of being a study with the purpose of 
recommending an effective protocol of joint action involving general practitioners 
(GP), psychiatrists and neurologists, among others.  Like other comorbidities, dementia 
and depression have to be seen as a public health problem in Portugal, and in the 
world [25]. People living with dementia have poor access to appropriate healthcare, 
even in most high-income countries, where only around 50% of people living with 
dementia receive a diagnosis. In low and middle-income countries, less than 10% of 
cases are diagnosed. As the populations age, due to increasing life expectancy, the 
number of people with dementia is increasing [25]. The recommendation of a good 
proposal to identify cases of dementia, would include players already involved, for 
example between the referral hospital and primary health care centres, such as the 
maternal health protocol presently in action. The contribution of this thesis lies in that 
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it was able to profile cognitive impairment and depression in primary health care 
settings. It was also able to determine the main factors associated with dementia and 
depression and these are largely consistent accepted hypotheses. One of the strengths 
of this study is that it presents a set of internationally validated tools that can be 
employed and appear to do well in primary care settings. Further validations can of 
course be considered. Similar studies have already been carried out in other countries 
[63].  
 
5.5 Polypharmacy and Potentially Inappropriate Medication in the 
pcb-Cohort 
The elderly population is at risk of polypharmacy and Potentially 
Inappropriate Medication Use (PIM). Polypharmacy is a problem because individuals 
over 65 years old often have to deal with multiple illnesses [256]. The Beers Criteria is 
a guide to improve medical prescription [257]. Further interest arises in its use as a 
tool in primary care settings [258]. The aim of this part of the work was to identify and 
analyse polypharmacy and PIM in the pcb-Cohort. 
 
As mentioned, in the elderly, the increase in medication is particularly due to 
co-morbidities arising with ageing. Another important feature are the physiological 
changes: pharmacokinetics and pharmacodynamics, these are all important because 
what is observed is increased susceptibility to polypharmacy, drug interactions, 
adverse drug reactions, prescribing cascade, poor compliance, and potential 
inappropriate prescribing [175] . 
In the pcb-Cohort 366 participants are 65 years old or older and medication 
information was available for 361.  Results show that the average number medications 
taken by individuals in the pcb-Cohort is in the range of that found in other studies. In 
Austria, the average number of different drugs prescribed per person was 9.0, (7.9 in 
men and 9.7 in women) [259]. In Ireland, the average number of different medications 
per patient was 5 (range 1–19) [260]. In the pcb-Cohort the average number 
medications is 5 in men and 7 in women. However, polypharmacy prevalence in the 
pcb-Cohort is strikingly high; 94.5% of the 361 individuals are subject to polypharmacy. 
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Multivariate analyses, using logistic regression, revealed the factors that 
significantly contribute to increased risk of polypharmacy; 1.9 times greater in patients 
over 75; 2.6 times in patients with low average of schooling; 2 times in patients with 
CVD, and the risk for the presence of PIM1 increases 4.6 times in the same patient 
group (Table 45).  
The presence of polypharmacy itself does not denote inappropriate or 
incorrect use of medications. Older adults with more than one chronic medical 
condition typically require polypharmacy to manage their conditions [261].  Patients 
who take multiple medications are at higher risk of experiencing medication-related 
problems [164].  Another problem is that there is an economic burden caused by 
polypharmacy because older adults who live on a fixed income often have difficulty 
affording their medications [261]. In the literature, positive associations of neurological 
motor dysfunction, older age, cognitive impairment, disability in activities of daily 
living were associated with polypharmacy [256]. 
 
The Beers Criteria is a tool with great relevance in European countries [166]. It 
is known that applying the Beers Criteria can decrease by 0.5 the number of 
medications in patients admitted to acute geriatric centres [262]. Relative to PIM1, we 
found that 47.4% of individuals in the pcb-Cohort use at least one PIM medication 
(Table 49). This is strikingly high compared to studies showing a much lower 
prevalence of inappropriate medication usage in Europe and in the United States 
[263,264]. A study in Finland estimated the prevalence rate of inappropriate 
prescribing to be 12.5%, 1.3%, and 0.2% for individuals taking at least 1, 2, or 3 
inappropriate PIM1 drugs, respectively [263]. For the pcb-Cohort individuals taking at 
least 1, 2, 3 or 4 inappropriate PIM1 drugs show a prevalence of 29.6%, 14.7%, 2.5% 
and 0.6% respectively. 
In the pcb-Cohort, the more frequent PIM1 medications are Benzodiazepines: 
with 44.1% of the prescriptions falling into PIM1 (Table 49). The prescription of this 
medication is inappropriate because of the extended sedation and increased risk of 
falls [265]. Benzodiazepines are also associated with cognitive problems and represent 
an increased risk of developing dementia [266,267]. There are reports that 
Benzodiazepines were prescribed for approximately one in three elderly hospitalized 
_______________________________________________________________________ 
 
_______________________________________________________________________ 
Characterization of the pcb-Cohort in the Aveiro region of Portugal 171 
 
patients and that a large proportion was inappropriate [268]. Also, commonly 
prescribed Beers Criteria drugs used in dentistry include Benzodiazepines and long-
acting non-steroidal anti-inflammatory analgesics [269].  
 
Table 49 Comparative PIM prevalence  
REF Country PIM Prevalence Main PIMs 
pcb-Cohort Aveiro, 
Portugal 
47.4% Benzodiazepines (44.1%), 
vasodilators (25.5%), 
drugs with antimuscarinic properties (16.7%),  
benzodiazepines long-acting (8.6%). 
[269] USA 
(dentistry) 
3 in 10 older adults visiting the dentist  Benzodiazepines long-acting and/or 
nonsteroidal anti-inflammatory analgesics. 
[270] France 53.6% in patients ≥ 75 years old Vasodilators (19.4%), 
drugs with antimuscarinic properties (19.3%),  
benzodiazepines long-acting (17.8%). 
[271] 
 
France  geriatric teaching hospital 26.7%  
 
24% of these patients with PIM1 use at the 
time of hospital admission, namely 
psychotropics. 
[272] Taiwan metropolitan hospital (14.4%) 
academic medical centres (11.1%) 
Antihistamines (4.8% of all prescriptions in 
48.3% of elderly patients),  
muscle relaxants/antispasmodics (4.0% and 
40.3%, respectively), 
long-acting benzodiazepines (2.4% and 21.4%). 
 
 
Beyond the above-mentioned PIM1 drugs, another important group of drugs 
in this group are the antipsychotics. In the pcb-Cohort there is a frequency of 4.4% 
PIM1 due to antipsychotic drugs. Antipsychotics are associated with restlessness which 
characteristically occurs after large initial doses and may resemble an exacerbation of 
the condition being treated (akathisia) [273]. Antipsychotics are associated with 
worsening Parkinsonism as psychosis and dementia are frequently comorbidities in 
patients with Parkinson’s Disease (PD). Safety risks associated with antipsychotics 
mean that this class of drugs should be used with precaution [274].  
Also, of concern is the use of aspirin, which is typically used for primary 
prevention of cardiac events, it should nonetheless be used with caution in adult’s ≥80 
years old. Aspirin can cause bleeding of the gastrointestinal tract followed iron 
deficiency anaemia, in fact there is a lack of evidence in what regards benefit versus 
risk in aspirin usage in individuals ≥80 years old [166,275]. In the pcb-Cohort 12  
(17.6%) of 86 patients, aged 80 years old use Aspirin.  
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Of equal interest in the pcb-Cohort, are the 4 patients diagnosed with chronic 
Kidney disease, of which 1 is taking NSAIDs. In chronic kidney disease, stages IV and V 
NSAIDs should be avoided because they may increase the risk for kidney Injury [166]. 
Although only one patient is in this situation it is nonetheless undesirable. NSAIDs in 
the elderly are effective for the treatment of Musculoskeletal diseases although the 
risk of serious adverse events (mainly gastrointestinal) is also clearly high [276]. 
Vasodilators should also be avoided in patients over 65 years [166], since they are an 
important cause of Syncope in this age group [277]. In our study, 94 (24.7%) patients 
were taking a vasodilator. Fortunately, there are no cases of Syncope in these patients. 
Multivariate analyses, using logistic regression, permitted identifying the 
factors that significantly contribute to increasing the risk of PIM1 (Table 42). Regarding 
the risk of PIM1, attention should be given to women with 1.3 times increased risk and 
the group with cognitive impairment (NCD) with an increased risk of 2.6 times. 
Regarding patients with polypharmacy, these are 4.6 times more likely to take PIM1. In 
literature, positive associations with PIM1 were found with recent hospitalization, 
number of prescriptions, and comorbidity including circulatory diseases, endocrine and 
metabolic disorders  [166,269,271]. 
 
Beers criteria goes beyond a list of medications, it is a guide for good medical 
practice. It assists with determining when a drug should or should not be used, 
although individual situations should always be considered. 
For example:  the use of amitriptyline (an anti-depressive) is not as a first drug 
of choice for depression but can be used for neuropathic pain given its secondary 
benefits. In fact, a good command of clinical pharmacology is absolutely necessary for 
a correctly prescribing medications and the Beers criteria can strongly assist 
[257,262,278]. But the Beers Criteria are not perfect, not all inappropriate medications 
are considered. The other flaw is that these criteria do not over adverse drug reactions 
[279,280]. 
In closing, the Beers criteria are not the only tool for assisting with drug 
prescribing. There are other tools, such as the START/STOP tool [262]. The pcb-Cohort 
was not designed with tools to apply the latter. However, the possibility of evaluating 
medication and STOP / START application and subsequent comparison with our results 
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of the Beers criteria presented here is not completely ruled out. In follow, up work we 
aim to raise awareness among primary care colleagues so that they apply the Beers 
criteria and then evaluate the effectiveness of this intervention. Namely to monitor the 
medications inappropriately prescribed. 
 
 
5.6 Limitations  
This study focussed on dementia and depression thus some important 
characteristics were not collected, like smoking and obesity, also imaging data or 
neurochemical CSF analyses were not available; some questions necessary to apply 
DSM-5 criteria to depressive disorder were not included; and details regarding 
cardiovascular risk. Some of this information would have been useful to carry out 
further association studies. 
Another important consideration is that the study group was collected from 
primary health care centres and thus best reflects the patients attending these types 
facilities. Finally, several shorter tests were proposed for putative depression, for 
example the GDS4-8, for wider usage further validation studies should be carried out. 
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This study shows the merit of carrying out cognitive tests on younger subjects; 
in the age group of 50–65 years, 71 individuals were identified as possibly demented or 
demented. One may conclude that for the pcb-Cohort, the APOE ε4 allele, female 
gender, ageing, and low education are risk factors. The most unexpected finding was a 
strong correlation between GID and high CDR scores.  This hitherto unreported 
correlation deserves further investigation. It is expected that the methodology used in 
the pcb-Cohort may serve as an effective tool to identify possible markers and risk 
factors for similar studies and as such may contribute to dementia diagnosis in a 
primary care setting. 
This study presents a set of validated tools that can be employed in a primary 
care setting to identify potential dementia cases. Ageing is a known risk factor for 
dementia; however, in the pcb-Cohort, age group subdivisions allowed for the 
identification of potential dementia cases among younger volunteers. This is 
important, since it can endorse cognitive testing of younger patients in a primary care 
setting. In fact, a major strength of the pcb-Cohort study is that it identified 64 subjects 
with suspected dementia and 7 with mild dementia; these individuals were flagged for 
follow-up studies.  Additionally, considering the available comorbidity data, GID 
appears to be a risk factor; this should be considered in future studies. 
Relative to depression, GDS4Lit is not an adequate tool for screening for 
depression in Portuguese patients in the pcb-Cohort. Our results show that GDS8 is a 
simple tool compatible with primary care clinicians and capable of identifying high-risk 
older patients who could be targeted for subsequent depression screening. Restricting 
depression screening to patients identified as high risk by the GDS8 may enable 
clinicians to maximize the potential benefits of screening while minimizing possible 
harms. Therefore, we recommend that in usual practice the GDS8 be applied and 
followed up when justifiable by a formal diagnostic procedure to establish the 
presence depression.  
The work here presented is to our knowledge the first genotyping APOE study 
in the Aveiro region of Portugal. In this region, the main genotyping isε3ε3 andε4 
carriers are potential cases of dementia and depression. 
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Relative to medication, in the pcb-Cohort there is a high prevalence of PIM 
and polypharmacy among primary care patients over 65. Using the Beers criteria is a 
helpful guide and a good screening tool to detect PI prescription. We therefore 
recommend its use at the point of care. 
 
Future studies in the pcb-Cohort will focus on reassessing patients; evaluating 
the progression of dementia in the region of Aveiro; study the presence and/or 
evolution of comorbidities; apply the STOP / START criteria and compare with Beers 
Criteria and conduct primary health care training and support as requested in the 
health community. 
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Supplementary table 1 Table I of the Beers Criteria 
Table I of the Beers Criteria:  2012 AGS Beers Criteria for Potentially Inappropriate 
Medication Use in Older Adults – PIM1 (section 1 of 6) 
 Organ System/ 
Therapeutic Category/Drug(s) 
Recommendation. Rationale. Quality of Evidence (QE) & 
Strength of Recommendation (SR) 
A
n
ti
ch
o
li
n
e
rg
ic
s 
(e
x
cl
u
d
e
s 
T
C
A
s)
 
First-generation antihistamines (as single  
agent or as part of combination products) 
Brompheniramine  
   Carbinoxamine  
   Chlorpheniramine  
   Clemastine  
   Cyproheptadine  
   Dexbrompheniramine  
   Dexchlorpheniramine  
   Diphenhydramine (oral)  
   Doxylamine  
   Hydroxyzine  
   Promethazine  
   Triprolidine 
Avoid. 
Highly anticholinergic; clearance reduced with advanced 
age. and tolerance develops when used as hypnotic; 
increased risk of confusion. dry mouth. constipation. 
and other anticholinergic effects/toxicity. 
Use of diphenhydramine in special situations such as 
acute treatment of severe allergic reaction may be 
appropriate. 
QE=High (Hydroxyzine and Promethazine). Moderate 
(All others); SR=Strong 
Antiparkinsonian agents 
   Benztropine (oral) 
   Trihexyphenidyl 
Avoid. 
Not recommended for prevention of extrapyramidal 
symptoms with antipsychotics; more effective agents 
available for treatment of Parkinson disease. 
QE=Moderate; SR=Strong 
Antispasmodics 
   Belladonna alkaloids 
   Clidinium-chlordiazepoxide 
   Dicyclomine 
   Hyoscyamine 
   Propantheline 
   Scopolamine 
Avoid except in short-term palliative care to decrease 
oral secretions.  
Highly anticholinergic. uncertain effectiveness. 
QE=Moderate; SR=Strong 
A
n
ti
th
ro
m
b
o
ti
c 
Dipyridamole. oral short-acting* (does not  
apply to the extended-release combination 
with aspirin) 
Avoid. 
May cause orthostatic hypotension; more effective 
alternatives available; IV form acceptable for use in 
cardiac stress testing. 
QE=Moderate; SR=Strong 
Ticlopidine* Avoid. 
Safer. effective alternatives available. 
QE=Moderate; SR=Strong 
A
n
ti
-i
n
fe
ct
iv
e
 
Nitrofurantoin  Avoid 
For long-term suppression; avoid in patients with 
CrCl<60 mL/min. 
Potential for pulmonary toxicity; safer alternatives 
available; lack of efficacy in patients with CrCl<60 
mL/min due to inadequate drug concentration in the 
urine. 
QE=Moderate; SR=Strong 
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Table I of the Beers Criteria (continued section 2 of 6) 
 Organ System/ 
Therapeutic Category/Drug(s) 
Recommendation. Rationale. Quality of Evidence 
(QE) & Strength of Recommendation (SR) 
C
a
rd
io
v
a
sc
u
la
r 
Alpha1blockers 
   Doxazosin 
   Prazosin 
   Terazosin 
 
Avoid use as an antihypertensive. 
High risk of orthostatic hypotension; not recommended 
as routine treatment for hypertension; alternative 
agents have superior risk/benefit profile. 
QE=Moderate; SR=Strong 
Alpha agonists 
   Clonidine 
   Guanabenz* 
   Guanfacine* 
   Methyldopa* 
   Reserpine (>0.1 mg/day)* 
Avoid clonidine as a first-line antihypertensive. Avoid 
others as listed. 
High risk of adverse CNS effects; may cause bradycardia 
and orthostatic hypotension; not recommended as 
routine treatment for hypertension. 
QE=Low; SR=Strong 
Antiarrhythmic drugs (Class Ia. Ic. III) 
   Amiodarone 
   Dofetilide 
   Dronedarone 
   Flecainide 
   Ibutilide  
   Procainamide 
   Propafenone 
   Quinidine 
   Sotalol 
Avoid antiarrhythmic drugs as first-line treatment of 
atrial fibrillation. 
Data suggest that rate control yields better balance of 
benefits and harms than rhythm control for most older 
adults. 
Amiodarone is associated with multiple toxicities, 
including thyroid disease. pulmonary disorders. and QT 
interval prolongation.  
QE=High; SR=Strong 
Disopyramide*  
 
Avoid. 
Disopyramide is a potent negative inotrope and 
therefore may induce heart failure in older adults; 
strongly anticholinergic; other antiarrhythmic drugs 
preferred. 
QE=Low; SR=Strong 
Dronedarone  
 
Avoid in patients with permanent atrial fibrillation or  
heart failure.  
Worse outcomes have been reported in patients taking 
dronedarone who have permanent atrial fibrillation or 
heart failure.  In general. rate control is preferred over 
rhythm control for atrial fibrillation. 
QE=Moderate; SR=Strong 
Digoxin>0.125 mg/day  
 
Avoid 
In heart failure. higher dosages associated with no 
additional benefit and may increase risk of toxicity; 
decreased renal clearance may increase risk of toxicity. 
QE=Moderate; SR=Strong 
Nifedipine. immediate release*  
 
Avoid. 
Potential for hypotension; risk of precipitating 
myocardial ischemia. 
QE=High; SR=Strong 
Spironolactone>25 mg/day  
 
Avoid in patients with heart failure or with a CrCl<30  
mL/min. 
In heart failure. the risk of hyperkalaemia is higher in 
older adults if taking>25 mg/day. 
QE=Moderate; SR=Strong 
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Table I of the Beers Criteria (continued section 3 of 6) 
 Organ System/ 
Therapeutic Category/Drug(s) 
Recommendation 
Rationale. Quality of Evidence (QE) & Strength of 
Recommendation (SR) 
C
e
n
tr
a
l 
N
e
rv
o
u
s 
S
y
st
e
m
 
Tertiary TCAs. alone or in combination: 
   Amitriptyline 
   Chlordiazepoxide- 
   amitriptyline 
   Clomipramine 
   Doxepin>6 mg/day 
   Imipramine 
   Perphenazine-amitriptyline 
   Trimipramine 
Avoid 
Highly anticholinergic, sedating and cause orthostatic 
hypotension;  
the safety profile of low-dose doxepin (≤6 mg/day) is 
comparable to that of placebo. 
QE=High; SR=Strong 
Antipsychotics. first(conventional) and 
second(atypical) generation (see online for 
full list) 
 
Avoid use for behavioural problems of dementia 
unless non-pharmacologic options have failed, and 
patient is threat to self or others 
Increased risk of cerebrovascular accident (stroke) and 
mortality in persons with dementia. 
QE=Moderate; SR=Strong 
Thioridazine 
Mesoridazine 
 
Avoid 
Highly anticholinergic and greater risk of QT-interval 
prolongation. 
QE=Moderate; SR=Strong 
Barbiturates 
   Amobarbital* 
   Butabarbital* 
   Butalbital 
   Mephobarbital* 
   Pentobarbital* 
   Phenobarbital 
   Secobarbital* 
Avoid 
High rate of physical dependence; tolerance to sleep 
benefits;  
greater risk of overdose at low dosages. 
QE=High; SR=Strong 
Benzodiazepines 
Short- and intermediate-acting: 
   Alprazolam 
        Estazolam 
        Lorazepam 
        Oxazepam 
        Temazepam 
        Triazolam 
Long-acting: 
        Clorazepate 
        Chlordiazepoxide 
   Chlordiazepoxide-amitriptyline 
   Clidinium-chlordiazepoxide 
        Clonazepam 
        Diazepam 
        Flurazepam 
   Quazepam 
Avoid benzodiazepines (any type) for treatment of 
insomnia, agitation or delirium 
Older adults have increased sensitivity to 
benzodiazepines and decreased metabolism of long-
acting agents. In general, all benzodiazepines increase 
risk of cognitive impairment, delirium, falls, fractures, 
and motor vehicle accidents in older adults. 
May be appropriate for seizure disorders, rapid eye 
movement sleep disorders, benzodiazepine withdrawal, 
ethanol withdrawal, severe generalized anxiety 
disorder, periprocedural anaesthesia and end-of-life 
care. 
QE=High; SR=Strong 
Chloral hydrate*  
 
Avoid 
Tolerance occurs within 10 days and risk outweighs the 
benefits considering overdose with doses only 3 times 
the recommended dose. 
QE=Low; SR=Strong 
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Table I of the Beers Criteria (continued section 4 of 6) 
 Organ System/ 
Therapeutic Category/Drug(s) 
Recommendation 
Rationale. Quality of Evidence (QE) & Strength of 
Recommendation (SR) 
C
e
n
tr
a
l 
N
e
rv
o
u
s 
S
y
st
e
m
 
Meprobamate  
 
Avoid 
High rate of physical dependence; very sedating. 
QE=Moderate; SR=Strong 
Nonbenzodiazepine  
hypnotics 
   Eszopiclone 
   Zolpidem 
   Zaleplon 
 
Avoid chronic use (>90 days) 
Benzodiazepine-receptor agonists that have adverse 
events like those of benzodiazepines in older adults 
(e.g. delirium. falls. fractures); minimal improvement in 
sleep latency and duration. 
QE=Moderate; SR=Strong 
Ergot mesylates* 
Isoxsuprine* 
 
Avoid 
Lack of efficacy. 
QE=High; SR=Strong 
E
n
d
o
cr
in
e
 
Androgens 
   Methyltestosterone* 
   Testosterone 
 
Avoid unless indicated for moderate to severe 
hypogonadism 
Potential for cardiac problems and contraindicated in 
men with prostate cancer. 
QE=Moderate; SR=Weak 
Desiccated thyroid  
 
Avoid 
Concerns about cardiac effects; safer alternatives 
available. 
QE=Low; SR=Strong 
Oestrogens with or without progestins  
 
Avoid oral and topical patch. Topical vaginal cream: 
Acceptable to use low-dose intravaginal estrogenic for 
the management of dyspareunia. lower urinary tract 
infections. and other vaginal symptoms 
Evidence of carcinogenic potential (breast and 
endometrium); lack of cardioprotective effect and 
cognitive protection in older women. Evidence that 
vaginal oestrogens for treatment of vaginal dryness is 
safe and effective in women with breast cancer. 
especially at dosages of oestradiol<25 mcg twice 
weekly. 
QE=High (Oral and Patch). Moderate (Topical); 
SR=Strong (Oral and Patch). Weak (Topical) 
Growth hormone  Avoid. except as hormone replacement following 
pituitary gland removal 
Effect on body composition is small and associated with 
edema, arthralgia, carpal tunnel syndrome, 
gynecomastia. impaired fasting glucose. 
QE=High; SR=Strong 
Insulin. sliding scale  
 
Avoid 
Higher risk of hypoglycaemia without improvement in 
hyperglycaemia management regardless of care setting. 
QE=Moderate; SR=Strong 
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Table I of the Beers Criteria (continued section 5 of 6) 
 Organ System/ 
Therapeutic Category/Drug(s) 
Recommendation  
Rationale. 
Quality of Evidence (QE) & Strength of Recommendation 
(SR) 
E
n
d
o
cr
in
e
 
Megestrol  Avoid 
Minimal effect on weight; increases risk of thrombotic events 
and possibly death in older adults. 
QE=Moderate; SR=Strong 
Sulfonylureas. long-duration 
   Chlorpropamide 
   Glyburide 
 
Avoid 
Chlorpropamide: prolonged half-life in older adults; can cause 
prolonged hypoglycaemia; causes SIADH 
Glyburide: higher risk of severe prolonged hypoglycaemia in 
older adults. 
QE=High; SR=Strong 
G
a
st
ro
in
te
st
in
a
l 
Metoclopramide  Avoid unless for gastroparesis 
Can cause extrapyramidal effects including tardive dyskinesia; 
risk may be further increased in frail older adults. 
QE=Moderate; SR=Strong 
Mineral oil. given orally  Avoid 
Potential for aspiration and adverse effects; safer alternatives 
available. 
QE=Moderate; SR=Strong 
Trimethobenzamide  
 
Avoid 
One of the least effective antiemetic drugs; can cause 
extrapyramidal adverse effects. 
QE=Moderate; SR=Strong 
P
a
in
 M
e
d
ic
a
ti
o
n
s 
Meperidine  Avoid 
Not an effective oral analgesic in dosages commonly used; may 
cause neurotoxicity; safer alternatives available. 
QE=High; SR=Strong 
Non-COX-selective NSAIDs. oral  
   Aspirin>325 mg/day 
   Diclofenac 
   Diflunisal 
   Etodolac 
   Fenoprofen 
   Ibuprofen 
   Ketoprofen 
   Meclofenamate 
   Mefenamic acid 
   Meloxicam 
   Nabumetone 
   Naproxen 
   Oxaprozin 
   Piroxicam 
   Sulindac 
   Tolmetin 
Avoid chronic use unless other alternatives are not effective, 
and patient can take gastroprotective agent (proton pump 
inhibitor or misoprostol) 
Increases risk of GI bleeding/peptic ulcer disease in high-risk 
groups. including those ≥75 years old or taking oral or 
parenteral corticosteroids. anticoagulants. or antiplatelet 
agents. Use of proton pump inhibitor or misoprostol reduces 
but does not eliminate risk. Upper GI ulcers. gross bleeding. or 
perforation caused by NSAIDs occur in approximately 1% of 
patients treated for 3–6 months. and in about 2%–4% of 
patients treated for 1 year.  
These trends continue with longer duration of use. 
QE=Moderate; SR=Strong 
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Table I of the Beers Criteria (continued section 6 of 6) 
 Organ System/ 
Therapeutic Category/Drug(s) 
Recommendation 
Rationale. Quality of Evidence (QE) & Strength of 
Recommendation (SR) 
P
a
in
 M
e
d
ic
a
ti
o
n
s 
Indomethacin 
Ketorolac. includes parenteral 
 
Avoid 
Increases risk of GI bleeding/peptic ulcer disease in high-risk 
groups (See Non-COX selective NSAIDs) 
Of all the NSAIDs, indomethacin has most adverse effects. 
QE=Moderate (Indomethacin). High (Ketorolac); SR=Strong 
Pentazocine*  Avoid 
Opioid analgesic that causes CNS adverse effects. including 
confusion and hallucinations, more commonly than other 
narcotic drugs; is also a mixed agonist and antagonist; safer 
alternatives available. 
QE=Low; SR=Strong 
Skeletal muscle relaxants 
   Carisoprodol 
   Chlorzoxazone 
   Cyclobenzaprine 
   Metaxalone 
   Methocarbamol 
   Orphenadrine 
Avoid 
Most muscle relaxants poorly tolerated by older adults, 
because of anticholinergic adverse effects. Sedation, 
increased risk of fractures; effectiveness at dosages tolerated 
by older adults is questionable. 
QE=Moderate; SR=Strong 
*Infrequently used drugs. Table 1 Abbreviations: ACEI-angiotensin converting-enzyme inhibitors; ARB-
angiotensin receptor blockers; CNS-central nervous system; COX-cyclooxygenase; CrCl-creatinine clearance; GI-
gastrointestinal; NSAIDs-non-steroidal anti-inflammatory drugs; SIADH-syndrome of inappropriate antidiuretic 
hormone secretion; SR-Strength of Recommendation; TCAs-tricyclic antidepressants; QE-Quality of Evidence 
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Supplementary table 2 Table II of the Beers Criteria 
Table II of the 2012 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older 
Adults Due to Drug Disease or Drug-Syndrome Interactions That May Exacerbate the Disease 
or Syndrome – PIM2 (section 1 of 4) 
 Disease or  
Syndrome 
 
Drug(s)  
 
Recommendation  
Rationale. Quality of Evidence(QE) & 
Strength of Recommendation (SR) 
C
a
rd
io
v
a
sc
u
la
r 
Heart failure  
 
NSAIDs and COX-2 inhibitors 
Nondihydropyridine CCBs (avoid 
only for systolic heart failure) 
   Diltiazem 
   Verapamil 
 
Pioglitazone. rosiglitazone 
 
Cilostazol 
Dronedarone 
Avoid 
Potential to promote fluid retention and/or 
exacerbate heart failure. 
QE=Moderate (NSAIDs, CCBs, Dronedarone).  
High (Thiazolidinediones (glitazones).  
Low (Cilostazol); SR=Strong 
Syncope  
 
Acetylcholinesterase inhibitors 
(AChEIs) 
 
Peripheral alpha blockers  
   Doxazosin 
   Prazosin 
   Terazosin 
 
Tertiary TCAs 
 
Chlorpromazine, thioridazine and 
olanzapine 
Avoid 
Increases risk of orthostatic hypotension or 
bradycardia. 
QE=High (Alpha blockers).  
Moderate (AChEIs.  
TCAs and antipsychotics);  
SR=Strong (AChEIs and TCAs).  
Weak (Alpha blockers and antipsychotic). 
C
e
n
tr
a
l 
N
e
rv
o
u
s 
S
y
st
e
m
 
Chronic  
seizures or  
epilepsy 
 
Bupropion 
Chlorpromazine 
Clozapine 
Maprotiline 
Olanzapine 
Thioridazine 
Thiothixene 
Tramadol 
Avoid 
Lowers seizure threshold; may be acceptable in 
patients with well-controlled seizures in whom 
alter-native agents have not been effective. 
QE=Moderate; SR=Strong 
 
Delirium  
 
All TCAs 
Anticholinergics  
Benzodiazepines 
Chlorpromazine 
Corticosteroids 
H2-receptor antagonist 
Meperidine 
Sedative hypnotics 
Thioridazine 
Avoid 
Avoid in older adults with or at high risk of 
delirium because of inducing or worsening 
delirium in older adults; if discontinuing drugs 
used chronically, taper to avoid withdrawal 
symptoms. 
QE=Moderate; SR=Strong 
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Table II of the Beers Criteria (continued section 2 of 4) 
 Disease or  
Syndrome 
 
Drug(s)  
 
Recommendation.  
Rationale. Quality of Evidence(QE) & 
Strength of Recommendation (SR) 
C
e
n
tr
a
l 
N
e
rv
o
u
s 
S
y
st
e
m
 
Dementia  
& cognitive  
impairment 
Avoid. 
 
Anticholinergics (see online for full 
list) 
Benzodiazepines 
H2-receptor antagonists 
Zolpidem 
Antipsychotics. chronic and as-
needed use 
 
Avoid due to adverse CNS effects 
Avoid antipsychotics for behavioural problems 
of dementia unless non-pharmacologic options 
have failed, and patient is a threat to 
themselves or others.  
Antipsychotics are associated with an increased 
risk of cerebrovascular accident (stroke) and 
mortality in persons with dementia. 
QE=High; SR=Strong 
History  
of falls or  
fractures 
 
Anticonvulsants 
Antipsychotics 
Benzodiazepines 
Nonbenzodiazepine hypnotics 
   Eszopiclone 
   Zaleplon 
   Zolpidem 
 
TCAs/SSRIs 
Avoid unless safer alternatives are not avail 
able; avoid anticonvulsants except for seizure 
Ability to produce ataxia. impaired 
psychomotor function. syncope. and additional 
falls; shorter-acting benzodiazepines are not 
safer than long-acting ones. 
QE=High; SR=Strong 
Insomnia Oral decongestants 
   Pseudoephedrine 
   Phenylephrine Stimulants 
   Amphetamine 
   Methylphenidate 
   Pemoline Theobromines 
   Theophylline 
   Caffeine 
Avoid 
CNS stimulant effects. 
QE=Moderate; SR=Strong 
 
Parkinson’s  
disease 
All antipsychotics (except for 
quetiapine and clozapine) 
Antiemetics 
   Metoclopramide 
   Prochlorperazine 
   Promethazine 
 
Avoid 
Dopamine receptor antagonists with potential 
to worsen parkinsonian symptoms. 
Quetiapine and clozapine appear to be less 
likely to precipitate worsening of Parkinson 
disease. 
QE=Moderate; SR=Strong 
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Table II of the Beers Criteria (continued section 3 of 4) 
 Disease or  
Syndrome 
 
Drug(s)  
 
Recommendation.  
Rationale. Quality of Evidence(QE) & 
Strength of Recommendation (SR) 
G
a
st
ro
in
te
st
in
a
l 
Chronic  
constipation 
 
Oral antimuscarinics for urinary 
incontinence 
   Darifenacin 
   Fesoterodine 
   Oxybutynin (oral) 
   Solifenacin 
   Tolterodine 
   Trospium 
 
Nondihydropyridine CCB 
   Diltiazem 
   Verapamil 
 
First-generation antihistamines as 
single agent or part of combination 
products 
   Brompheniramine (various) 
   Carbinoxamine 
   Chlorpheniramine 
   Clemastine (various) 
   Cyproheptadine 
   Dexbrompheniramine 
   Dexchlorpheniramine (various) 
   Diphenhydramine 
   Doxylamine 
   Hydroxyzine 
   Promethazine 
   Triprolidine 
 
Anticholinergics/antispasmodics  
   Antipsychotics 
   Belladonna alkaloids 
   Clidinium-chlordiazepoxide 
   Dicyclomine 
   Hyoscyamine 
   Propantheline 
   Scopolamine 
   Tertiary TCAs (amitriptyline. 
Clomipramine, doxepin, imipramine, 
and trimipramine) 
Avoid unless no other alternatives 
 
Can worsen constipation; agents for urinary 
incontinence: antimuscarinics overall differ 
in incidence of constipation; response 
variable; consider alternative  
agent if constipation develops. 
 
QE=High (For Urinary Incontinence). 
Moderate/Low (All  
Others);  
SR=Strong 
History of  
gastric or  
duodenal  
ulcers 
 
Aspirin (>325 mg/day) 
Non–COX-2 selective NSAIDs 
 
Avoid unless other alternatives are not 
effective, and patient can take 
gastroprotective agent (proton-pump 
inhibitor or misoprostol) 
May exacerbate existing ulcers or cause 
new/additional ulcers. 
QE=Moderate; SR=Strong 
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Table II of the Beers Criteria (continued section 4 of 4) 
 Disease or  
Syndrome 
 
Drug(s)  
 
Recommendation.  
Rationale. Quality of Evidence(QE) & 
Strength of Recommendation (SR) 
K
id
n
e
y
/U
ri
n
a
ry
 T
ra
ct
 
Chronic kidney 
disease stages 
IV and V 
 
NSAIDs 
Triamterene(alone or in 
combination) 
 
Avoid 
May increase risk of kidney injury. 
May increase risk of acute kidney injury. 
QE=Moderate (NSAIDs). Low (Triamterene);  
SR=Strong (NSAIDs). Weak (Triamterene) 
Urinary  
incontinence  
(all types) in  
women 
Oestrogen oral and transdermal 
(excludes intravaginal estrogenic) 
 
Avoid in women 
Aggravation of incontinence. 
QE=High; SR=Strong 
Lower  
urinary tract  
symptoms.  
benign  
prostatic  
hyperplasia 
Inhaled anticholinergic agents 
 
Strongly anticholinergic drugs. 
except  
antimuscarinics for urinary 
incontinence. 
Avoid in men 
May decrease urinary flow and cause urinary 
retention. 
QE=Moderate; SR=Strong (Inhaled agents). 
Weak (All others) 
Stress or  
mixed  
urinary 
incontinence 
Alpha-blockers 
   Doxazosin 
   Prazosin 
   Terazosin 
Avoid in women 
Aggravation of incontinence. 
QE=Moderate; SR=Strong 
Table 2 Abbreviations: CCBs-calcium channel blockers; AChEIs-acetylcholinesterase inhibitors; CNS-central 
nervous system; COX-cyclooxygenase; NSAIDs-nonsteroidal anti-inflammatory drugs; SR-Strength of 
Recommendation; SSRIs-selective serotonin reuptake inhibitors; TCAs-tricyclic antidepressants; QE-Quality of 
Evidence. 
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Supplementary table 3 Table III of the Beers Criteria 
Table III of the Beers Criteria:  2012 AGS Beers Criteria for Potentially Inappropriate 
Medications to Be Used with Caution in Older Adults- PIM3 
Drug(s)  
 
Recommendation.  
Rationale. Quality of Evidence (QE) & Strength of 
Recommendation (SR) 
Aspirin for primary 
prevention of cardiac 
events 
Use with caution in adults ≥80 years old 
Lack of evidence of benefit versus risk in individuals ≥80 years old. 
QE=Low; SR=Weak 
Dabigatran Use with caution in adults ≥75 years old or if CrCl<30 mL/min 
Increased risk of bleeding compared with warfarin in adults ≥75 years 
old; lack of evidence for efficacy and safety in patients with CrCl<30 
mL/min 
QE=Moderate; SR=Weak 
Prasugrel  Use with caution in adults ≥75 years old 
Greater risk of bleeding in older adults; risk may be offset by benefit in 
highest risk older patients (e.g. those with prior myocardial infarction or 
diabetes). 
QE=Moderate; SR=Weak 
Antipsychotics 
Carbamazepine 
Carboplatin 
Cisplatin 
Mirtazapine 
SNRIs 
SSRIs 
TCAs 
Vincristine 
Use with caution 
May exacerbate or cause SIADH or hyponatremia; need to monitor 
sodium level closely when starting or changing dosages in older adults 
due to increased risk. 
QE=Moderate;  
SR=Strong 
Vasodilators  
 
Use with caution 
May exacerbate episodes of syncope in individuals with history of 
syncope. 
QE=Moderate; SR=Weak 
Table 3 Abbreviations: CrCl-creatinine clearance; SIADH-syndrome of inappropriate antidiuretic 
hormone secretion; SSRIs-selective serotonin reuptake inhibitors; SNRIs-serotonin–norepinephrine 
reuptake inhibitors; SR-Strength of Recommendation; TCAs-tricyclic antidepressants; QE-Quality of 
Evidence. 
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Annex III  
Questionnaires Applied During the 
Clinical Interview 
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Attachments 2 – Questionnaire 
 
“Estudo Epidemiológico e Genotípico de pacientes com Demência na Região Baixo Vouga 
/Aveiro/Portugal”. 
CÓDIGO PACIENTE: ________________________    Data: ____/____/______ 
Parte I – Critérios de Inclusão e Exclusão 
Os critérios de inclusão para a amostra serão:  
a) Idade entre os 50 e 90 anos de idade; 
b) Queixa subjectiva de alteração de memória. ou qualquer outra alteração da cognição 
confirmada por informante; 
c) Presença de informante capaz de fornecer dados fidedignos; 
 
Os critérios de exclusão para a amostra serão: 
d) Ter cancro e está em tratamento com quimioterapia ou radioterapia; 
e) Fazer uso de drogas ilícitas; 
f) Fazer uso de drogas psiquiátricas. 
Parte II – Características Epidemiológicas/Sócio-Demográficas 
 
1. Nome:_________________________________________________________________
_______ 
2. Dt.Ncto:____/____/____    Idade: ____________ 
3. Género:    F               M 
4. Profissão:______________________________________________________________
_______ 
5. Est. Civil:  
Casado      Solteiro     União de Facto      Viúva    Separado 
6. Com quem vive:  
Sozinho     Acompanhado      
7. Se vive acompanhado. o grau de parentesco:  
Companheiro (a)   Filho (a)    Irmã (o) Sobrinho (a)    Pessoa contratada  Vive em 
um lar   
Outros: ________________________ 
8. Escolaridade: 
 0-2 anos de literacia 
 3-6 anos de literacia 
 >7 anos de literacia 
9. Cor:   caucasiana negróide  asiática  outra 
10. Freguesia:____________________________________ 
11. Concelho:__________________________________________ 
12. Distrito:__________________________________________ 
13. Renda Familiar Mensal:   
<1 salário   1-5 salarios    5-10 salarios  >10 salários 
221
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“Estudo Epidemiológico e Genotípico de pacientes com Demência na Região Baixo Vouga 
/Aveiro/Portugal”. 
CÓDIGO PACIENTE: ________________________    Data: ____/____/______ 
Parte III– Características Clínicas 
Peso :___________________ Altura:__________________ IMC:____________________ 
Glicémia: ⃝ jejum ⃝pós-prandial_____________ Colesterol:______________ 
Queixa principal: 
Histórico Patológico Pregresso: 
o DM  dislipidemia  
o HTA   
o Doenças do Aparelho Gastrointestinal:______________________________________ 
o Doenças do Aparelho Respiratório: _______________________________________ 
o Doenças do Aparelho Cardiovascular: _____________________________________ 
o Doenças do Aparelho Osteoarticular: ______________________________________ 
o Doenças do Aparelho Génito-Urinário: ____________________________________ 
o Doenças Neurodegenerativas: ____________________________________________ 
o Doenças Psiquiátricas:___________________________________________________ 
o Doenças Hematológicas: ________________________________________________ 
o Doenças Oncológicas: __________________________________________________ 
o Outras: ______________________________________________________________ 
o Etilismo 
 
História Familiar: 
o DM   
o HTA   
o Doenças do Aparelho Gastrointestinal:______________________________________ 
o Doenças do Aparelho Respiratório: _______________________________________ 
o Doenças do Aparelho Cardiovascular: _____________________________________ 
o Doenças do Aparelho Osteoarticular: ______________________________________ 
o Doenças do Aparelho Génito-Urinário: ____________________________________ 
o Doenças Neurodegenerativas: ____________________________________________ 
o Doenças Psiquiátricas:___________________________________________________ 
o Doenças Hematológicas: ________________________________________________ 
o Doenças Oncológicas: __________________________________________________ 
o Outras: ______________________________________________________________ 
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Estudo Epidemiológico e Genotípico de pacientes com Demência na Região Baixo Vouga 
/Aveiro/Portugal”. 
CÓDIGO PACIENTE: ________________________    Data: ____/____/______ 
Uso de Medicamentos 
o CARDIOTONICOS o ANTIARRITMICOS o ANTI-HIPERTENSORES 
o VASODILATADORES o VENOTRÓPICOS o ANTIDISLIPIDÉMICOS 
o ANTIASMÁTICOS E 
BRONCODILATADORE
S 
o ANTITUSSICOS E 
EXPECTORANTES 
o ANTI-ÁCIDOS E ANTI-
ULCEROSOS 
o TTO GOTA o AINES o CORTICOIDES 
o TTO ARTROSE o HORMONA TIROIDE o ANSIOLITICOS 
o ANTIDM ORAL o INSULINA o LITIO 
o ANTIPSICOTICOS o ANTIDEPRESSORES o OUTROS 
 
Droga Dose Tempo de 
Uso 
Indicação 
Médica 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
Achados sugestivos de DEMÊNCIA NÃO-ALZHEIMER (outras etiologias) 
 Presente Ausente 
Alteração precoce na marcha (ataxia)    
Incontinência urinária precoce   
Flutuação na cognição: variação pronunciada na atenção e/ou alerta   
Alucinações visuais precoces. recorrentes e bem estruturadas   
Presença de parkinsonismo precoce   
Quedas de repetição   
Sensibilidade exagerada a neurolépticos   
Comportamento anti-social ou desinibição precoces   
Hiperoralidade. hiperfagia ou hipersexualidade precoces   
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“Estudo Epidemiológico e Genotípico de pacientes com Demência na Região Baixo Vouga 
/Aveiro/Portugal”. 
CÓDIGO PACIENTE: ________________________    Data: ____/____/______ 
 
Parte IV– AVALIAÇÃO COGNITIVA 
1. AVALIAÇÃO CLÍNICA DA DEMÊNCIA – CDR 
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“Estudo Epidemiológico e Genotípico de pacientes com Demência na Região Baixo Vouga 
/Aveiro/Portugal”. 
CÓDIGO PACIENTE: ________________________    Data: ____/____/______ 
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“Estudo Epidemiológico e Genotípico de pacientes com Demência na Região Baixo Vouga 
/Aveiro/Portugal”. 
CÓDIGO PACIENTE: ________________________    Data: ____/____/______ 
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“Estudo Epidemiológico e Genotípico de pacientes com Demência na Região Baixo Vouga 
/Aveiro/Portugal”. 
CÓDIGO PACIENTE: ________________________    Data: ____/____/______ 
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“Estudo Epidemiológico e Genotípico de pacientes com Demência na Região Baixo Vouga 
/Aveiro/Portugal”. 
CÓDIGO PACIENTE: ________________________    Data: ____/____/______ 
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“Estudo Epidemiológico e Genotípico de pacientes com Demência na Região Baixo Vouga 
/Aveiro/Portugal”. 
CÓDIGO PACIENTE: ________________________    Data: ____/____/______ 
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“Estudo Epidemiológico e Genotípico de pacientes com Demência na Região Baixo Vouga 
/Aveiro/Portugal”. 
CÓDIGO PACIENTE: ________________________    Data: ____/____/______ 
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“Estudo Epidemiológico e Genotípico de pacientes com Demência na Região Baixo Vouga 
/Aveiro/Portugal”. 
CÓDIGO PACIENTE: ________________________    Data: ____/____/______ 
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1. MINI EXAME DO ESTADO MENTAL 
Mini-Mental de Folstein (1975).  adaptado por Brucki et al  (2003) 
 
Orientação Temporal 
(05 pontos) 
Dê um ponto para cada 
ítem 
Ano   
Mês         
Dia do mês        
Dia da semana         
Semestre/Hora aproximada  
 
Orientação Espacial 
(05 pontos) 
Dê um ponto para cada 
ítem 
País    
Distrito   
Terra   
Local geral: que local é este aqui (apontando ao 
redor num sentido mais amplo: hospital. casa de 
repouso.  própria casa) 
 
Andar ou local específico: em que local nós 
estamos (consultório.dormitório. sala. apontando 
para o chão) 
 
 
Retenção(3 pontos) 
(contar um ponto por cada 
palavra correctamente 
repetida) 
“Vou dizer três palavras; 
queria que as repetisse. 
mas só depois de eu as 
dizer todas. procure sabê-
las de cor.” 
 
 
Repetir: Pêra.  Gato. Bola 
 
  
 
Atenção e Cálculo 
(5 pontos) 
Dê 1 ponto para cada 
acerto.  Considere a tarefa 
com melhor 
aproveitamento. 
 
“Agora peco-lhe que me diga quantos são 30 
menos 3 e depois ao número encontradovoltar a 
tirar 3 e repete assim ate eu dizer para parar” 
 
30__27___24___21___18___15____ 
 
  
Memória de Evocação 
(3 pontos) 
 
“Veja se consegue dizer as 3 palavras que pedi a 
pouco para decorar” 
 
  
Nomear dois objetos 
 
(2 pontos) 
 
 
Mostrar um Relógio e caneta 
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Linguagem (1 ponto)   
 “Repita a frase que eu vou dizer: O RATO ROEU A 
ROLHA” 
 
  
Comando de estágios 
(3 pontos) 
Dê 1 ponto para cada ação 
correta) 
 
 
 
“Apanhe esta folha de papel com a mão direita. 
dobre-a ao meio e coloque-a no chão” 
  
Escrever uma frase 
completa 
(1 ponto ) 
 
 
 
“Escreva alguma frase que tenha começo. meio e 
fim” 
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Ler e executar 
(1 ponto ) 
 
 
 
FECHE 
OS 
OLHOS 
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Copiar diagrama 
(1 ponto ) 
 
 
Copiar dois pentágonos com interseção 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
PONTUAÇÃO FINAL (escore=0 a 30 pontos) 
 
 
Considera-se com defeito cognitivo:  
• 22 para 0 a 2 anos de literacia  
 
• 24 para 3 a 6 anos de literacia  
 
• 27 para literacia igual ou superior a 7 anos  
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ESCALA GERIÁTRICA DE DEPRESSÃO (Yesavage. 1983) 
1. De uma forma geral. está satisfeito (a) com a sua vida  Sim ( ) Não ( ) 
2. Abandonou muitas das suas actividades e interesses?  Sim ( ) Não ( ) 
3. Sente que sua vida está vazia?     Sim ( ) Não ( ) 
4. Anda muitas vezes aborrecido(a)?     Sim ( ) Não ( ) 
5. Está bem-disposto a maior parte do tempo?    Sim ( ) Não ( ) 
6. Anda com medo que lhe vá acontecer alguma coisa má?  Sim ( ) Não ( ) 
7. Sente-se feliz a maior parte do tempo?    Sim ( ) Não ( ) 
8. Sente-se desamparado(a)?      Sim ( ) Não ( ) 
9. Prefere ficar em casa. em vez de sair e fazer outras coisas?    
        Sim ( ) Não ( ) 
10. Sente que tem mais problemas de memória do que as outras pessoas?   
        Sim ( ) Não ( ) 
11. Sente que é maravilhoso estar vivo(a)?    Sim ( ) Não ( ) 
12. Sente-se inútil nas condições actuais?    Sim ( ) Não ( ) 
13. Sente-se cheio de energia?      Sim ( ) Não ( ) 
14. Sente que a sua situação é desesperada?    Sim ( ) Não ( ) 
15. Acha que a maioria das pessoas está melhor que o (a) Senhor (a)?   
        Sim ( ) Não ( ) 
 
 
 
 
 
 
 
Pontuação para GDS de 15 ítens 
• 1 ponto para as respostas SIM nas questões: 2. 3. 4. 6. 8. 9. 10. 12. 14. 15 
• 1 ponto para as respostas NÃO nas questões: 1. 5. 11. 13 
• 0-5=sem depressão 
• >5=depressão 
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ACTIVIDADES BÁSICAS DE VIDA DIÁRIA: 
 (Lawton & Brody. 1969)- ÍNDICE DE KATZ 
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1. ACTIVIDADE INSTRUMENTAIS DE VIDA DIÁRIA- Pfeffer. 1982; Duarte et al. 2007. 
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As diferentes áreas que compõem a funcionalidade do idoso são conhecidas como actividades de 
vida diária (AVDs) e subdividem-se em:  
i. Actividades Básicas de Vida Diária (ABVDs). onde estão incluídas as actividades relacionadas 
com o autocuidado como alimentar-se. cuidar da sua higiene pessoal. vestir-se. mobilizar-se. 
manter controlo dos esfíncteres; 
ii. Actividades Instrumentais de Vida Diária (AIVDs). que indicam a capacidade do indivíduo ter 
uma vidaindependente dentro da comunidade onde vive e inclui a capacidade para preparar 
refeições. realizar compras. utilizartransportes. cuidar da casa. utilizar telefone. administrar 
as próprias finanças. tomar medicação. 
 
 
 
• AIVDs: O Índice varia entre 8 e 30 pontos de acordo com os seguintes pontos decorte: 8 
pontos – Independente; 9 a 20 pontos- Moderadamente dependente. necessita de 
UMA CERTA AJUDA;>20 PONTOS- SEVERAMENTE DEPENDENTE. NECESSITA DE MUITA AJUDA. 
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/Aveiro/Portugal”. 
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Consentimento Informado 
Por favor. leia e escreva as suas iniciais nos quadrados seguintes 
1. Eu confirmo que percebi a informação que me foi dada e tive a 
oportunidade de questionar e de me esclarecer. 
 
2. Eu percebo que a minha participação é voluntária e que sou livre de 
desistir. em qualquer altura. sem dar nenhuma explicação. sem que isso 
afecte qualquer serviço de saúde que me é prestado. 
 
3. Eu compreendo que os dados recolhidos durante a investigação são 
confidenciais e só os investigadores responsáveis pelo projecto da 
Universidade de Aveiro/Centro de Biologia Celular têm acesso a eles. E dou 
portanto. autorização para que os mesmos tenham acesso a esta 
informação. 
 
4. Eu percebo que os resultados clínicos e laboratoriais realizados durante a 
investigação poder ser publicadas em Jornais Científicos. usadas na própria 
investigação ou em outras. sem que haja qualquer quebra de 
confidencialidade. E dou portanto. autorização para a utilização desta 
informação para esses fins. 
5. Eu confirmo que fui esclarecida de todos os aspectos éticos da pesquisa e 
estou de acordo com todos eles. 
6. Eu concordo em participar do estudo. 
 
 
________________________ 
Nome do Paciente 
 
 
___________ 
Data 
___________________________ 
Assinatura 
________________________ 
Nome da pessoa responsável 
pelo paciente 
 
 
___________ 
Data 
___________________________ 
Assinatura 
 
  
_______________________________________________________________________ 
 
_______________________________________________________________________ 
Characterization of the pcb-Cohort in the Aveiro region of Portugal 247 
 
 
“Estudo Epidemiológico e Genotípico de pacientes com Demência na Região Baixo Vouga 
/Aveiro/Portugal”. 
CÓDIGO PACIENTE: ________________________    Data: ____/____/______ 
 
Consentimento Informado 
a) Folha de Informação: O pedido do Consentimento 
Título do Projecto: “Estudo Epidemiológico e Genotípico de pacientes com Demência na Região 
Baixo Vouga II/Aveiro/Portugal”. 
Nome dos Investigadores: Odete Abreu Beirão Cruz e Silva e Ilka Martins Rosa 
Informações: 
• O Sr./Sra. Está convidado/a a participar num estudo de investigação clínica. 
• Leia com atenção as informações abaixo. Caso as mesmas não sejam claras. ou necessitar 
de informação adicional. por favor pergunte aos investigadores (contacto ao fim do 
documento). 
• Use o tempo que precisar para decidir se deseja ou não participar. 
• Este projecto proporciona a garantia formal de confidencialidade e de ocultação da 
identidade dos participantes; 
• O participante tem todo o direito de revogar o consentimento e abandonar o estudo. em 
qualquer altura e sem quaisquer prejuízos assistenciais ou outros; 
Qual é o objectivo do estudo? 
• Realizar o “Estudo Epidemiológico e Genotípico de pacientes com Demência na Região 
Baixo Vouga II/Aveiro/Portugal”. em pacientes atendidos no Agrupamento de Saúde Baixo 
Vouga II; 
• Realizar testes que visam testar a memória. outras funções e a capacidade em realizar 
tarefas do dia-a-dia; 
• Realizar análises ao sangue para pesquisa de demência; 
Caso eu decida participar. qual a metodologia do estudo? 
• Em um primeiro momento. as pessoas entre 50-90 anos. serão convidadas a participarem 
do estudo. 
• Será realizada recolha de dados relativamente a dados demográficos e clínicos gerais; 
• Serão realizados testes de cognição reconhecidos cientificamente em três momentos. com 
intervalo de 01 ano cada um; 
• Uma vez o paciente apresente alguma alteração dos testes de cognição. serão convidados 
a continuarem na pesquisa para realizarem análises ao sangue. para genotipagem e 
pesquisa de marcadores para Demência; 
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• Genotipagem é o estudo do conjunto de genes de uma pessoa que lhe confere as 
características que a mesma possui. e neste caso estamos especificamente a pesquisar se o 
paciente possui genes que predisponha à Doença de Alzheimer ou outras demências; 
• Marcadores são substâncias que podem ser detectadas no sangue ou em outro líquido 
corporal. para caracterizar determinada patologia. 
• A colheita sanguínea será através da punção periférica de uma veia. a ser realizada no 
mesmo dia da entrevista. caso o paciente cumpra os critérios e consinta. 
• Não é necessário estar em jejum para a colheita de sangue. 
• A recolha será realizada pela médica. Dra Ilka. Médica pesquisadora. com registo na Ordem 
dos Médicos de Portugal. sob número 50652; 
• As análises serão realizadas no Centro de Biologia Celular. na Universidade de Aveiro. 
laboratório de reconhecimento europeu no Diagnóstico de Doença de Alzheimer através de 
Biomarcadores; 
• Os resultados serão analisados estatisticamente e devidamente tratados. conforme todo o 
protocolo de ética exigido. com garantia da confidencialidade. 
 
Quais os efeitos secundários de qualquer procedimento que eu vá receber quando eu participar? 
• Não há efeitos secundários previsto. 
Quais as desvantagens caso eu decida não participar do estudo? 
• Não existe desvantagem. caso decida não participar. 
Quais os possíveis benefícios. caso eu decida participar do estudo. 
• Contribuir para a caracterização da população entre 50-90 anos atendida em Agrupamento 
de Saúde Baixo Vouga II; 
• Contribuir para o rastreio de demência em Portugal; 
• Possibilidade de realizar exames específicos e sensíveis e de custo inferior aos de imagem 
para diagnóstico de demência. nomeadamente Doença de Alzheimer; 
• Enriquecer o conhecimento científico em Portugal; 
Quem é que está a organizar e a financiar o estudo? 
• Universidade de Aveiro- Centro de Biologia Celular 
• O projecto não se responsabiliza por despesas com deslocamentos; 
Contactos para mais informações sobre o estudo: 
• Dra. Ilka Martins – 969299332 
________________________ 
Investigador 
_____________ 
Data 
______________________________ 
Assinatura 
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b) Declaração de consentimento pelo Paciente 
 
Por favor. leia e escreva as suas iniciais nos quadrados seguintes 
 
1. Eu confirmo que percebi a informação que me foi dada e tive a 
oportunidade de questionar e de me esclarecer. 
 
2. Eu percebo que a minha participação é voluntária e que sou livre de 
desistir. em qualquer altura. sem dar nenhuma explicação. sem que isso 
afecte qualquer serviço de saúde que me é prestado. 
 
3. Eu compreendo que os dados recolhidos durante a investigação são 
confidenciais e só os investigadores responsáveis pelo projecto da 
Universidade de Aveiro/Centro de Biologia Celular têm acesso a eles. E dou 
portanto. autorização para que os mesmos tenham acesso a esta 
informação. 
 
4. Eu percebo que os resultados clínicos e laboratoriais realizados durante a 
investigação poder ser publicadas em Jornais Científicos. usadas na própria 
investigação ou em outras. sem que haja qualquer quebra de 
confidencialidade. E dou portanto. autorização para a utilização desta 
informação para esses fins. 
5. Eu confirmo que fui esclarecida de todos os aspectos éticos da pesquisa e 
estou de acordo com todos eles. 
6. Eu concordo em participar do estudo. 
 
 
________________________ 
Nome do Paciente 
 
 
___________ 
Data 
___________________________ 
Assinatura 
________________________ 
Nome da pessoa responsável 
pelo paciente 
___________ 
Data 
___________________________ 
Assinatura 
 
